

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40
minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source
(CS) field
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5 AUG 24 CA/CAPLUS enhanced with legal status information for
U.S. patents
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in
CAS REGISTRY
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM
thesaurus
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and
Taiwanese Content Expanded
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human
translated claims for Chinese Applications and
Utility Models
NEWS 10 NOV 23 Addition of SCAN format to selected STN databases
NEWS 11 NOV 23 Annual Reload of IFI Databases
NEWS 12 DEC 01 FRFULL Content and Search Enhancements
NEWS 13 DEC 01 DGENE, USGENE, and PCTGEN: new percent identity
feature for sorting BLAST answer sets
NEWS 14 DEC 02 Derwent World Patent Index: Japanese FI-TERM
thesaurus added
NEWS 15 DEC 02 PCTGEN enhanced with patent family and legal status
display data from INPADOCDB
NEWS 16 DEC 02 USGENE: Enhanced coverage of bibliographic and
sequence information
NEWS 17 DEC 21 New Indicator Identifies Multiple Basic Patent
Records Containing Equivalent Chemical Indexing
in CA/CAPLUS
NEWS 18 JAN 12 Match STN Content and Features to Your Information
Needs, Quickly and Conveniently

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

*CSCORP - ChemSources - USA and International (Company Directory)
*GEOREF - Geological Reference File 1785-present

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 13:39:34 ON 24 JAN 2010

```
=> file reg
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                0.22          0.22
```

FILE 'REGISTRY' ENTERED AT 13:39:43 ON 24 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 JAN 2010 HIGHEST RN 1202965-77-2
DICTIONARY FILE UPDATES: 22 JAN 2010 HIGHEST RN 1202965-77-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10520621\Struc 5.str



```

chain nodes :
6 13 14
ring nodes :
1 2 3 4 5 7 8 9 10 11 12
chain bonds :
2-14 3-6 5-13 6-7
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-5 2-3 2-14 3-4 3-6 4-5 5-13 6-7
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12

```

G1:O,S,NH

Match level :



1:Atom 2:Atom 3:Atom 4:CLASS 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

10520621b.trn

=>

Uploading C:\Program Files\Stnexp\Queries\10520621\Struc 6.str



```
chain nodes :
6 13 14
ring nodes :
1 2 3 4 5 7 8 9 10 11 12
chain bonds :
2-14 3-6 5-13 6-7
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-5 2-3 2-14 3-4 3-6 4-5 5-13 6-7
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 7 :
```

G1:O,S,NH

```
Match level :
1:Atom 2:Atom 3:Atom 4:CLASS 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS
```


L2 STRUCTURE UPLOADED

=> l1 not l2

SAMPLE SEARCH INITIATED 13:40:18 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 17203 TO ITERATE

11.6% PROCESSED 2000 ITERATIONS 14 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 336203 TO 351917
PROJECTED ANSWERS: 1750 TO 3066

L3 14 SEA SSS SAM L1 NOT L2

=> l1 not l2 full

FULL SEARCH INITIATED 13:40:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 347014 TO ITERATE

100.0% PROCESSED 347014 ITERATIONS 3393 ANSWERS
SEARCH TIME: 00.00.03

L4 3393 SEA SSS FUL L1 NOT L2

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	192.03	192.25

FILE 'CAPLUS' ENTERED AT 13:40:40 ON 24 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jan 2010 VOL 152 ISS 5
FILE LAST UPDATED: 22 Jan 2010 (20100122/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> 14

L5 358 L4

=> d ibib abs hitstr 358

L5 ANSWER 358 OF 358 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1911:11504 CAPLUS

DOCUMENT NUMBER: 5:11504

ORIGINAL REFERENCE NO.: 5:2072d-i,2073a-b

TITLE: Hydantoins: Synthesis of Phenylalanine and of Tyrosine

AUTHOR(S): Wheeler, Henry L.; Hoffman, Charles

CORPORATE SOURCE: Sheffield Lab., Yale Univ.

SOURCE: American Chemical Journal (1911), 45, 568-83

CODEN: ACJOAZ; ISSN: 0096-4085

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.

AB Hydantoin readily condenses with aldehydes, the product may be reduced and then hydrolyzed to the amino acids, thus phenylalanine and tyrosine may be synthesized in 2 operations. Benzalhydantoin, formula (I), was prepared by heating together 20 g. fused NaOAc, 40 cc. glacial AcOH, 10 drops Ac2O and 15 g. BzH. Yield, 80%. Ten g. of (I), 3 g. red P, and 45 cc. HI (d. 1.7) were boiled for 45 mins.; 4-benzylhydantoin (phenylalaninehydantoin) (II), was isolated from the resulting mixture, colorless flat, lancet-shaped crystals from alc., or H2O, m. 190°. Phenylalanine and KCNO warmed with dilute HCl also yield (II). When reduced with Al-Hg (I) yields an aluminum compound, 4-benzylhydantoic acid and (II). The acid was also obtained by hydrolyzing (II) with NaOH, on warming with dilute HCl (II) is regenerated. A 71% yield of phenylalanine was obtained by reducing (II) in presence of red P with HI. On boiling 5 g. of (II) with 33 g. Ba(OH)2 in 30 cc. H2O for 5 h. a 23.7% yield of benzylhydantoin and a 73% yield of phenylalanine was obtained. Anisalhydantoin brownish yellow prisms from alc., m. 243-4° was obtained from hydantoin and the aldehyde. It is not hydrolyzed by cold alkali, but when warmed gives p-methoxyphenylpyruvic acid. On adding Br to anisalhydantoin in glacial AcOH, bromoanisylhydantoin was obtained, long light yellow crystals from alc., m. 247°. Anisalhydantoin (5 g.), red P (2 g.) and HI (25 cc.) were boiled under a reflux condenser for 4 h., then 6-8 g. I added and the boiling continued for 5 h., an 89.1% yield of tyrosine was obtained. When the hydantoin (5 g.), red P (1.5 g.) and HI (25 cc.) were boiled for 6 h. 76% tyrosine and 20% tyrosine hydantoin (4-p-hydroxybenzylhydantoin) was obtained, by varying the conditions an 83% yield of the latter was obtained. It appears as small, colorless prisms from H2O, m. 257-8°, it gives an intense Millon reaction (cf. J. Physiol. Chemical, 6, 253). Tyrosinohydantoic acid (4-p-hydroxybenzylhydantoic acid) prisms m. 172° may be prepared by boiling the hydantoin with dilute alkali, but it is best prepared from tyrosine and KCNO. Tyrosinehydantoin (4.8 g.) and Ba(OH)2 (30 g.) in 30 cc. H2O were boiled for 6 h., a 79.6% yield of tyrosine was obtained. Piperonal condenses with hydantoin in presence of glacial AcOH and AcONa giving an 86% yield of piperonalhydantoin, yellow prisms from alc. on


AcOH, m. 245°. Furfuralhydantoin, yield, 76%, dark yellow prisms from alc., m. 232°, dissolves in concentrate H₂SO₄, giving an intense green color. 3,5-Dichloro-p-hydroxybenzalhydantoin, yield, 73%, light yellow long slender needles from alc. + AcOH, m. 300° (decompose). Ammonium salt, orange. p-Nitrobenzalhydantoin, lemon-yellow prisms from H₂O, m. 254° (decompose), dissolves in N KOH to blood-red solution. Anisaldehyde condenses with 1-phenylhydantoin forming 1-phenylanisalhydantoin, yellow prisms from alc., m. 251°, yield, 80%. Under similar conditions the aldehyde could not be condensed with 3-phenyl- or 1,3-diphenylhydantoin. The latter is best prepared from phenylisocyanate and phenylglycine.

IT 52036-17-6P, Hydantoin, 5-piperonylidene-
RL: PREP (Preparation)

(preparation of)

RN 52036-17-6 CAPLUS

CN 2,4-Imidazolidinedione, 5-(1,3-benzodioxol-5-ylmethylene)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

=> d ibib abs hitstr 351-357

L5 ANSWER 351 OF 358 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1952:22823 CAPLUS

DOCUMENT NUMBER: 46:22823

ORIGINAL REFERENCE NO.: 46:3885e-h

TITLE: Substances having influence on the photographic process. III. Relation of chemical constitution with the fog inhibiting action of thioimidazole compounds

AUTHOR(S): Oba, Seichi; Koseki, Yasuo; Fukawa, Kihachi

SOURCE: J. Soc. Sci. Phot. Japan (1951), 13(No. 3), 33-8

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable


AB Three species of thioimidazole and 20 species of oxothioimidazole compds. were synthesized and the relation between the chemical structure and the fog inhibiting action was compared. 2(3H)-imidazolethione (I) 218-20°, 2,3-dihydro-2-thio-5-imidazolepropionic acid 197-9°, 5-isobutyl-2(3H)-imidazolethione 172-4°, 2-thiohydantoin 225-30°, 1-acetyl-2-thiohydantoin 174°, 3-methyl-2-thiohydantoin 203-5°, 3-allyl-2-thiohydantoin 250°, 3-allyl-5-methyl-2-thiohydantoin 213°, 3-allyl-5,5-dimethyl-2-thiohydantoin 226°, 3-allyl-5-ethyl-2-thiohydantoin 210°, 3-allyl-5-isobutyl-2-thiohydantoin 210-11°, 3-phenyl-2-thiohydantoin 210°, 4-oxo-3-phenyl-2-thio-5-imidazolidinepropionic acid 130-3°,

3-phenyl-5-isobutyl-2-thiohydantoin 176-8°,
 5-isobutyl-2-thiohydantoin 172°,
 1-acetyl-5-isobutyl-2-thiohydantoin 132°,
 5-ethylidene-2-thiohydantoin 255-8°, 5-butyldiene-2-thiohydantoin
 160-3°, 5-benzylidene-2-thiohydantoin,
 5-o-hydroxybenzylidene-2-thiohydantoin 250°,
 5-(3,4-methylenedioxybenzylidene)-2-thiohydantoin 285°,
 5-cinnamylidene-2-thiohydantoin 230° and
 5-(p-dimethylaminobenzylidene)thiohydantoin 250-5° (m.ps. given)
 were studied. Thioimidazole derivs. are effective in both neutral and NH3
 solution, but oxothioimidazole derivs. are effective only in neutral solution

I

is most effective.


IT 28824-65-9, Hydantoin, 5-piperonylidene-2-thio-
 (as photographic fog inhibitor)
 RN 28824-65-9 CAPLUS
 CN 4-Imidazolidinone, 5-(1,3-benzodioxol-5-ylmethylene)-2-thioxo- (CA INDEX
 NAME)



L5 ANSWER 352 OF 358 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1949:50545 CAPLUS
 DOCUMENT NUMBER: 43:50545
 ORIGINAL REFERENCE NO.: 43:9046d-h
 TITLE: Synthesis of N-(3-methoxybenzyl)-N-methyl-3-methoxy-
 4,5-methylenedioxyphenethylamine
 AUTHOR(S): Hamlin, K. E.; Weston, Arthur W.
 SOURCE: Journal of the American Chemical Society (1949), 71,
 2210-12
 CODEN: JACSAT; ISSN: 0002-7863
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 43:50545
 AB Oxidation of isomyristicin with H2O2 and V2O5 yields 57%
 myristicinaldehyde, 5,3,4-MeO(CH2O2)C6H2CHO (I); the rhodanine derivative on
 hydrolysis gives a quant. yield of
 α -thiono- β -(3-methoxy-4,5-methylenedioxyphenyl)propionic acid,
 m. 156-8°, and, on further crystallization, 227-8° (decomposition)
 [Redemann, et al., C.A. 43, 2212a, gave 153-4° (decomposition)]; NH2OH
 gives 92% of the α -oximino derivative, m. 159-60° (R. gave
 150-1°). I (9 g.), 3 g. MeNO2, 0.43 g. AmNH2, and 60 cc. 95% EtOH,
 kept 1 week at room temperature, give 90%
 3-methoxy-4,5-methylenedioxy- β -nitrostyrene (II), yellow, m.
 210-11°; reduction of 6 g. II in ether with 4.2 g. LiAlH4 in 200
 cc. ether (added during 24 hrs.) gives 49% 3,4,5-MeO(CH2O2)C6H2CH2CH2NH2
 (III), b1 132°, nD25 1.5507. III (8.5 g.) and 6 g. 3-MeOC6H4CHO in
 50 cc. EtOH, refluxed 0.5 hr., give 82%
 N-(3-methoxybenzylidene)-3-methoxy-4,5-methylenedioxyphenethylamine (IV),

b0.75 215°, m. 39-41°; 10.5 g. V in 50 cc. MeOH, reduced over 1.5 g. Raney Ni at 2 atmospheric, gives 80% of the N-(3-methoxybenzyl) analog (V), b0.75 210-15°, nD25 1.5726; oxalate, m. 222° (decomposition); 6 g. V and 60 cc. anhydrous HCO2H, refluxed 48 hrs., give 5 g. of the N-formyl derivative (VI), orange oil (a small sample crystallized and m. 88-90°); reduction of VI with LiAlH4 in ether gives 87% N-(3-methoxybenzyl)-N-methyl-3-methoxy-4,5-methylenedioxyphenethylamine, b0.5 198-200°, nD25 1.5643 (HCl salt, m. 170-1°); this is different from α -fagarine (C.A. 29, 2298.7).

IT 874500-51-3P, Rhodanine, 5-(5-methoxypiperonylidene)-
 RL: PREP (Preparation)
 (preparation of)
 RN 874500-51-3 CAPLUS
 CN 4-Thiazolidinone, 5-[(7-methoxy-1,3-benzodioxol-5-yl)methylene]-2-thioxo-
 (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)


L5 ANSWER 353 OF 358 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1949:10936 CAPLUS
 DOCUMENT NUMBER: 43:10936
 ORIGINAL REFERENCE NO.: 43:22114,2212a-c
 TITLE: Synthesis of certain compounds related to
 α -fagarine
 AUTHOR(S): Redemann, C. Ernst; Wisegarver, Burnett B.; Icke,
 Roland N.
 SOURCE: Journal of Organic Chemistry (1948), 13, 886-90
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable

AB Isomyristicin, formed by refluxing myristicin with EtOH-KOH, was oxidized to myristicinaldehyde (I), m. 131-2°, in 41% yield. I reacted with rhodanine in AcONa and AcOH at boiling temperature, forming 5-myristicylidenerhodanine (II), m. 254-5°.


α -Mercapto- β -(3,4-methylenedioxy-5-methoxyphenyl)propionic acid (III), prepared by treating II with 4 N NaOH, then acidifying with HCl, m. 153-4°; oxime (IV), prepared with NH2OH, m. 150-1°. IV + Ac2O formed (3,4-methylenedioxy-5-methoxyphenyl)acetone (V), m. 89-90°, from which H reduction with Raney Ni in MeOH/NH3 solution gave homomyristicicylamine (VI). Hydrogenation of a mixture of VI and m-MeOC6H4CHO over the Adams catalyst, PtO2, gave N-(m-methoxybenzyl)homomyristicicylamine-HCl (VII), m. 142-3°. VII was treated successively with Me2SO4, NaOH, HONO, then NaOH again, to form N-methyl-N-(m-methoxybenzyl)homomyristicicylamine. The action of HCHO followed by HCl on the free base from VII caused cyclization. The free base from VII also reacted with Ac2O to form

2-(m-methoxybenzyl)-6,7-methylenedioxy-8-methoxy-1,2,3,4-tetrahydroisoquinoline, m. 189-91°. The base from the aqueous filtrates from the cyclization, treated with Ac₂O, gave 2-(m-methoxybenzyl)-6-methoxy-7,8-methylenedioxy-1,2,3,4-tetrahydroisoquinoline, m. 120-5°.

IT 874500-51-3P, Rhodanine, 5-(5-methoxypiperonylidene)-
 RL: PREP (Preparation)
 (preparation of)
 RN 874500-51-3 CAPLUS
 CN 4-Thiazolidinone, 5-[(7-methoxy-1,3-benzodioxol-5-yl)methylene]-2-thioxo-
 (CA INDEX NAME)



L5 ANSWER 354 OF 358 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1932:57877 CAPLUS
 DOCUMENT NUMBER: 26:57877
 ORIGINAL REFERENCE NO.: 26:5929b-d
 TITLE: Amino acids. III. Piperonylalanine
 AUTHOR(S): Deulofeu, Venancio; Mendive, Jorge
 SOURCE: Z. physiol. Chem. (1932), 211, 1-4
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB cf. C. A. 26, 4603. N-Benzoylpiperonylalanine, m. 181-2°, was prepared by Na-Hg reduction of the corresponding aminoacrylic acid, and saponified by Ba(OH)₂ hydrolysis to piperonylalanine (I). m. 262-4° (PhNCO derivative m. 192-3°). Piperonal-2-thiohydantoin, m. 288-90°, resulted from direct condensation of piperonal and thiohydantoin with Ac₂O + AcONa, and was converted by treatment with ClCH₂CO₂H into piperonalhydantoin, which in turn was reduced by Na-Hg to piperonylhydantoin, m. 182-3°. Hydrolysis of the latter by Ba(OH)₂ gave I. Condensation of piperonal with diketopiperazine in the presence of Ac₂O-AcONa yielded dipiperonaldiketopiperazine, infusible at 300°, which was reduced by Zn-AcOH to dipiperonyldiketopiperazine, m. 251-2°, and the latter hydrolyzed by Ba(OH)₂ to I.
 IT 28824-65-9P, Hydantoin, 5-piperonylidene-2-thio-
 RL: PREP (Preparation)
 (preparation of)
 RN 28824-65-9 CAPLUS
 CN 4-Imidazolidinone, 5-(1,3-benzodioxol-5-ylmethylene)-2-thioxo- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L5 ANSWER 355 OF 358 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1932:17036 CAPLUS

DOCUMENT NUMBER: 26:17036

ORIGINAL REFERENCE NO.: 26:1790a-d

TITLE: Dyes derived from thiohydantoin. II

AUTHOR(S): Namjoshi, Vishnu Ganesh; Dutt, Sikkhibhushan

SOURCE: Journal of the Indian Chemical Society (1931), 8,
241-6

CODEN: JICSAH; ISSN: 0019-4522

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB cf. C. A. 25, 3839. Thiohydantoin (I) was condensed with a series of aromatic aldehydes in AC20 to form acetylated benzal derivs. The Ac group was assumed to be on the enol form of the CO group because it was comparatively stable and the Ac derivs. were all more highly colored than the compds. resulting from their hydrolysis. Reversion of the free enol form to the keto form following KOH hydrolysis could be followed in some instances by the change in m. p. Though the acetylated benzal compds. were sparingly soluble in most ordinary solvents, the deacetylated keto forms were more soluble and were freely soluble in NaOH. They are dyes for wool,

silk

and cotton. The following derivs. of I were prepared: benzal, m. 259° (mono-Ac derivative, m. 260°), o-, m- and p-nitrobenzal, m. 249°, 257° and 266°, resp. (mono-Ac derivs., m. 241°, 263° and 270°, resp.), o-, m- and p-hydroxybenzal, m. 231°, 256° and 270°, resp. (di-Ac derivs., m. 237°, 250° and 265°, resp.), m- and p-benzal, both m. above 285° (di-Ac derivs., both m. above 285°), 3,5-dihydroxybenzal, m. 210° (tri-Ac derivative, m. 240°), p-methoxybenzal, m. 255° (mono-Ac derivative, m. 265°), 3,4-methylenedioxybenzal, m. 283° (mono-Ac derivative, m. 275°), vanillal, m. 240° (di-Ac derivative, m. 261°), cinnamal, m. 260° (mono-Ac derivative, m. 267°), p-dimethylaminobenzal, m. 252° (mono-Ac derivative, m. 272°), and 2,3-thiocarbamidoquinoline, m. 213°. All of the above are tabulated with their crystalline appearance, wave length of absorption maxima and shade which the deacetylated compds. dye wool and silk. The shades range from yellow to orange-red.


IT 28824-65-9P, Hydantoin, 5-piperonylidene-2-thio-

RL: PREP (Preparation)

(preparation of)

RN 28824-65-9 CAPLUS

CN 4-Imidazolidinone, 5-(1,3-benzodioxol-5-ylmethylene)-2-thioxo- (CA INDEX
NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L5 ANSWER 356 OF 358 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1917:5513 CAPLUS

DOCUMENT NUMBER: 11:5513

ORIGINAL REFERENCE NO.: 11:1137h-1,1138a-h

TITLE: Rhodanines, parabanic acids and related compounds

AUTHOR(S): Stieger, Karl H.

CORPORATE SOURCE: Lab. of R. Andreasch, Graz

SOURCE: Monatshefte fuer Chemie (1916), 37, 635-58

CODEN: MOCMB7; ISSN: 0026-9247

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.

AB cf. C. A. 6, 3422. To complete the series of substituted rhodanines the isoamyl series are described. Notation I is used.

γ -Isoamylrhodanine was prepared according to Miolati and v. Braun (Ber. 35, 3387), clear, thick oil, b14 200°. The condensation products were prepared in glacial AcOH by heating with an equivalent amount for 0.5-1 hr. under reflux. β -Benzal- γ -isoamylrhodanine, C15H17ONS2, woolly needles of light Cd-yellow color from alc., m. 105°. β -o-Hydroxybenzal- γ -isoamylrhodanine, C15H17O2NS2, dark Cr yellow needles from 50% alc., m. 175°. β -p-Hydroxybenzal- γ -isoamylrhodanine, dark yellow needles from alc., m. 161°. β -p-Methoxybenzal- γ -isoamylrhodanine, C16H19O2NS2, long, light Cr-yellow prismatic needles, m. 116°, from alc. β -p-Nitrobenzal- γ -isoamylrhodanine, C15H16O3N2S2, yellow, nearly quadratic rhombic tables, from acetone, m. 163°. β -Dimethyl-p-aminobenzal- γ -isoamylrhodanine, C17H22ON2S2, carmine-red rhombic crystals, from alc., m. 154°. β -Methylene-3,4-dioxybenzal- γ -isoamylrhodanine, yellow needles from alc., m. 111°. Isoamylthioparabanic acid (II), prepared by the action of (CN)2 on C5H11NHC(S)NH2 with subsequent warming with HCl, yellow, compact pointed needles from alc., m. 125°. The aqueous solution is slightly acid. Desulfurized with AgNO3, isoamylparabanic acid is formed, long white needles from H2O, m. 106°. Isoamylphenylthioparabanic acid, light yellow, fine needles from alc., m. 94°. Isoamylphenylparabanic acid, felt of white needles from dilute alc., m. 85°. Diisoamylthioparabanic acid, could not be obtained crystalline. The desulfurized product also would not crystalline. Di-p-hydroxyphenylthioparabanic acid, felt of yolk-yellow needles from dilute alc., which do not m. 360°. Di-p-hydroxyphenylparabanic acid, fine, short needles, which do not m. 360°. Isoamyl-p-tolylthiourea, from iso-AmNCS and p-MeC6H4NH2, compact, prismatic needles from hot alc., m. 217°. Isoamyl-p-tolylthioparabanic acid, citron-yellow, fine needles, m. 111°. Isoamyl-p-tolylparabanic acid, long, thin needles, m.


90°. An alc. solution of PhNCS and Et₂NH gave only an oil. When this was treated with (CN)₂ and then warmed with HCl, a non-cryst. sirup remained. When distilled under 15 mm. sulfocarbaniide distilled over 142°. This indicates that the (CN)₂ reacted with the urea complex. β-m-Nitrobenzal mustard oil acetic acid, prepared from 3 g. mustard oil acetic acid and 3.9 g. m-O₂NC₆H₄CHO and 1 g. NaOH, fine, light yellow powder from AcOH, sinters 200°, m. 277° (decomposition). β-m-Nitrobenzal isothiohydantoin, from equimol. amts. of the components in NaOH and subsequent heating with AcOH, yellow needles, sinters 200°, m. 260° (decomposition). The 1st product of the condensation is m-nitrobenzal isothiohydantoinic acid, HN:C(NH₂)SC(CO₂H):CHC₆H₄NO₂, which loses H₂O upon warming with AcOH or BzOEt. β-Methylene-3,4-dihydroxybenzal isothiohydantoin, fine yellow plates from AcOH, decomp. about 215°. The same compds. may be prepared by the use of AcOH and AcONa. Di-p-hydroxyphenylthiohydantoin, prepared by heating mol. amts. of the dry components on the H₂O bath, long rhombic columns from dilute alc., m. 236°. It gives the characteristic purple-red thioglycolic acid reaction with FeCl₃ and NH₃. Attempts to condense thiodiglycolic acid with aldehydes gave only brown smears. 3,3'-Thiodicumarinyl (III) was obtained by the action of 5 g. S(CH₂CO₂H)₂ and 10 g. HOC₆H₄CHO in AcOH containing 15 g. Ac₂O and 3-4 g. AcONa, the mixture being boiled for 3 for hrs., which forms yellowish white hair-like needles from PhNH₂, m. 288-9°. When heated to a certain point, the substance decomp. explosively.

IT 300829-97-4P, 4-Thiazolidone, 2-imino-5-piperonylidene-
RL: PREP (Preparation)

(preparation of)

RN 300829-97-4 CAPLUS

CN 4(5H)-Thiazolone, 2-amino-5-(1,3-benzodioxol-5-ylmethylene)- (CA INDEX NAME)



L5 ANSWER 357 OF 358 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1914:10607 CAPLUS
DOCUMENT NUMBER: 8:10607
ORIGINAL REFERENCE NO.: 8:1573c-1,1574a
TITLE: Isothiohydantoin and related compounds
AUTHOR(S): Kucera, Franz
CORPORATE SOURCE: Graz
SOURCE: Monatshefte fuer Chemie (1914), 35, 137-57
CODEN: MOCMB7; ISSN: 0026-9247
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.

AB Phenylrhodanine and C₆H₄(CO)₂O b. with AcOH and AcONa a short time gave β-phthalyl-v-phenylrhodanine (I), deep yellow needles, m. 234°. v-Phthalylrhodanine, thin leaflets with the color of pulverized K₂Cr₂O₇, m. 245° (decompose); from AcOH it forms brownish yellow scales with a bronze luster. To establish the constitution the

action of PhNHNH2 was tried on the latter but this was decomposed, forming phthalylphenylhydrazine, p-Dimethylominoanilino-v-phenylrhodanine, from phenylrhodanine mid Me3NC2H4NO dark brownish red powder, m. unsharp at 206°. β -Methylenedioxybenzalmustard oil acetic acid (II), from piperonal and mustard oil acetic acid, with the use of AcONa in a yield of 65%, fine, orange needles, m. 249°. Heated with alc. KOH in an attempt to split the product, the potassium salt was obtained in fine, hair-like crystals, do not m. 295°.


β -Benzaldisothiohydantoin, prepared from isothiohydantoin and BzH with NaOH, slightly yellow leaflets, sinters 280°. Sodium salt, white, flat needles, hydrolyzed by H2O. Ethylthiohydantontion upon oxidation with KClO2 and HCl gave HO2CH2SO3H and EtNHCONH2 (probably resulting from the action of the mineral acid upon EtNHCONHCOCH2SO3H).

Ethylenedi-v-monophenylthiurea, prepared by heating mol. amts. of C2H4Br2 and PhNHC(SH):NH at 125° and isolated as the hydrobromide, short needles from alc. m. 220° (decompose). Picrate, fine, hair-like crystals, m. 201°. The free base is quite unstable; it trysts. from alc. in quadratic tables which soon decompose, forming offensive smelling products. Upon oxidation with Ba(ClO3)2 and HCl it gives C2H6(SO3H)3 and PhNHCONH2. Ethylenedi-v-ethylphenylthiurea, C2H4[SC(:NEt)NHP]2. thick prisms, m. 204-5° (decompose).


n-Benzyl-v-phenyldihydrothiohydantoin (III), by heating equimol. amts. of PhNHC(SH):NCH2Ph and C2H4Br2 at 165° until the evolution of HBr ceases, amorphous product. Its structure was shown by oxidation to benzylphenyltaurocarbaminic acid: anhydride (IV), long needles from alc., m. 139-40°. Hydrolyzed with alc. Ba(OH)2, PhCH2NH2 was isolated as the platinate. n-Phenyl-v-p-tolyldihydrothiohydantoin (cf. Will and Bielschowsky, Ber., 15, 1309), from C2H4Br2 and PhN: C(SH)NC7H7 by heating to 170° for 2.5 hrs., leaflets m. 92°. Oxidized with Ba(ClO3)2 and HCl it gives a compound C16H16N2O3S, needles, m. 181°.

Saponified with Ba(OH)2 this gives PhNH2 and p-tolytaurine.

IT 6318-41-8P, 2,4(3,5)-Thiazolidinedione, 5-piperonylidene-128061-50-7P, 2,4(3,5)-Thiazolidinedione, 5-piperonylidene-, potassium salt
 RL: PREP (Preparation)
 (preparation of)
 RN 6318-41-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-(1,3-benzodioxol-5-ylmethylene)- (CA INDEX NAME)



RN 128061-50-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-(1,3-benzodioxol-5-ylmethylene)-, potassium salt (1:1) (CA INDEX NAME)




● K

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

=> 15 and inflammation
227689 INFLAMMATION
L6 33 L5 AND INFLAMMATION

=> d ibib abs hitstr 1-33

L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1399894 CAPLUS
DOCUMENT NUMBER: 152:51198
TITLE: Discovery of (Z)-5-(4-Methoxybenzylidene)thiazolidine-2,4-dione, a Readily Available and Orally Active Glitazone for the Treatment of Concanavalin A-Induced Acute Liver Injury of BALB/c Mice
AUTHOR(S): Luo, Youfu; Ma, Liang; Zheng, Hao; Chen, Lijuan; Li, Rui; He, Chunmei; Yang, Shengyong; Ye, Xia; Chen, Zhizhi; Li, Zicheng; Gao, Yan; Han, Jing; He, Gu; Yang, Li; Wei, Yuquan
CORPORATE SOURCE: State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, Peop. Rep. China
SOURCE: Journal of Medicinal Chemistry (2010), 53(1), 273-281
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI




I

AB A large amount of evidence suggests that monocytes/macrophages infiltration is implicated in a variety of inflammatory diseases including acute liver injury. Monocyte chemoattractant protein 1 (MCP-1) plays a crucial role in the process of macrophages recruitment. We herein presented a small-mol. library and a feasible quick screening method of evaluating potency of inhibition of chemotaxis of RAW264.7 cells stimulated by MCP-1. Fifty-three small mols. were synthesized and screened, and four compds. (2g, 2h, 4f, and 6h) showed inhibitory effects with IC50 values range from 0.72 to 20.47 μ M, with compound 4f (I) being the most efficient. Further in vivo studies demonstrated that oral administration of 2g, 2h, 4f, or 6h decreases, most significantly for 4f, the serum levels of alanine aminotransaminase (ALT) and aspartate aminotransaminase (AST) in ConA-induced acute liver injury BALB/c mice. Histopathol. evaluation liver sections confirmed 4f as a potent, orally active compound for hepatoprotective effects against ConA-induced acute liver injury in BALB/c mice.

IT 648450-29-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methoxybenzylidene thiazolidinediones for treatment of liver injury)

RN 648450-29-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-(6-quinoxalinylmethylene)- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:1247587 CAPLUS
 DOCUMENT NUMBER: 151:491153
 TITLE: Preparation of 5-(quinoxalin-6-ylmethylene)thiazolidine-2,4-dione for treatment of inflammatory diseases
 INVENTOR(S): Chen, Lijuan; Wei, Yuquan; Luo, Youfu; Wu, Xiaohua
 PATENT ASSIGNEE(S): Sichuan University, Peop. Rep. China
 SOURCE: Faming Zhuanli Shengqing Gongkai Shuomingshu, 20pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101550135	A	20091007	CN 2008-10045968	20080902
PRIORITY APPLN. INFO.:			CN 2008-10045968	20080902
OTHER SOURCE(S):		CASREACT 151:491153		

AB The present invention relates to the preparation of 5-(quinoxalin-6-ylmethylene)thiazolidine-2,4-dione (AS-605240) and the use

of the title compound to prepare medical agents for the prevention and treatment of inflammatory diseases such as myocarditis, hepatitis, colitis, or pancreatitis. The preparation method comprises (A) reacting 3,4-diaminotoluene with glyoxal in water in the presence of an inorg. alkali at 70 - 120 °C for 0.5 - 3 h to obtain 6-methylquinoxaline; (B) bromination of 6-methylquinoxaline in halogenated hydrocarbon in the presence of light, initiator, and a bromination reagent to obtain 6-bromomethylquinoxaline; (C) reacting 6-bromomethylquinoxaline in the presence of an inorg. alkali in DMSO to obtain 6-quinoxalinecarboxaldehyde; (D) reacting 6-quinoxalinecarboxaldehyde and 2,4-dioxothiazolidine in the presence of β -alanine in acetic acid to obtain the title compound. The therapeutic value of AS-605240 in the treatment of Con A induced hepatic injury and other inflammatory diseases was confirmed in pharmacol. expts. (data given).

IT 648450-29-7P, AS 605240


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of

5-(quinoxalin-6-ylmethylene)thiazolidine-2,4-dione for treatment of inflammatory diseases)

RN 648450-29-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-(6-quinoxalinylmethylene)- (CA INDEX NAME)



L6 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:553103 CAPLUS

DOCUMENT NUMBER: 150:506989

TITLE: Phosphatidylinositol-3 kinase (PI3K) inhibitors for treatment of diseases by inhibition of type I interferon (IFN) production

INVENTOR(S): Barrat, Franck; Guiducci, Cristiana; Soumelis, Vassili

PATENT ASSIGNEE(S): Dynavax Technologies Corp., USA; Institut Curie; Institut National de la Sante et de la Recherche Medicale (INSERM)

SOURCE: PCT Int. Appl., 65pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009058361	A1	20090507	WO 2008-US12372	20081030
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,			

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20090131512 A1 20090521 US 2008-290654 20081030
 PRIORITY APPLN. INFO.: US 2007-1093P P 20071031
 US 2008-10674P P 20080110


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides methods for decreasing type I interferon (IFN) production by human plasmacytoid dendritic cells in response to TLR activation. In another aspect, the invention provides methods of treating an individual with a disease caused or characterized by the presence of pathogenic type I IFN, by administering to the individual a composition comprising a phosphatidylinositol-3 kinase (PI3K) inhibitor in an amount sufficient to inhibit pathogenic type I IFN production in said individual. In certain embodiments, the PI3K inhibitor is specific for the delta subunit of PI3K. The disease characterized or caused by increased production of type I IFN may be, for example, an autoimmune disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriasis or Sjogren's disease.

IT 648449-76-7, AS 604850
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phosphatidylinositol-3 kinase (PI3K) inhibitors for treatment of diseases via inhibition of type I interferon (IFN) production)

RN 648449-76-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:425227 CAPLUS

DOCUMENT NUMBER: 150:398530

TITLE: Preparation of carbazole-rhodanine derivatives as up-regulating TFF agents and their preparation, pharmaceutical compositions, and use in the treatment of diseases associated with TFF production

INVENTOR(S): Kuroda, Takeshi; Yamauchi, Takahito; Shinohara, Tomokazu; Oshima, Kunio; Kitajima, Chiharu; Nagao, Hitoshi; Ishiyama, Hironobu; Ota, Kazuhide; Takano, Masaaki; Sumida, Takumi

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 95pp.

DOCUMENT TYPE: CODEN: JKXXAF
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1 Japanese
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2009073766	A	20090409	JP 2007-244630	20070921


PRIORITY APPLN. INFO.: JP 2007-244630
 OTHER SOURCE(S): MARPAT 150:398530
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Carbazole-rhodanine compds. of formula [I; wherein A is a bond, lower alkylene and lower alkylidene; X is O and S; R1 is H, lower (un)substituted alkyl, (un)substituted lower alkylphenyl, lower cycloalkylalkyl, Ph, etc; R2 is lower alkoxy, phenyl-(un)substituted lower alkyl, carboxy lower alkoxy, lower alkoxycarbonyl lower alkoxy, and hydroxy; R3 is a H, (un)substituted lower alkyl, lower cycloalkylalkyl, lower carboxyalkyl, etc.; n is 0-7; and their salts thereof] are claimed. Compds. of formula I induce the production of trefoil factor family 2 (TFF2), and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, eye diseases, cancers, and wounds. Example compound II was prepared by reductive aldol condensation of 9-benzenesulfonyl-9H-carbazole-3-carbaldehyde with rhodanine. All the invention compds. were evaluated for their up-regulating TFF2 activity. From the assay, it was determined that II exhibited TFF2 production promoting activity of 1000% or higher at 10⁻⁶ M concentration


IT 953795-37-4P 953795-48-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of carbazole-rhodanine derivs. as up-regulating TFF agents useful in treatment of diseases associated with TFF production)

RN 953795-37-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-(2,2,2-trifluoroacetyl)-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)



RN 953795-48-7 CAPLUS

CN 4-Thiazolidinone, 2-thioxo-5-[[9-(2,2,2-trifluoroacetyl)-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




IT 953796-27-5P 953797-10-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of carbazole-rhodanine derivs. as up-regulating TFF agents useful in treatment of diseases associated with TFF production)


RN 953796-27-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(9-benzoyl-9H-carbazol-3-yl)methylene]- (CA INDEX NAME)



RN 953797-10-9 CAPLUS

CN 4-Thiazolidinone, 5-[(9-benzoyl-9H-carbazol-3-yl)methylene]-2-thioxo- (CA INDEX NAME)




IT	503826-94-6P	890999-51-6P	953796-08-2P
	953796-10-6P	953796-11-7P	953796-12-8P
	953796-13-9P	953796-14-0P	953796-15-1P
	953796-16-2P	953796-17-3P	953796-18-4P
	953796-19-5P	953796-20-8P	953796-21-9P
	953796-22-0P	953796-23-1P	953796-24-2P
	953796-25-3P	953796-26-4P	953796-28-6P
	953796-29-7P	953796-30-0P	953796-31-1P
	953796-32-2P	953796-33-3P	953796-34-4P
	953796-35-5P	953796-36-6P	953796-37-7P
	953796-38-8P	953797-06-3P	953797-07-4P
	953797-08-5P	953797-09-6P	953797-11-0P
	953797-12-1P	953797-13-2P	953797-14-3P
	953797-15-4P	953797-16-5P	953797-17-6P
	953797-18-7P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of carbazole-rhodanine derivs. as up-regulating TFF agents useful in treatment of diseases associated with TFF production)


RN 503826-94-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(9-ethyl-9H-carbazol-3-yl)methylene]- (CA INDEX NAME)




RN 890999-51-6 CAPLUS

CN 4-Thiazolidinedione, 5-[(9-ethyl-9H-carbazol-3-yl)methylene]-2-thioxo- (CA INDEX NAME)




RN 953796-08-2 CAPLUS


CN 2,4-Thiazolidinedione, 5-[(9-(phenylmethyl)-9H-carbazol-3-yl)methylene]- (CA INDEX NAME)




RN 953796-10-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[4-(2-pyridinyl)phenyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-11-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[4-(3-pyridinyl)phenyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)



RN 953796-12-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[4-(3-thienyl)phenyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-13-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[4-(4-nitrophenyl)methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-14-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(4-methylphenyl)sulfonyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-15-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[[1,1'-biphenyl]-4-ylsulfonyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-16-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(4-chlorophenyl)sulfonyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-17-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-18-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-1-methoxy-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-19-5 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-5,8-dimethyl-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)



RN 953796-20-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-1-methyl-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-21-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-8-methyl-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-22-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-8-methoxy-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-23-1 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-1,8-dimethyl-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-24-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-1,8-dimethoxy-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)



RN 953796-25-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-(9H-carbazol-3-ylmethylene)- (CA INDEX NAME)




RN 953796-26-4 CAPLUS
 CN 9H-Carbazole-9-carboxylic acid, 3-[(2,4-dioxo-5-thiazolidinylidene)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 953796-28-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(6-chloro-3-pyridinyl)methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-29-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(6-phenyl-3-pyridinyl)methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-30-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[[6-(3-thienyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-31-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[[6-(2-chlorophenyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-32-2 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[9-[[6-(2-thienyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-33-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[6-(3-furanyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-34-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-([2,3'-bipyridin]-5-ylmethyl)-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-35-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-([2,2'-bipyridin]-5-ylmethyl)-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-36-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-(2-quinolinylmethyl)-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-37-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[6-(4-morpholinyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-38-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[6-(5-chloro-2-thienyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953797-06-3 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-(phenylmethyl)-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-07-4 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-[[4-(2-pyridinyl)phenyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 953797-08-5 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-[[4-(3-thienyl)phenyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-09-6 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-[(4-methylphenyl)sulfonyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-11-0 CAPLUS

CN 4-Thiazolidinone, 5-[[9-[[6-(3-thienyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-12-1 CAPLUS

CN 4-Thiazolidinone, 5-[[9-[[6-(3-thienyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-13-2 CAPLUS

CN 4-Thiazolidinone, 5-[[9-[[6-(2-chlorophenyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-14-3 CAPLUS


CN 4-Thiazolidinone, 5-[[9-[[6-(2-thienyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-15-4 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-[[6-(3-furanyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-16-5 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-[(2,2'-bipyridin)-5-ylmethyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 953797-17-6 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-(2-quinolinylmethyl)-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-18-7 CAPLUS
 CN 4-Thiazolidinone, 5-[[[9-[[6-(4-morpholinyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




L6 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:239019 CAPLUS
 DOCUMENT NUMBER: 150:260183
 TITLE: Preparation of thiazolidine compounds as PI3K inhibitors
 INVENTOR(S): Noronha, Glenn; Mak, Chi Ching; Palanki, Moorthy
 PATENT ASSIGNEE(S): Targeen Inc., USA
 SOURCE: PCT Int. Appl., 48pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009026346	A1	20090226	WO 2008-US73684	20080820
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			US 2007-956831P	P 20070820
			US 2007-977147P	P 20071003
			US 2008-20786P	P 20080114
			US 2008-22217P	P 20080118
			US 2008-51424P	P 20080508
OTHER SOURCE(S):	MARPAT 150:260183			


GI



I




II



III


AB Title compds. I and II [Z = S or O; X = S, O or NR₁₂; R₂ = H or alkyl; R₃ and R₄ independently = H, halo, hydroxyalkyl, alkoxy, carboxy, etc.; or R₂ and R₃, or R₃ and R₄, form, together with the carbon atoms to which they are attached, a 5 or 6 membered carbocycle or heterocycle ring; R₁₂ = (un)substituted alkyl, aryl, heterocycle, or cycloalkyl], and their pharmaceutically acceptable salts or N-oxides, are prepared and disclosed. Thus, e.g., III was prepared by reacting 4-(thiophen-2-yl)quinazoline-6-carboxaldehyde (preparation given) with thiazolidine-2,4-dione. The compds. of the invention were tested for their inhibitory activity against the isoforms of PI3-Kinase in enzyme assays, e.g., III exhibited IC₅₀ value of 15 nM against PI3K-γ and 11 nM against PI3K-α, resp. The invention compds. may be used in inflammatory or immune-mediated disorders. The disclosure provides for treating respiratory or ocular disorders, treating arthritis, or may be used to treat cancer.

IT 1119898-99-5P 1121529-06-3P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thiazolidine compds. as PI3K inhibitors)
 RN 1119898-99-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(2-furyl)-6-quinazolinyl]methylene]- (CA INDEX NAME)




RN 1121529-06-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(2-thienyl)-6-quinazolinyl]methylene]-, (5Z)-
(CA INDEX NAME)

Double bond geometry as shown.




IT 1121529-07-4P, 5-[[4-(Benzo[b]thiophen-3-yl)quinazolin-6-yl]methylene]thiazolidine-2,4-dione 1121529-08-5P, (Z)-5-[[4-(Thiophen-3-yl)quinazolin-6-yl]methylene]thiazolidine-2,4-dione 1121529-09-6P, (Z)-5-[[4-(4,5,6,7-Tetrahydrothieno[3,2-c]pyridin-2-yl)quinazolin-6-yl]methylene]thiazolidine-2,4-dione 1121529-10-9P, 5-[[4-[3-(Methyl)thiophen-2-yl]quinazolin-6-yl]methylene]thiazolidine-2,4-dione 1121529-11-0P, 5-[[4-[4-(Methyl)thiophen-3-yl]quinazolin-6-yl]methylene]thiazolidine-2,4-dione 1121529-12-1P, 5-[[4-[5-(3,5-Dimethylisoxazol-4-yl)thiophen-2-yl]quinazolin-6-yl]methylene]thiazolidine-2,4-dione 1121529-23-4P, 5-[[4-(Thiophen-2-yl)quinazolin-6-yl]methylene]thiazolidine-2,4-dione 1121529-24-5P, 5-[[4-(Thiophen-3-yl)quinazolin-6-yl]methylene]thiazolidine-2,4-dione
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolidine compds. as PI3K inhibitors)
RN 1121529-07-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(benzo[b]thien-3-yl)-6-quinazolinyl]methylene]-
(CA INDEX NAME)



RN 1121529-08-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(3-thienyl)-6-quinazolinyl]methylene]-, (5Z)-
(CA INDEX NAME)


Double bond geometry as shown.



RN 1121529-09-6 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-6-quinazolinyl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 1121529-10-9 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-(3-methyl-2-thienyl)-6-quinazolinyl]methylene]- (CA INDEX NAME)




RN 1121529-11-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(4-methyl-3-thienyl)-6-quinazolinyl]methylene]- (CA INDEX NAME)




RN 1121529-12-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[5-(3,5-dimethyl-4-isoxazolyl)-2-thienyl]-6-quinazolinyl]methylene]- (CA INDEX NAME)



RN 1121529-23-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(2-thienyl)-6-quinazolinyl]methylene]- (CA INDEX NAME)



RN 1121529-24-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(3-thienyl)-6-quinazolinyl]methylene]- (CA
 INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:237961 CAPLUS
 DOCUMENT NUMBER: 150:260182
 TITLE: Preparation of thiazolidinone compounds as
 phosphatidylinositol-3-kinase (PI3K) inhibitors
 Noronha, Glenn; Cao, Jianguo; Chow, Chun P.; Renick,
 Joel
 INVENTOR(S): Targegen Inc., USA
 PATENT ASSIGNEE(S): PCT Int. Appl., 102pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009026345	A1	20090226	WO 2008-US73683	20080820
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				


TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:


US 2007-956831P P 20070820
US 2007-977147P P 20071003
US 2008-20786P P 20080114
US 2008-22217P P 20080118
US 2008-51424P P 20080508

OTHER SOURCE(S):
GI

CASREACT 150:260182; MARPAT 150:260182



I



II

AB Title compds. I and II [Z = S or O; X = S, O or NR₁₂; R₂ = H or alkyl; R₃, R₄ = H, halo, alkyl, etc.; R₁₂ = alkyl, aryl, heterocycle, etc.] or pharmaceutically acceptable salts or N-oxides thereof were prepared. For example, reaction of 6-bromo-4-chloroquinoline with tributyl(vinyl)tin followed by oxidative cleavage using OsO₄ and NaIO₄, coupling reaction with 4-methylthiophene-2-boronic acid and condensation with thiazolidine-2,4-dione afforded compound I [X = O; Z = S; R₂, R₄ = H; R₃ = methyl]. In PI3K inhibition assays, I [X = O; Z = S; R₂-R₄ = H] showed the IC₅₀ (nM) of 54 and 65 for PI3K- γ and PI3K- α , resp.

Compds. I and II are claimed useful for the treatment of tumor cell proliferation, pain, etc.

IT 1119898-45-1P, (Z)-5-[[4-(5-Chlorothiophen-2-yl)quinolin-6-yl]methylene]-1,3-thiazolidine-2,4-dione


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of thiazolidinone compds. as phosphatidylinositol-3-kinase (PI3K) inhibitors)

RN 1119898-45-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(5-chloro-2-thienyl)-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



IT 1119898-38-2P, (Z)-5-[[4-(4-Methylthien-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-39-3P,
 (Z)-5-[[4-(3-Methylthien-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-41-7P, (Z)-5-[[4-(Benzo[b]thien-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-42-8P,
 (Z)-5-[[4-(Thien-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-43-9P, (Z)-5-[[4-[5-(Hydroxymethyl)thien-2-yl]quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-44-0P,
 5-[[4-(5-Phenylthien-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-46-2P, 5-[[4-[5-(3,5-Dimethylisoxazol-4-yl)thien-2-yl]quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-47-3P,
 5-[[4-(2,3-Dihydrothieno[3,4-b][1,4]dioxin-5-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-48-4P,
 (Z)-5-[[4-(Benzo[b]thien-3-yl)quinolin-6-yl]methylene]-1,3-thiazolidine-2,4-dione 1119898-49-5P,
 (Z)-5-[[4-(Furan-2-yl)quinolin-6-yl]methylene]-1,3-thiazolidine-2,4-dione 1119898-50-8P, (Z)-5-[[4-(Benzo[b]furan-2-yl)quinolin-6-yl]methylene]-1,3-thiazolidine-2,4-dione 1119898-52-0P,
 1119898-54-2P 1119898-55-3P,
 5-[6-[(2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]thiophene-2-carboxamide 1119898-56-4P,
 2-[6-[(2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]benzo[b]thiophene-6-carbonitrile 1119898-57-5P,
 2-[6-[(2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]benzo[b]thiophene-4-carbonitrile 1119898-58-6P,
 2-[6-[(2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]benzo[b]thiophene-7-carbonitrile 1119898-59-7P,
 (Z)-2-[6-[(2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]-3-methylbenzo[b]thiophene-6-carbonitrile 1119898-60-0P,
 (Z)-2-[6-[(2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]-3-methylbenzo[b]thiophene-4-carbonitrile 1119898-61-1P,
 N-tert-Butyl-3-[5-[6-[(2,4-dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]thien-2-yl]-1-benzenesulfonamide 1119898-62-2P,
 (Z)-5-[[4-(4-Methylthien-3-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-63-3P, (Z)-5-[[4-(4,5,6,7-Tetrahydrothieno[3,2-c]pyridin-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-64-4P, 3-Methyl-5-[6-[(Z)-(2,4-dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]thiophene-2-carbonitrile 1119898-65-5P, (Z)-5-[[4-[5-(3-Isopropylphenyl)thien-2-yl]quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-66-6P,
 (Z)-5-[[4-[5-(3-Isopropoxyphenyl)thien-2-yl]quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-67-7P,

(Z)-5-[4-[5-(2,6-Dimethoxyphenyl)thien-2-yl]quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-68-8P,
 (Z)-5-[6-[2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]-N-(3-hydroxyphenyl)thiophene-2-carboxamide 1119898-69-9P,
 (Z)-5-[6-[2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]-N-(4-hydroxyphenyl)thiophene-2-carboxamide 1119898-70-2P,
 (Z)-5-[6-[2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]-N-[4-(morpholinomethyl)phenyl]thiophene-2-carboxamide 1119898-71-3P,
 (Z)-5-[6-[2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]-N-[3-(morpholinomethyl)phenyl]thiophene-2-carboxamide 1119898-72-4P,
 (Z)-5-[5-[6-[2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]thien-2-yl]methylene]thiazolidine-2,4-dione 1119898-74-6P,
 (Z)-5-[4-[5-(3-Methoxyphenylcarbonyl)thien-2-yl]quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-76-8P,
 5-[4-[5-(3-Hydroxyphenylethynyl)thien-2-yl]quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-77-9P,
 2-Phenylimino-5-[4-(thien-2-yl)quinolin-6-yl]methylene]thiazolidin-4-one 1119898-79-1P, 2-(2-Chloro-5-fluorophenylimino)-5-[4-(thien-2-yl)quinolin-6-yl]methylene]thiazolidin-4-one 1119898-80-4P,
 5-[4-(Thien-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-81-5P, 5-[4-(Benzo[b]thien-3-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-83-7P,
 5-[4-(5-Hydroxymethylthien-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-85-9P, 5-[4-(Furan-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-87-1P,
 5-[4-(Benzofuran-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-89-3P, 5-[4-(5-Chlorothiophen-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-90-6P,
 5-[4-(4-Methylthien-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-91-7P, 5-[6-[2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]thiophene-2-carboxylic acid 1119898-93-9P, 5-[6-[2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]thiophene-2-carboxamide N-[2-(pyrrolidin-1-yl)ethyl] 1119898-95-1P,
 5-[4-(3-Methylthien-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-97-3P, 5-[4-(Benzo[b]thien-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119898-99-5P,
 5-[4-(Furan-2-yl)quinazolin-6-yl]methylene]thiazolidine-2,4-dione 1119899-01-2P, 5-[4-[5-(3-Isopropylphenyl)thien-2-yl]quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119899-02-3P,
 5-[4-[5-(3-Isopropoxyphenyl)thien-2-yl]quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119899-03-4P,
 5-[4-[5-(2,6-Dimethoxyphenyl)thien-2-yl]quinolin-6-yl]methylene]thiazolidine-2,4-dione 1119899-05-6P,
 5-[4-(4-Methylthien-3-yl)quinolin-6-yl]methylene]thiazolidin-2,4-dione 1119899-07-8P, 5-[6-[2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]thiophene-2-carboxamide N-(3-methoxyphenyl) 1119899-09-0P, 5-[6-[2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]thiophene-2-carboxamide N-(3-hydroxyphenyl) 1119899-11-4P, 5-[6-[2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]thiophene-2-carboxamide N-(4-hydroxyphenyl) 1119899-12-5P, 5-[6-[2,4-Dioxothiazolidin-5-ylidene)methyl]quinolin-4-yl]thiophene-2-carboxamide N-[4-(morpholin-4-yl)methyl]phenyl] 1119899-13-6P, 5-[4-(4,5,6,7-Tetrahydrothieno[3,2-c]pyridin-2-yl)quinolin-6-yl]methylene]thiazolidine-2,4-dione
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazolidinone compds. as phosphatidylinositol-3-kinase (PI3K) inhibitors)

RN 1119898-38-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(4-methyl-2-thienyl)-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 1119898-39-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(3-methyl-2-thienyl)-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 1119898-41-7 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-(4-benzo[b]thien-2-yl-6-quinolinyl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 1119898-42-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(2-thienyl)-6-quinolinyl]methylene]-, (5Z)-
 (CA INDEX NAME)

Double bond geometry as shown.




RN 1119898-43-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[5-(hydroxymethyl)-2-thienyl]-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.




RN 1119898-44-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(5-phenyl-2-thienyl)-6-quinolinyl]methylene]-
 (CA INDEX NAME)



RN 1119898-46-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[5-(3,5-dimethyl-4-isoxazolyl)-2-thienyl]-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 1119898-47-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(2,3-dihydrothieno[3,4-b]-1,4-dioxin-5-yl)-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 1119898-48-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(4-benzo[b]thien-3-yl-6-quinolinyl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 1119898-49-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(2-furanyl)-6-quinolinyl]methylene]-, (5Z)-
 (CA INDEX NAME)

Double bond geometry as shown.



RN 1119898-50-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(2-benzofuranyl)-6-quinolinyl]methylene]-,
 (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 1119898-52-0 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[6-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-, 2,2,2-trifluoroacetate (1:?)
 (CA INDEX NAME)

CM 1

CRN 1119898-51-9
CMF C18 H10 N2 O4 S2

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 1119898-54-2 CAPLUS
CN 2-Thiophenecarboxamide, 5-[6-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-N-[2-(1-pyrrolidinyl)ethyl]-, 2,2,2-trifluoroacetate (1:?)
(CA INDEX NAME)

CM 1

CRN 1119898-53-1
CMF C24 H22 N4 O3 S2

Double bond geometry as shown.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 1119898-55-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]- (CA INDEX NAME)




RN 1119898-56-4 CAPLUS

CN Benzo[b]thiophene-6-carbonitrile, 2-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]- (CA INDEX NAME)




RN 1119898-57-5 CAPLUS

CN Benzo[b]thiophene-4-carbonitrile, 2-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]- (CA INDEX NAME)



RN 1119898-58-6 CAPLUS


CN Benzo[b]thiophene-7-carbonitrile, 2-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]- (CA INDEX NAME)



RN 1119898-59-7 CAPLUS

CN Benzo[b]thiophene-6-carbonitrile, 2-[6-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 1119898-60-0 CAPLUS

CN Benzo[b]thiophene-4-carbonitrile, 2-[6-[(Z)-(2,4-dioxo-5-


thiazolidinylidene)methyl]-4-quinolinyl]-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 1119898-61-1 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[5-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-2-thienyl]- (CA INDEX NAME)



RN 1119898-62-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[[4-(4-methyl-3-thienyl)-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 1119898-63-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[4-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 1119898-64-4 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[6-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-3-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 1119898-65-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[5-[3-(1-methylethyl)phenyl]-2-thienyl]-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 1119898-66-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[5-[3-(1-methylethoxy)phenyl]-2-thienyl]-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 1119898-67-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[5-(2,6-dimethoxyphenyl)-2-thienyl]-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 1119898-68-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-N-(3-hydroxyphenyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 1119898-69-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-N-(4-hydroxyphenyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 1119898-70-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-N-[4-(4-morpholinylmethyl)phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1119898-71-3 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-N-[3-(4-morpholinylmethyl)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 1119898-72-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[5-[6-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-2-thienyl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 1119898-74-6 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[6-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-N-(3-methoxyphenyl)- (CA INDEX NAME)


Double bond geometry as shown.




RN 1119898-76-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[5-[2-(3-hydroxyphenyl)ethynyl]-2-thienyl]-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 1119898-77-9 CAPLUS
 CN 4(5H)-Thiazolone, 2-(phenylamino)-5-[[4-(2-thienyl)-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 1119898-79-1 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-chloro-5-fluorophenyl)amino]-5-[[4-(2-thienyl)-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 1119898-80-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(2-thienyl)-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 1119898-81-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(benzo[b]thien-3-yl)-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 1119898-83-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[5-(hydroxymethyl)-2-thienyl]-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 1119898-85-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(2-furanyl)-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 1119898-87-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(2-benzofuranyl)-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 1119898-89-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(5-chloro-2-thienyl)-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 1119898-90-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-methyl-2-thienyl)-6-quinolinyl]methylene]- (CA INDEX NAME)



RN 1119898-91-7 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]- (CA INDEX NAME)




RN 1119898-93-9 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 1119898-95-1 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-(3-methyl-2-thienyl)-6-quinolinyl]methylene]-
(CA INDEX NAME)




RN 1119898-97-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-benzo[b]thien-2-yl-6-quinolinyl]methylene]-
(CA INDEX NAME)




RN 1119898-99-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(2-furanyl)-6-quinazolinyl]methylene]- (CA
INDEX NAME)




RN 1119899-01-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[5-[3-(1-methylethyl)phenyl]-2-thienyl]-6-
quinolinyl]methylene]- (CA INDEX NAME)




RN 1119899-02-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[5-[3-(1-methylethoxy)phenyl]-2-thienyl]-6-quinolinyl]methylene]- (CA INDEX NAME)



RN 1119899-03-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[5-(2,6-dimethoxyphenyl)-2-thienyl]-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 1119899-05-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-methyl-3-thienyl)-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 1119899-07-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-N-(3-methoxyphenyl)- (CA INDEX NAME)




RN 1119899-09-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-N-(3-hydroxyphenyl)- (CA INDEX NAME)




RN 1119899-11-4 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-N-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 1119899-12-5 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinolinyl]-N-[4-(4-morpholinylmethyl)phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 1119899-13-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-6-quinoliny]methylene]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:272749 CAPLUS

DOCUMENT NUMBER: 149:394176
 TITLE: Genetic and Pharmacological Targeting of Phosphoinositide 3-Kinase- γ Reduces Atherosclerosis and Favors Plaque Stability by Modulating Inflammatory Processes
 AUTHOR(S): Fougerat, Anne; Gayral, Stephanie; Gourdy, Pierre; Schambourg, Alexia; Rueckle, Thomas; Schwarz, Matthias K.; Rommel, Christian; Hirsch, Emilio; Arnal, Jean-Francois; Salles, Jean-Pierre; Perret, Bertrand; Breton-Douillon, Monique; Wymann, Matthias P.; Laffargue, Muriel
 CORPORATE SOURCE: Departement Lipoproteines et Mediateurs Lipidiques, INSERM U563, Toulouse, Fr.
 SOURCE: Circulation (2008), 117(10), 1310-1317
 CODEN: CIRCAZ; ISSN: 0009-7322
 PUBLISHER: Lippincott Williams & Wilkins
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Background- The role of inflammation at all stages of the atherosclerotic process has become an active area of investigation, and there is a notable quest for novel and innovative drugs for the treatment of atherosclerosis. The lipid kinase phosphoinositide 3-kinase- γ (PI3Ky) is thought to be a key player in various inflammatory, autoimmune, and allergic processes. These properties and the expression of PI3Ky in the cardiovascular system suggest that PI3Ky plays a role in atherosclerosis. Methods and Results- Here, we demonstrate that a specific PI3Ky inhibitor (AS605240) is effective in murine models of established atherosclerosis. I.p. administration of AS605240 (10 mg/kg daily) significantly decreased early atherosclerotic lesions in apolipoprotein E-deficient mice and attenuated advanced atherosclerosis in low-d. lipoprotein receptor-deficient mice. Furthermore, PI3Ky levels were elevated in both human and murine atherosclerotic lesions. Comparison of low-d. lipoprotein receptor-deficient mice transplanted with wild-type or PI3Ky-deficient bone marrow demonstrated that functional PI3Ky in the hematopoietic lineage is required for atherosclerotic progression. Alleviation of atherosclerosis by targeting of PI3Ky activity was accompanied by decreased macrophage and T-cell infiltration, as well as increased plaque stabilization. Conclusions- These data identify PI3Ky as a new target in atherosclerosis with the potential to modulate multiple stages of atherosclerotic lesion formation, such as fatty streak constitution, cellular composition, and final fibrous cap establishment.

IT 648450-29-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (AS 605240; genetic and pharmacol. targeting of phosphoinositide 3-kinase- γ reduces atherosclerosis and favors plaque stability by modulating inflammatory processes)

RN 648450-29-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-(6-quinoxalinylmethylene)- (CA INDEX NAME)





OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(11 CITINGS)
REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1364001 CAPLUS
DOCUMENT NUMBER: 148:33718
TITLE: Thiazolidinedione derivatives as PI3 kinase inhibitors
and their preparation and use in the treatment of
diseases
INVENTOR(S): Darcy, Michael Gerard; Knight, Steven David; Adams,
Nicholas D.; Schmidt, Stanley J.
PATENT ASSIGNEE(S): Smithkline Beecham Corp., USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007/136940	A2	2007/1129	WO 2007-US66359	20070411
WO 2007/136940	A3	20081204		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007253956	A1	2007/1129	AU 2007-253956	20070411
CA 2649224	A1	2007/1129	CA 2007-2649224	20070411
EP 2004189	A2	20081224	EP 2007-811839	20070411
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2009533467	T	20090917	JP 2009-505582	20070411
US 20080255115	A1	20081016	US 2007-844404	20070824
MX 2008013174	A	20081021	MX 2008-13174	20081010
IN 2008DN08515	A	20090501	IN 2008-DN8515	20081010
US 20090306074	A1	20091210	US 2008-296708	20081010
KR 2008108611	A	20081215	KR 2008-727465	20081110

CN 101466377 A 20090624 CN 2007-80021801 20081211
 PRIORITY APPLN. INFO.: US 2006-791134P P 20060411
 WO 2007-US66359 W 20070411
 OTHER SOURCE(S): CASREACT 148:33718; MARPAT 148:33718
 GI




AB Invented is a method of inhibiting the activity/function of PI3 kinases using thiazolidinedione derivs. of formula I. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiazolidinedione derivs. Compds. of formula I wherein R1 is (un)substituted heteroaryl; R2 is H, (un)substituted C1-6 alkyl, and (un)substituted aryl(alkyl); each R3 and R4 are independently H, halo, acyl, (un)substituted amino, (un)substituted C1-6 alkyl, etc.; n is 0 - 2; and their pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof are claimed. Example compound II was prepared by ethenylation of 6-bromo-4-chloroquinoline; the resulting 4-chloro-6-ethenylquinoline underwent oxidation to give 4-chloro-6-quinolinecarboxaldehyde, which underwent cross-coupling with 4-pyridinylboronic acid to give compound II. All the invention compds. were evaluated for their PI3 kinase inhibitory activity.

IT 958852-01-2P 958852-02-3P 958852-04-5P
 958852-05-6P 958852-06-7P 958852-07-8P
 958852-08-9P 958852-09-0P 958852-10-3P
 958852-11-4P 958852-12-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in the treatment of diseases)

RN 958852-01-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(4-pyridinyl)-6-quinolinyl]methylene]-, (5Z)-
(CA INDEX NAME)


Double bond geometry as shown.



RN 958852-02-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(3-pyridinyl)-6-quinolinyl]methylene]-, (5Z)-
(CA INDEX NAME)


Double bond geometry as shown.



RN 958852-04-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(2-methoxy-5-pyrimidinyl)-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 958852-05-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(2-methoxy-4-pyridinyl)-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 958852-06-7 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[6-(4-morpholinyl)-3-pyridinyl]-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 958852-07-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 958852-08-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(6-methoxy-3-pyridinyl)-6-piperidinyl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 958852-09-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(3-pyridazinyl)-6-quinolinyl]methylene]-,
 (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 958852-10-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(2-pyridinyl)-6-quinolinyl]methylene]-, (5Z)-
 (CA INDEX NAME)

Double bond geometry as shown.




RN 958852-11-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(6-amino-3-pyridinyl)-6-quinolinyl]methylene]-,
 (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 958852-12-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(1,2-dihydro-2-oxo-4-pyridinyl)-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1270534 CAPLUS

DOCUMENT NUMBER: 147:522220

TITLE: Carbostyryl compounds and their preparation, pharmaceutical compositions, and their transcription promoting activity of TFF2 for treatment and/or prevention of various diseases

INVENTOR(S): Kuroda, Takeshi; Yamauchi, Takahito; Shinohara, Tomokazu; Oshima, Kunio; Kitajima, Chiharu; Nagao, Hitoshi; Fukushima, Tae; Tomoyasu, Takahiro; Ishiyama, Hironobu; Ota, Kazuhide; Takano, Masaaki; Sumida, Takumi; Miyamoto, Motoyuki

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 338 pp.




CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007291079	A	20071108	JP 2007-81610	20070327
PRIORITY APPLN. INFO.:			JP 2006-84990	A 20060327
OTHER SOURCE(S):	MARPAT 147:522220			

GI



AB The invention provides carbostyryl compds. represented by formula (I) or salts thereof, and their pharmaceutical compns., prepsns. and use for transcription promotion activity of TFF2. The carbostyryl compds. or salts thereof, of the invention, induces the production of TFF, and thus are usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds. Compds. of formula I [wherein A is a bond, a lower alkylene group, or a lower alkylidene group; X is O or S; the dotted line is a single or a double bond; R4 and R5 are independently H, with the provision that dotted line is a double bond; or R4-R5 may be linked together to form a CH=CH-CH=CH group; R1 is H, lower alkyl, (un)substituted Ph lower alkyl, cycloalkyl lower alkyl, phenoxy lower alkyl, naphthyl lower alkyl, lower alkoxy lower alkyl, carboxyl lower alkyl, lower alkoxy carbonyl lower alkyl, (un)substituted pyridyl lower alkyl, cyano lower alkyl, etc.; R2 is H,


lower alkoxy, lower alkyl, carboxy lower alkyl, lower alkoxy carbonyl lower alkoxy, HO, (un)substituted Ph lower alkoxy, (un)substituted piperidinyl(oxy) lower alkyl, lower alkenyloxy, (un)substituted pyridyl lower alkoxy, lower alkynyloxy, Ph lower alkenyloxy, Ph lower alkynyloxy, (un)substituted furyl lower alkoxy, (un)substituted oxadiazolyl lower alkyl, or (un)substituted thiazolyl lower alkoxy, etc.; R3 is H, lower (HO-substituted) alkyl, cycloalkyl lower alkyl, carboxyl lower alkyl, lower alkoxy carbonyl lower alkyl, (un)substituted Ph lower alkyl, naphthyl lower alkyl, (un)substituted furyl lower alkyl, (un)substituted thiazolyl lower alkyl, (un)substituted tetrazolyl, or (un)substituted benzothienyl, etc.; and their pharmaceutically acceptable salts] are claimed. Example compound (II) was prepared by heterocyclization of 2-chloro-3-(8-methoxy-1-methyl-2-oxo-1,2-dihydroquinolin-5-yl)propionic acid with thiourea. All the invention compds. were evaluated for the transcription promoting activity of hTFF2. From the assay, it was determined that some invention compds., including compound (III), showed TFF2 production activity of 1000% or higher at a test compound concentration of 10-6M concentration. Some invention compds. showed a TFF2 production promoting activity of 300% or higher at a test compound concentration is less than 10-5M and preferably more than 10-6M. Example compound III and a few other compds. showed >20% healing ratio of the ulcerated area, which indicated that these compds. may be effective in preventing and/or treating mucosal injury.

IT 882007-18-3P 882007-24-1P 882007-32-1P 882007-38-7P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate and intermediate; preparation of carbostyryl compds. and their transcription promoting activity of TFF2 for treatment and/or prevention of various diseases)

RN 882007-18-3 CAPLUS


CN Benzoic acid, 4-[[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3,4-dihydro-8-methoxy-2-oxo-1(2H)-quinolinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 882007-24-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-hydroxy-2-oxo-1-(phenylmethyl)-5-quinoliny)methylene]- (CA INDEX NAME)




RN 882007-32-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[5,6-dihydro-6-oxo-5-(phenylmethyl)-2-phenanthridinyl)methylene]- (CA INDEX NAME)




RN 882007-38-7 CAPLUS
 CN 2-((1H)-Quinolinone, 1-([1,1'-biphenyl]-4-ylmethyl)-3,4-dihydro-8-methoxy-5-
 [(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



IT 882007-48-9P 882019-15-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of carbostyryl compds. and their transcription
 promoting activity of TFF2 for treatment and/or prevention of various
 diseases)
 RN 882007-48-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-[(4-
 nitrophenyl)methyl]-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)



RN 882019-15-0 CAPLUS
 CN 2((1H)-Quinolinone, 1-[(4-bromophenyl)methyl]-3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



IT	882007-03-6P	882007-05-8P	882007-06-9P
	882007-07-0P	882007-39-8P	882007-43-4P
	882007-44-5P	882007-45-6P	882007-46-7P
	882007-47-8P	882007-49-0P	882007-50-3P
	882007-51-4P	882007-52-5P	882007-53-6P
	882007-54-7P	882007-55-8P	882007-56-9P
	882007-57-0P	882007-58-1P	882007-59-2P


882007-60-5P	882007-61-6P	882007-62-7P
882007-63-8P	882007-64-9P	882007-65-0P
882007-66-1P	882007-67-2P	882007-68-3P
882007-69-4P	882007-70-7P	882007-71-8P
882007-72-9P	882007-73-0P	882007-74-1P
882007-75-2P	882007-76-3P	882007-77-4P
882007-78-5P	882007-79-6P	882007-80-9P
882007-81-0P	882007-82-1P	882007-83-2P
882007-84-3P	882007-85-4P	882007-86-5P
882007-87-6P	882007-88-7P	882007-89-8P
882007-90-1P	882007-91-2P	882007-92-3P
882007-93-4P	882007-94-5P	882007-95-6P
882007-96-7P	882007-97-8P	882007-98-9P
882007-99-0P	882008-00-6P	882008-01-7P
882013-64-1P	882013-65-2P	882013-67-4P
882013-69-6P	882018-67-9P	882018-70-4P
882018-72-6P	882018-74-8P	882018-76-0P
882018-78-2P	882018-80-6P	882018-82-8P
882018-85-1P	882018-87-3P	882018-88-4P
882018-90-8P	882018-92-0P	882018-94-2P
882018-96-4P	882018-98-6P	882019-00-3P
882019-01-4P	882019-03-6P	882019-05-8P
882019-06-9P	882019-08-1P	882019-09-2P
882019-11-6P	882019-13-8P	882019-14-9P
882019-17-2P	882019-19-4P	882019-21-8P
882019-23-0P	882019-25-2P	882019-27-4P
882019-29-6P	882019-31-0P	882019-33-2P
882019-78-5P	882019-79-6P	882019-80-9P
882019-81-0P	882019-82-1P	882019-83-2P
882019-84-3P	882019-85-4P	882019-86-5P
882019-87-6P	882019-88-7P	882019-89-8P
882019-90-1P	882019-91-2P	882019-92-3P
882019-93-4P	882019-94-5P	882019-95-6P
882019-96-7P	882019-97-8P	882019-98-9P
882019-99-0P	882020-00-0P	882020-01-1P
882020-02-2P	882020-03-3P	882020-04-4P
882020-05-5P	882020-06-6P	882020-07-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of carbostyryl compds. and their transcription
promoting activity of TTF2 for treatment and/or prevention of various
diseases)


RN 882007-03-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(1,2-dihydro-8-methoxy-1-methyl-2-oxo-5-
quinolinyl)methylene]- (CA INDEX NAME)




RN 882007-05-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(4-bromophenyl)methyl]-1,2-dihydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-06-9 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(1,1'-biphenyl)-4-ylmethyl]-1,2,3,4-tetrahydro-2-oxo-7-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-07-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-2-oxo-8-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-39-8 CAPLUS

CN 2(1H)-Quinolone, 1-[(4-bromophenyl)methyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882007-43-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(phenylmethyl)-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-44-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-45-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-46-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-3-ylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-47-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-2-ylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-49-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-[(4-methoxyphenyl)methyl]-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-50-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-51-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(4-bromophenyl)methyl]-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-52-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[(4-(phenylmethoxy)phenyl)methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-53-6 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1-[(4-fluorophenyl)methyl]-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-54-7 CAPLUS
 CN Benzonitrile, 4-[[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3,4-dihydro-8-methoxy-2-oxo-1(2H)-quinolinyl]methyl]- (CA INDEX NAME)




RN 882007-55-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-[(4-methylphenyl)methyl]-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-56-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[(4-phenoxyphenyl)methyl]-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-57-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(1,2,3,4-tetrahydro-8-methoxy-1-methyl-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)



RN 882007-58-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl)methylene]- (CA INDEX NAME)




RN 882007-59-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(1-butyl-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl)methylene]- (CA INDEX NAME)




RN 882007-60-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(3-phenylpropyl)-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-61-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(2-phenylethyl)-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-62-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(1-ethyl-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl)methylene]- (CA INDEX NAME)




RN 882007-63-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-(cyclopropylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-64-9 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(2-phenoxyethyl)-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-65-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-(cyclohexylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-66-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-(2-methoxyethyl)-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-67-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-(diphenylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-68-3 CAPLUS

CN 1(2H)-Quinolinepropanenitrile, 5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3,4-dihydro-8-methoxy-2-oxo- (CA INDEX NAME)




RN 882007-69-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(4-phenylbutyl)-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-70-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(5-phenylpentyl)-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-71-8 CAPLUS

CN 1(2H)-Quinolinepropanoic acid, 5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3,4-dihydro-8-methoxy-2-oxo-, ethyl ester (CA INDEX NAME)




RN 882007-72-9 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-(1-naphthalenyl)methyl]-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)



RN 882007-73-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-(2-naphthalenylmethyl)-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-74-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-8-butoxy-1,2,3,4-tetrahydro-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-75-2 CAPLUS

CN Acetic acid, 2-[[1-([1,1'-biphenyl]-4-ylmethyl)-5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-1,2,3,4-tetrahydro-2-oxo-8-quinolinyl]oxy]-1,1-dimethylethyl ester (CA INDEX NAME)




RN 882007-76-3 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-8-hydroxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-77-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-8-(methoxymethoxy)-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)



RN 882007-78-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[[6-(3-thienyl)-3-pyridinyl]methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-79-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[(6-phenyl-3-pyridinyl)methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)



RN 882007-80-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-[[6-(4-phenyl-3-pyridinyl)methyl]-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 882007-81-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[[6-(4-phenyl-1-piperazinyl)-3-pyridinyl]methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 882007-82-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-[[6-(4-methyl-1-piperazinyl)-3-pyridinyl]methyl]-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 882007-83-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([2,2'-bipyridin]-5-ylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 882007-84-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(2-quinolinylmethyl)-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-85-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-1-(2-naphthalenylmethyl)-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-86-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(1,2,3,4-tetrahydro-2-oxo-1-phenyl-5-quinolinyl)methylene]- (CA INDEX NAME)




RN 882007-87-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(6-chloro-3-pyridinyl)methyl]-1,2,3,4-tetrahydro-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-88-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(1,1'-biphenyl)-4-ylmethyl]-1,2,3,4-tetrahydro-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-89-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(4-bromophenyl)methyl]-1,2,3,4-tetrahydro-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-90-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydro-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-91-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-1-[(4-methylphenyl)methyl]-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-92-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-2-oxo-8-phenyl-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-93-4 CAPLUS

CN Benzoic acid, 4-[[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3,4-dihydro-2-oxo-1(2H)-quinolinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 882007-94-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-1-[(4-nitrophenyl)methyl]-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-95-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-8-methyl-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-96-7 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-8-chloro-1,2,3,4-tetrahydro-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)



RN 882007-97-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-2-oxo-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-98-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-[(4-bromophenyl)methyl]-1,2,3,4-tetrahydro-2-oxo-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-99-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-1-[(4-nitrophenyl)methyl]-2-oxo-6-quinoliny]methylene]- (CA INDEX NAME)




RN 882008-00-6 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-6-quinoliny]methylene]- (CA INDEX NAME)



RN 882008-01-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-8-methyl-2-oxo-6-quinoliny]methylene]- (CA INDEX NAME)




RN 882013-64-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(5-ethyl-5,6-dihydro-6-oxo-2-phenanthridinyl)methylene]- (CA INDEX NAME)




RN 882013-65-2 CAPLUS

CN 6(5H)-Phenanthridinone, 2-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-5-(phenylmethyl)- (CA INDEX NAME)




RN 882013-67-4 CAPLUS

CN 6(5H)-Phenanthridinone, 5-ethyl-2-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 882013-69-6 CAPLUS

CN 6(5H)-Phenanthridinone, 5-([1,1'-biphenyl]-4-ylmethyl)-2-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-67-9 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(phenylmethyl)- (CA INDEX NAME)




RN 882018-70-4 CAPLUS

CN 2(1H)-Quinolinone, 1-[[4-(1,1-dimethylethyl)phenyl]methyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-72-6 CAPLUS

CN 2(1H)-Quinolinone, 1-[[1,1'-biphenyl]-3-ylmethyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-74-8 CAPLUS

CN 2(1H)-Quinolinone, 1-[(1,1'-biphenyl)-2-ylmethyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-76-0 CAPLUS


CN 2(1H)-Quinolinone, 1-[(4-chlorophenyl)methyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 882018-78-2 CAPLUS
 CN 2((1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[(4-phenoxyphenyl)methyl]- (CA INDEX NAME)




RN 882018-80-6 CAPLUS
 CN 2((1H)-Quinolinone, 3,4-dihydro-8-methoxy-1-methyl-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-82-8 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-85-1 CAPLUS


CN 2(1H)-Quinolinone, 1-butyl-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-87-3 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(3-phenylpropyl)- (CA INDEX NAME)



RN 882018-88-4 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(2-phenylethyl)- (CA INDEX NAME)




RN 882018-90-8 CAPLUS
 CN 2(1H)-Quinolinone, 1-ethyl-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-92-0 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(2-phenoxyethyl)- (CA INDEX NAME)




RN 882018-94-2 CAPLUS

CN 2(1H)-Quinolinone, 1-(cyclohexylmethyl)-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-96-4 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-1-(2-methoxyethyl)-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-98-6 CAPLUS

CN 2(1H)-Quinolinone, 1-(diphenylmethyl)-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-00-3 CAPLUS

CN 2(1H)-Quinolinone, 1-(cyclopropylmethyl)-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-01-4 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-phenyl- (CA INDEX NAME)




RN 882019-03-6 CAPLUS

CN 2(1H)-Quinololinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(4-phenylbutyl)- (CA INDEX NAME)




RN 882019-05-8 CAPLUS

CN 2(1H)-Quinololinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(5-phenylpentyl)- (CA INDEX NAME)




RN 882019-06-9 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-1-(1-naphthalenylmethyl)-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-08-1 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-1-(2-naphthalenylmethyl)-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-09-2 CAPLUS

CN 2-(1H)-Quinolinone, 1-([1,1'-biphenyl]-4-ylmethyl)-8-butoxy-3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-11-6 CAPLUS

CN Acetic acid, 2-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-2-oxo-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-8-quinolinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882019-13-8 CAPLUS

CN 2((1H)-Quinolinone, 1-([1,1'-biphenyl]-4-ylmethyl)-3,4-dihydro-8-hydroxy-5-[(4-oxo-2-thioxo-5-thiazolidinylydene)methyl]- (CA INDEX NAME)




RN 882019-14-9 CAPLUS


CN 2((1H)-Quinolinone, 1-([1,1'-biphenyl]-4-ylmethyl)-3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylydene)methyl]- (CA INDEX NAME)




RN 882019-17-2 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-1-(1-naphthalenylmethyl)-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-19-4 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[[6-(3-thienyl)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 882019-21-8 CAPLUS
 CN 2-(1H)-Quinolinone, 1-[(4-chlorophenyl)methyl]-3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-23-0 CAPLUS
 CN 2-(1H)-Quinolinone, 3,4-dihydro-1-[(4-methylphenyl)methyl]-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 882019-25-2 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(2-quinolinylmethyl)- (CA INDEX NAME)




RN 882019-27-4 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-1-[[6-(methylphenylamino)-3-pyridinyl]methyl]-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-29-6 CAPLUS

CN 2(1H)-Quinolinone, 1-[(6-chloro-3-pyridinyl)methyl]-3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-31-0 CAPLUS

CN 2(1H)-Quinolinone, 8-methoxy-1-methyl-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 882019-33-2 CAPLUS


CN 2-(1H)-Quinolinone, 1-[(4-bromophenyl)methyl]-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 882019-78-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-2-oxo-1-[[4-(1-piperidinylmethyl)phenyl)methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 882019-79-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[[1,2,3,4-tetrahydro-2-oxo-1-[[3-(1-piperidinylmethyl)phenyl]methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882019-80-9 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-2-oxo-1-[[6-(1-piperidinylmethyl)-2-pyridinyl]methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882019-81-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-2-oxo-1-[[6-[(phenylthio)methyl]-2-pyridinyl]methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)



RN 882019-82-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-[(6-[1,1'-biphenyl]-4-yl-3-pyridinyl)methyl]-
 1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX
 NAME)


PAGE 1-A






RN 882019-83-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[[6-(phenylamino)-3-pyridinyl)methyl]-5-quinolinyl)methylene]- (CA INDEX NAME)



RN 882019-84-3 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[[6-(trifluoromethyl)-3-pyridinyl)methyl]-5-quinolinyl)methylene]- (CA INDEX NAME)



RN 882019-85-4 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[[6-(2-pyridinylamino)-3-pyridinylmethyl]-5-quinolinyl]methylene]- (CA INDEX NAME)

PAGE 1-A







RN 882019-86-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-[(2-chloro-5-thiazolyl)methyl]-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882019-87-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[(2-phenyl-5-thiazolyl)methyl]-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882019-88-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[[2-(3-phenylthienyl)-5-thiazolyl]methyl]-5-quinoliny]methylene]- (CA INDEX NAME)



RN 882019-89-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[[2-(3-pyridinyl)-5-thiazolyl]methyl]-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882019-90-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-1-[[4-
 [(methylphenylamino)methyl]phenyl]methyl]-2-oxo-5-quinolinyl]methylene]-
 (CA INDEX NAME)




RN 882019-91-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-2-oxo-1-[[3-

[(phenylthio)methyl]phenyl[methyl]-5-quinoliny[methylene]- (CA INDEX NAME)



RN 882019-92-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[1-[[4-[(2,3-dihydro-1H-indol-1-yl)methyl]phenyl]methyl]-1,2,3,4-tetrahydro-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 882019-93-4 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[(4-(1-piperidinylmethyl)phenyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 882019-94-5 CAPLUS


CN 2(1H)-Quinolinone, 3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[[3-(1-piperidinylmethyl)phenyl]methyl]- (CA INDEX NAME)




RN 882019-95-6 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[[4-[(phenylthio)methyl]phenyl]methyl]- (CA INDEX NAME)



RN 882019-96-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[5-[[3,4-dihydro-8-methoxy-2-oxo-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1(2H)-quinolinyl]methyl]-2-pyridinyl]- (CA INDEX NAME)




RN 882019-98-9 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[6-(phenylamino)-3-pyridinyl]methyl- (CA INDEX NAME)



RN 882019-99-0 CAPLUS
 CN 2(1H)-Quinolinone, 1-[(6-[1,1'-biphenyl]-4-yl-3-pyridinyl)methyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 882020-00-0 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[[6-(1-piperidinylmethyl)-2-pyridinyl]methyl]-
 (CA INDEX NAME)




RN 882020-01-1 CAPLUS

CN 2-(1H)-Quinolinone, 1-[(2-chloro-5-thiazolyl)methyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882020-02-2 CAPLUS

CN 2-(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[(2-phenyl-5-thiazolyl)methyl]- (CA INDEX NAME)




RN 882020-05-5 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-1-[[4-
 [(methylphenylamino)methyl]phenyl]methyl]-5-[(4-oxo-2-thioxo-5-
 thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882020-06-6 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-5-[(4-oxo-2-thioxo-5-

thiazolidinylidene)methyl]-1-[[3-[(phenylthio)methyl]phenyl]methyl]- (CA
INDEX NAME)



RN 882020-07-7 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-1-[(4-methoxy-3,5-dimethyl-2-
pyridinyl)methyl]-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA
INDEX NAME)



L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1204673 CAPLUS
DOCUMENT NUMBER: 147:486426

TITLE: Carbazole-rhodanine derivs. as up-regulating TFF agents and their preparation, pharmaceutical compositions and use in the treatment of diseases associated with TFF production

INVENTOR(S): Kuroda, Takeshi; Yamauchi, Takahito; Shinohara, Tomoichi; Oshima, Kunio; Kitajima, Chiharu; Nagao, Hitoshi; Ishiyama, Hironobu; Ohta, Kazuhide; Takano, Masaaki; Sumida, Takumi

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 154pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007119600	A1	20071025	WO 2007-JP57016	20070323
WO 2007119600	A9	20080502		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRIORITY APPLN. INFO.:			JP 2006-80451	A 20060323
OTHER SOURCE(S):	CASREACT 147:486426; MARPAT 147:486426			

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides the carbazole-rhodanine compds. of formula I and their salts thereof. Compds. of formula I induce the production of TFF2, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, eye diseases, cancers, and wounds. Compds. of formula I wherein A is a bond, lower alkylene and lower alkylidene; X is O and S; R1 is H, lower (un)substituted alkyl, (un)substituted lower alkylphenyl, lower cycloalkylalkyl, Ph, etc; R2 is lower alkoxy, phenyl-(un)substituted lower alkyl, carboxy lower alkoxy, lower alkoxy carbonyl lower alkoxy, and hydroxy; R3 is a H, (un)substituted lower alkyl, lower cycloalkylalkyl, lower carboxyalkyl, etc.; n is 0-7; and their salts thereof, are claimed. Example compound II was prepared by reductive aldol condensation of 9-benzenesulfonyl-9H-carbazole-3-carbaldehyde with rhodanine. All the invention compds. were evaluated for their up-regulating TFF2 activity. From the assay, it was determined that II exhibited TFF2 production promoting activity of 1000% or higher at 10-6 M concentration


IT 953795-37-4P 953795-48-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of carbazole-rhodanine derivs. as up-regulating TFF agents useful in the treatment of diseases associated with TFF production)
 RN 953795-37-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-(2,2,2-trifluoroacetyl)-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953795-48-7 CAPLUS
 CN 4-Thiazolidinone, 2-thioxo-5-[[9-(2,2,2-trifluoroacetyl)-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)



IT 953796-27-5P 953797-10-9P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of carbazole-rhodanine derivs. as up-regulating TFF agents useful in the treatment of diseases associated with TFF production)
 RN 953796-27-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-(benzoyl-9H-carbazol-3-yl)methylene]- (CA INDEX NAME)



RN 953797-10-9 CAPLUS
 CN 4-Thiazolidinone, 5-[(9-benzoyl-9H-carbazol-3-yl)methylene]-2-thioxo- (CA INDEX NAME)




IT	503826-94-6P	890999-51-6P	953796-08-2P
	953796-10-6P	953796-11-7P	953796-12-8P
	953796-13-9P	953796-14-0P	953796-15-1P
	953796-16-2P	953796-17-3P	953796-18-4P
	953796-19-5P	953796-20-8P	953796-21-9P
	953796-22-0P	953796-23-1P	953796-24-2P
	953796-25-3P	953796-26-4P	953796-28-6P
	953796-29-7P	953796-30-0P	953796-31-1P
	953796-32-2P	953796-33-3P	953796-34-4P
	953796-35-5P	953796-36-6P	953796-37-7P
	953796-38-8P	953797-06-3P	953797-07-4P
	953797-08-5P	953797-09-6P	953797-11-0P
	953797-12-1P	953797-13-2P	953797-14-3P
	953797-15-4P	953797-16-5P	953797-17-6P
	953797-18-7P		


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of carbazole-rhodanine derivs. as up-regulating TFF agents useful in the treatment of diseases associated with TFF production)


RN 503826-94-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(9-ethyl-9H-carbazol-3-yl)methylene]- (CA INDEX NAME)




RN 890999-51-6 CAPLUS
 CN 4-Thiazolidinone, 5-[(9-ethyl-9H-carbazol-3-yl)methylene]-2-thioxo- (CA INDEX NAME)




RN 953796-08-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-(phenylmethyl)-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-10-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[4-(2-pyridinyl)phenyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-11-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[4-(3-pyridinyl)phenyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-12-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[4-(3-thienyl)phenyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)



RN 953796-13-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[(4-nitrophenyl)methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-14-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[(4-methylphenyl)sulfonyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-15-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-([1,1'-biphenyl]-4-ylsulfonyl)-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-16-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(4-chlorophenyl)sulfonyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-17-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-18-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-1-methoxy-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-19-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-5,8-dimethyl-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-20-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-1-methyl-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-21-9 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-8-methyl-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-22-0 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-8-methoxy-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)



RN 953796-23-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-1,8-dimethoxy-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-24-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[(4-bromophenyl)methyl]-1,8-dimethoxy-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-25-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-(9H-carbazol-3-ylmethylene)- (CA INDEX NAME)




RN 953796-26-4 CAPLUS

CN 9H-Carbazole-9-carboxylic acid, 3-[(2,4-dioxo-5-thiazolidinylidene)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 953796-28-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(6-chloro-3-pyridinyl)methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-29-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[9-[(6-phenyl-3-pyridinyl)methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-30-0 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[9-[[6-(3-thienyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-31-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[6-(2-chlorophenyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-32-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[6-(2-thienyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-33-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[6-(3-furanyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-34-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-([2,3'-bipyridin]-5-ylmethyl)-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-35-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-([2,2'-bipyridin]-5-ylmethyl)-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-36-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-(2-quinolinylmethyl)-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-37-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[6-(4-morpholinyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953796-38-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[9-[[6-(5-chloro-2-thienyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]- (CA INDEX NAME)




RN 953797-06-3 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-(phenylmethyl)-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-07-4 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-[[4-(2-pyridinyl)phenyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 953797-08-5 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-[[4-(3-thienyl)phenyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-09-6 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-[(4-methylphenyl)sulfonyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-11-0 CAPLUS

CN 4-Thiazolidinone, 5-[[9-[[6-(3-thienyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-12-1 CAPLUS

CN 4-Thiazolidinone, 5-[[9-[[6-(3-thienyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-13-2 CAPLUS

CN 4-Thiazolidinone, 5-[[9-[[6-(2-chlorophenyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-14-3 CAPLUS


CN 4-Thiazolidinone, 5-[[9-[[6-(2-thienyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-15-4 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-[[6-(3-furanyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 953797-16-5 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-[(2,2'-bipyridin)-5-ylmethyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 953797-17-6 CAPLUS
 CN 4-Thiazolidinone, 5-[[9-(2-quinolinylmethyl)-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 953797-18-7 CAPLUS
 CN 4-Thiazolidinone, 5-[[[9-[[6-(4-morpholinyl)-3-pyridinyl]methyl]-9H-carbazol-3-yl]methylene]-2-thioxo- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1023525 CAPLUS
DOCUMENT NUMBER: 147:365485
TITLE: Preparation of thiazolones for use as PI3 kinase
inhibitors
INVENTOR(S): Dhanak, Dashyant; Knight, Steven David
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCI Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007103756	A2	20070913	WO 2007-US63114	20070302
WO 2007103756	A3	20080306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1993537	A2	20081126	EP 2007-757757	20070302

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, HR
 JP 2009528385 T 20090806 JP 2008-557507 20070302
 US 20090170848 A1 20090702 US 2008-281183 20081113
 PRIORITY APPLN. INFO.: US 2006-778585P P 20060302
 WO 2007-US63114 W 20070302
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 147:365485; MARPAT 147:365485
 GI




AB The title compds. I [R = (un)substituted aryl; Q = (un)substituted quinoxaliny, quinolinyl], useful for inhibiting the activity/function of PI3 kinases, were prepared and formulated. E.g., a multi-step synthesis of (5Z)-2-[(2,6-dichlorophenyl)amino]-5-[[3-(4-morpholinyl)-6-quinoxaliny]methylene]-1,3-thiazol-4(5H)-one, starting from 7-bromo-2(1H)-quinoxalinone, was given. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones I.

IT 916811-86-4P 916811-90-0P 916811-93-3P
 916811-95-5P 916811-98-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thiazolone compds. as PI3 kinase inhibitors useful in combination therapy of diseases)

RN 916811-86-4 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[3-(4-morpholinyl)-6-quinoxaliny]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 916811-90-0 CAPLUS

CN 2(1H)-Quinoxalinone, 7-[(Z)-(2-[(2,6-dichlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene)methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 916811-93-3 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[2-(methylamino)-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 916811-95-5 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[4-(dimethylamino)-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 916811-98-8 CAPLUS


CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[4-(4-methyl-1-piperazinyl)-6-quinolinyl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



IT 916811-94-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of thiazolone compds. as PI3 kinase inhibitors useful in
 combination therapy of diseases)
 RN 916811-94-4 CAPLUS
 CN 4(5H)-Thiazolone, 5-[(2-chloro-6-quinolinyl)methylenel]-2-[(2,6-
 dichlorophenyl)amino]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:1022578 CAPLUS
 DOCUMENT NUMBER: 147:365484
 TITLE: Preparation of thiazolones for use as PI3 kinase
 inhibitors
 INVENTOR(S): Dhanak, Dashyant; Knight, Steven David
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 129 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007103755	A2	20070913	WO 2007-US63113	20070302
WO 2007103755	A3	20080306		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1993536 A2 20081126 EP 2007-757756 20070302

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, HR

JP 2009528384 T 20090806 JP 2008-557506 20070302

US 20090048252 A1 20090219 US 2008-281181 20080829


PRIORITY APPLN. INFO.: US 2006-778272P P 20060302

WO 2007-US63113 W 20070302

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 147:365484

GI



AB The title compds. I [R = H, (un)substituted aryl, cycloalkyl, alkyl; R10 = H, alkyl, (CH2)mOH, (CH2)mCO2H; m = 0-6; Y = O, S, NR11; R11 = H, alkyl, (CH2)pOH, (CH2)pCO2H; p = 0-6; Q = (un)substituted benzoxazolyl, benzimidazolyl, etc.], useful for inhibiting the activity/function of PI3 kinases, were prepared and formulated. E.g., a multi-step synthesis of (5Z)-2-[(2-chlorophenyl)amino]-5-[(1-methyl-1H-benzimidazol-6-yl)methylidene]-1,3-thiazol-4(5H)-one, starting from 3-methoxy-4-nitrobenzoic acid, was given. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones I.

IT 864273-75-6P 864273-76-7P 864273-78-9P
 864273-82-5P 864273-85-8P 864273-90-5P
 864273-94-9P 864273-97-2P 864274-00-0P
 864274-01-1P 864274-03-3P 864274-05-5P
 864274-06-6P 864274-07-7P 864274-08-8P
 864274-09-9P 864274-10-2P 864274-11-3P
 864274-12-4P 864274-13-5P 864274-14-6P

864274-15-7P	864274-16-8P	864274-17-9P
864274-20-4P	864274-21-5P	864274-22-6P
864274-23-7P	864274-24-8P	864274-25-9P
864274-26-0P	864274-27-1P	864274-28-2P
864274-29-3P	864274-30-6P	864274-31-7P
864274-32-8P	864274-33-9P	864274-35-1P
864274-38-4P	864274-44-2P	864274-45-3P
864274-49-7P	864274-54-4P	864274-55-5P
864274-80-6P	864274-83-9P	864275-03-6P
864275-06-9P	864275-09-2P	864275-12-7P
864275-15-0P	864275-16-1P	864275-17-2P
864275-18-3P	864275-19-4P	864275-20-7P
864275-21-8P	864275-24-1P	864275-25-2P
864275-26-3P	864275-27-4P	864275-28-5P
864275-29-6P	864275-30-9P	864275-31-0P
864275-32-1P	864275-33-2P	864275-34-3P
864275-35-4P	864275-36-5P	864275-37-6P
864275-38-7P	864275-39-8P	864275-40-1P
864275-41-2P	864275-42-3P	864275-43-4P
864275-44-5P	864275-45-6P	864275-46-7P
864275-47-8P	864275-48-9P	864275-49-0P
864275-50-3P	864275-51-4P	864275-52-5P
864275-53-6P	864275-54-7P	864275-55-8P
864275-56-9P	864275-57-0P	864275-58-1P
864275-59-2P	864275-60-5P	864275-61-6P
864275-62-7P	864275-63-8P	864275-64-9P
949581-81-1P	949581-83-3P	949581-85-5P
949581-86-6P	949581-87-7P	949581-89-9P
949581-91-3P	949581-92-4P	949581-93-5P
949581-94-6P	949581-95-7P	949581-96-8P
949581-97-9P	949581-98-0P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted thiazolones as PI3 kinase inhibitors useful in combination therapy of diseases)

RN 864273-75-6 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[(1-methyl-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864273-76-7 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[(1,2-dimethyl-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864273-78-9 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864273-82-5 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-[2-(dimethylamino)ethyl]-2-methyl-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864273-85-8 CAPLUS


CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-methyl-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864273-90-5 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-methyl-2-(4-morpholinylmethyl)-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864273-94-9 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-methyl-2-(trifluoromethyl)-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864273-97-2 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[2-(1,1-dimethylethyl)-1-methyl-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864274-00-0 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[2-(1,1-dimethylethyl)-1-methyl-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864274-01-1 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[(1-methyl-1H-benzotriazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.




RN 864274-03-3 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)




RN 864274-05-5 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-difluorophenyl)amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)




RN 864274-06-6 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-fluorophenyl)amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)




RN 864274-07-7 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)




RN 864274-08-8 CAPLUS
 CN 4(5H)-Thiazolone, 5-[(2-methyl-6-benzoxazolyl)methylene]-2-[[2-(trifluoromethyl)phenyl]amino]- (CA INDEX NAME)




RN 864274-09-9 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,4-difluorophenyl)amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)




RN 864274-10-2 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2,5-dichlorophenyl)amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)




RN 864274-11-3 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2,4-dimethylphenyl)amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)




RN 864274-12-4 CAPLUS
CN Benzonitrile, 4-[[4,5-dihydro-5-[(2-methyl-6-benzoxazolyl)methylene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 864274-13-5 CAPLUS
CN Benzoic acid, 4-[[4,5-dihydro-5-[(2-methyl-6-benzoxazolyl)methylene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 864274-14-6 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2,4-dichlorophenyl)amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)




RN 864274-15-7 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2,5-difluorophenyl)amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)



RN 864274-16-8 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2-methyl-6-benzoxazolyl)methylene]-2-(phenylamino)- (CA INDEX NAME)




RN 864274-17-9 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2-methyl-6-benzoxazolyl)methylene]-2-[[2-(1-piperidinyl)ethyl]amino]- (CA INDEX NAME)




RN 864274-20-4 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-methoxyethyl)amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)




RN 864274-21-5 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-methyl-6-benzoxazolyl)methylene]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 864274-22-6 CAPLUS

CN Benzenesulfonamide, 3-[[4,5-dihydro-5-[(2-methyl-6-benzoxazolyl)methylene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 864274-23-7 CAPLUS

CN 4(5H)-Thiazolone, 2-[(4-hydroxybutyl)amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)




RN 864274-24-8 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(trans-4-hydroxycyclohexyl)amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry unknown.




RN 864274-25-9 CAPLUS
 CN 4(5H)-Thiazolone, 5-[(2-methyl-6-benzoxazolyl)methylene]-2-[(2-phenylethyl)amino]- (CA INDEX NAME)



RN 864274-26-0 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[4,5-dihydro-5-[(2-methyl-6-benzoxazolyl)methylene]-4-oxo-2-thiazolyl]amino]ethyl]- (CA INDEX NAME)




RN 864274-27-1 CAPLUS
 CN 4(5H)-Thiazolone, 2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)




RN 864274-28-2 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(4-chlorophenyl)amino]-5-[(2-methyl-6-

benzoxazolyl)methylene]- (CA INDEX NAME)




RN 864274-29-3 CAPLUS

CN 4(5H)-Thiazolone, 5-[(2-methyl-6-benzoxazolyl)methylene]-2-(3-pyridinylamino)- (CA INDEX NAME)




RN 864274-30-6 CAPLUS

CN Benzamide, 3-[[4,5-dihydro-5-[(2-methyl-6-benzoxazolyl)methylene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)



RN 864274-31-7 CAPLUS

CN 4(5H)-Thiazolone, 2-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)




RN 864274-32-8 CAPLUS

CN 4(5H)-Thiazolone, 2-[[[(1S)-1-(hydroxymethyl)-2-phenylethyl]amino]-5-[(2-methyl-6-benzoxazolyl)methylene]- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.



RN 864274-33-9 CAPLUS


CN Acetamide, N-[6-[(2-bromophenyl)amino]-4-oxo-5(4H)-thiazolylidene)methyl]-1H-benzimidazol-2-yl]-2-(dimethylamino)- (CA INDEX NAME)



RN 864274-35-1 CAPLUS

CN Carbamic acid, N-[6-[(2-bromophenyl)amino]-4-oxo-5(4H)-thiazolylidene)methyl]-1H-benzimidazol-2-yl]-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 864274-38-4 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-(3,3-dimethylbutyl)-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864274-44-2 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-(3,3-dimethylbutyl)-1H-benzimidazol-6-yl]methylene]-, (5Z)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864274-43-1
 CMF C23 H22 Cl2 N4 O S

Double bond geometry as shown.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 864274-45-3 CAPLUS
 CN 4(5H)-Thiazolone, 5-[[1-(2-cyclopropylethyl)-1H-benzimidazol-6-yl]methylene]-2-[(2,6-difluorophenyl)amino]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 864274-49-7 CAPLUS
 CN 4(5H)-Thiazolone, 5-[[1-(2-cyclohexylethyl)-1H-benzimidazol-6-


yl)methylene]-2-[(2,6-dichlorophenyl)amino]-, (5Z)-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 864274-48-6

CMF C25 H24 Cl2 N4 O S

Double bond geometry as shown.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 864274-54-4 CAPLUS

CN 4-(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-(2-cyclopropylethyl)-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864274-55-5 CAPLUS

CN 4(5H)-Thiazolone, 5-[[1-(2-cyclopropylethyl)-1H-benzimidazol-6-yl]methylene]-2-[(2,6-dichlorophenyl)amino]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864274-80-6 CAPLUS

CN 4(5H)-Thiazolone, 5-[[1-(2-cyclopentylethyl)-1H-benzimidazol-6-yl]methylene]-2-[(2,6-dichlorophenyl)amino]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864274-83-9 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-(2-cyclopentylethyl)-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-03-6 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-[2-(3-pyridinyl)ethyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-06-9 CAPLUS

CN 4(5H)-Thiazolone, 5-[[1-(cyclopropylmethyl)-1H-benzimidazol-6-yl]methylene]-2-[(2,6-dichlorophenyl)amino]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-09-2 CAPLUS

CN 4(5H)-Thiazolone, 5-[[1-(cyclopentyl-1H-benzimidazol-6-yl)methylene]-2-[(2,6-dichlorophenyl)amino]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-12-7 CAPLUS

CN 4(5H)-Thiazolone, 5-[(6-benzoxazolylmethylene)-2-[(2,6-dichlorophenyl)amino]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-15-0 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[(1-methyl-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-16-1 CAPLUS


CN 4(5H)-Thiazolone, 2-[(2,6-difluorophenyl)amino]-5-[(1-methyl-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-17-2 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,4-dimethylphenyl)amino]-5-[(1-methyl-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-18-3 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-methoxyphenyl)amino]-5-[(1-methyl-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-19-4 CAPLUS
 CN 4(5H)-Thiazolone, 5-[(1-methyl-1H-benzimidazol-6-yl)methylene]-2-[[2-(trifluoromethyl)phenyl]amino]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-20-7 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,4-difluorophenyl)amino]-5-[(1-methyl-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-21-8 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-chloro-4-fluorophenyl)amino]-5-[(1-methyl-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-24-1 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[(1,2-dimethyl-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-25-2 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-difluorophenyl)amino]-5-[(1,2-dimethyl-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-26-3 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(1,2-dimethyl-1H-benzimidazol-6-yl)methylene]-2-[(2,4-dimethylphenyl)amino]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 864275-27-4 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,4-difluorophenyl)amino]-5-[(1,2-dimethyl-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-28-5 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chloro-4-fluorophenyl)amino]-5-[(1,2-dimethyl-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-29-6 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-30-9 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chloro-4-fluorophenyl)amino]-5-[[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-31-0 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-[2-(dimethylamino)ethyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-32-1 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-[2-(dimethylamino)ethyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-33-2 CAPLUS


CN 4(5H)-Thiazolone, 2-[(2,4-difluorophenyl)amino]-5-[[1-[2-(dimethylamino)ethyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-34-3 CAPLUS
 CN 4(5H)-Thiazolone, 5-[[1-[2-(dimethylamino)ethyl]-1H-benzimidazol-6-yl]methylene]-2-(phenylamino)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-35-4 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-[2-(diethylamino)ethyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-36-5 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-[2-(diethylamino)ethyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-37-6 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-[3-(4-morpholinyl)propyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-38-7 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-[3-(4-morpholinyl)propyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 864275-39-8 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-[3-(4-methyl-1-piperazinyl)propyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-40-1 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-[3-(4-methyl-1-piperazinyl)propyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-41-2 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-[2-(1-pyrrolidinyl)ethyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-42-3 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-[2-(1-

pyrrolidinyl)ethyl]-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-43-4 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-[2-(1-piperidiny)ethyl]-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-44-5 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-[2-(1-piperidiny)ethyl]-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-45-6 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-difluorophenyl)amino]-5-[[1-[2-(1-piperidinyl)ethyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-46-7 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-[2-(dimethylamino)ethyl]-2-methyl-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-47-8 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,4-difluorophenyl)amino]-5-[[1-[2-

(dimethylamino)ethyl]-2-methyl-1H-benzimidazol-6-yl)methylene]-, (5Z)-
(CA INDEX NAME)


Double bond geometry as shown.



RN 864275-48-9 CAPLUS

CN 4(5H)-Thiazolone, 5-[[1-[2-(dimethylamino)ethyl]-2-methyl-1H-benzimidazol-6-yl)methylene]-2-(phenylamino)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-49-0 CAPLUS

CN 4(5H)-Thiazolone, 2-[[2-(2,6-dichlorophenyl)amino]-5-[[1-(2-hydroxyethyl)-2-methyl-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-50-3 CAPLUS

CN 4(5H)-Thiazolone, 2-[[2-(2-chlorophenyl)amino]-5-[[1-(2-methyl-1-[2-(1-piperidinyl)ethyl]-1H-benzimidazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-51-4 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[2-methyl-1-[2-(1-piperidinyl)ethyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-52-5 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-difluorophenyl)amino]-5-[[2-methyl-1-[2-(1-piperidinyl)ethyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-53-6 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-methyl-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-54-7 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,4-difluorophenyl)amino]-5-[[1-methyl-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 864275-55-8 CAPLUS


CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-methyl-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-56-9 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[2-[(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-57-0 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-methyl-2-(4-morpholinylmethyl)-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-58-1 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-methyl-2-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-59-2 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-methyl-2-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-60-5 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-methyl-2-(trifluoromethyl)-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-61-6 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1,2-(dimethylamino)ethyl]-2-(trifluoromethyl)-1H-benzimidazol-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-62-7 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[(1-methyl-1H-benzotriazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 864275-63-8 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[[1-[2-(dimethylamino)ethyl]-1H-benzotriazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 864275-64-9 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[1-[2-(dimethylamino)ethyl]-1H-benzotriazol-6-yl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 949581-81-1 CAPLUS
 CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[(2-phenyl-1H-benzimidazol-6-yl)methylene]-, (2Z,5Z)-, compd. with piperidine (1:1) (CA INDEX NAME)

CM 1

CRN 949581-80-0
 CMF C23 H14 Cl2 N4 O S

Double bond geometry as shown.




CM 2

CRN 110-89-4
 CMF C5 H11 N



RN 949581-83-3 CAPLUS
 CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[(2-(1-methylethyl)-1H-benzimidazol-6-yl)methylene]-, (2Z,5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 949581-85-5 CAPLUS
 CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(2-methylpropyl)-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)-, compd. with piperidine (1:1) (CA INDEX NAME)

CM 1

CRN 949581-84-4

CMF C21 H18 Cl2 N4 O S

Double bond geometry as shown.



CM 2


CRN 110-89-4

CMF C5 H11 N



RN 949581-86-6 CAPLUS
 CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(3-pyridinyl)-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 949581-87-7 CAPLUS

CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(hydroxymethyl)-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 949581-89-9 CAPLUS

CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(2-hydroxyethyl)-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 949581-91-3 CAPLUS

CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(2-pyridinyl)-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 949581-92-4 CAPLUS

CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[(2-methyl-1H-benzimidazol-6-yl)methylene]-, (2Z,5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 949581-93-5 CAPLUS

CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[(2-(4-pyridinyl)-1H-benzimidazol-6-yl)methylene]-, (2Z,5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 949581-94-6 CAPLUS

CN 4-Thiazolidinone, 5-[[1-(2-cyclopropylethyl)-2-(3-pyridinyl)-1H-benzimidazol-6-yl)methylene]-2-[(2,6-dichlorophenyl)imino]-, (2Z,5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 949581-95-7 CAPLUS

CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[1-methyl-2-(3-pyridinyl)-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 949581-96-8 CAPLUS

CN 4-Thiazolidinone, 5-[[2-(aminomethyl)-1H-benzimidazol-6-yl]methylene]-2-[(2,6-dichlorophenyl)imino]-, (2Z,5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 949581-97-9 CAPLUS

CN 4-Thiazolidinone, 5-(1H-benzimidazol-6-ylmethylene)-2-[(2,6-

dichlorophenyl)imino]-, (2Z,5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 949581-98-0 CAPLUS

CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(hydroxymethyl)-1-methyl-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)

Double bond geometry as shown.




IT 864274-18-0P 864274-37-3P 949581-99-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted thiazolones as PI3 kinase inhibitors useful in combination therapy of diseases)


RN 864274-18-0 CAPLUS

CN 4-Thiazolidinone, 5-[(2-methyl-6-benzoxazolyl)methylene]-2-thioxo- (CA INDEX NAME)



RN 864274-37-3 CAPLUS


CN 4(5H)-Thiazolone, 5-[(2-amino-1H-benzimidazol-6-yl)methylene]-2-[(2-bromophenyl)amino]- (CA INDEX NAME)



RN 949581-99-1 CAPLUS

CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1022549 CAPLUS

DOCUMENT NUMBER: 147:365483

TITLE: Preparation of thiazolones for use as PI3 kinase inhibitors

INVENTOR(S): Dhanak, Dashyant; Knight, Steven David

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 132 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007103754	A2	20070913	WO 2007-US63112	20070302
WO 2007103754	A3	20080306		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 EP 1993535 A2 20081126 EP 2007-757755 20070302
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, HR
 JP 2009528383 T 20090806 JP 2008-557505 20070302
 US 20090023742 A1 20090122 US 2008-281179 20080829
 PRIORITY APPLN. INFO.: US 2006-778428P P 20060302
 WO 2007-US63112 W 20070302

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 147:365483; MARPAT 147:365483
 GI




AB The title compds. I [R = cycloalkyl, naphthyl, (un)substituted Ph, etc.; Q = benzofuranyl, quinolinyl, Ph, etc.], useful for inhibiting the activity/function of PI3 kinases, were prepared E.g., a multi-step synthesis of II, starting 2-chloro-5-fluoroaniline, was given. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones I.

IT 701294-07-7P 701294-08-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of thiazolone compds. as PI3 kinase inhibitors useful in combination therapy of diseases)


RN 701294-07-7 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chloro-5-nitrophenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)



RN 701294-08-8 CAPLUS

CN 4(5H)-Thiazolone, 2-[(5-amino-2-chlorophenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)



IT	312592-90-8P	358403-58-4P	701293-19-8P
	701293-21-2P	701293-22-3P	701293-23-4P
	701293-24-5P	701293-25-6P	701293-26-7P
	701293-27-8P	701293-28-9P	701293-29-0P
	701293-30-3P	701293-31-4P	701293-32-5P
	701293-33-6P	701293-34-7P	701293-35-8P
	701293-36-9P	701293-37-0P	701293-38-1P
	701293-39-2P	701293-40-5P	701293-41-6P
	701293-42-7P	701293-43-8P	701293-44-9P
	701293-45-0P	701293-46-1P	701293-47-2P
	701293-48-3P	701293-49-4P	701293-50-7P
	701293-51-8P	701293-52-9P	701293-53-0P
	701293-55-2P	701293-56-3P	701293-57-4P
	701293-58-5P	701293-59-6P	701293-62-1P
	701293-70-1P	701293-71-2P	701293-72-3P
	701293-73-4P	701293-74-5P	701293-75-6P
	701293-76-7P	701293-77-8P	701293-78-9P
	701293-79-0P	701293-80-3P	701293-81-4P
	701293-82-5P	701293-83-6P	701293-84-7P
	701293-92-7P	701293-93-8P	701293-94-9P
	701293-95-0P	701293-99-4P	701294-03-3P
	701294-04-4P	701294-09-9P	701294-10-2P
	701294-11-3P	701294-12-4P	701294-13-5P
	701294-14-6P	701294-15-7P	701294-16-8P
	701294-17-9P	701294-18-0P	701294-19-1P
	701294-20-4P	701294-21-5P	701294-22-6P
	701294-23-7P	701294-24-8P	701294-25-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazolone compds. as PI3 kinase inhibitors useful in

combination therapy of diseases)


RN 312592-90-8 CAPLUS

CN 4(5H)-Thiazolone, 5-(1,3-benzodioxol-5-ylmethylene)-2-[(2-chlorophenyl)amino]- (CA INDEX NAME)




RN 358403-58-4 CAPLUS

CN 4(5H)-Thiazolone, 5-(1,3-benzodioxol-5-ylmethylene)-2-[(2-bromophenyl)amino]- (CA INDEX NAME)




RN 701293-19-8 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chloro-5-fluorophenyl)amino]-5-[(2,3-dihydro-5-benzofuranyl)methylene]- (CA INDEX NAME)




RN 701293-21-2 CAPLUS


CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[(2-oxo-2H-1-benzopyran-6-yl)methylene]- (CA INDEX NAME)




RN 701293-22-3 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[(2,3-dihydro-5-benzofuranyl)methylene]- (CA INDEX NAME)




RN 701293-23-4 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylene]-2-[(2,4,6-trimethylphenyl)amino]- (CA INDEX NAME)



RN 701293-24-5 CAPLUS
 CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[(2,4,6-trimethylphenyl)amino]- (CA INDEX NAME)




RN 701293-25-6 CAPLUS
 CN 4(5H)-Thiazolone, 2-(cyclohexylamino)-5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylene]- (CA INDEX NAME)




RN 701293-26-7 CAPLUS

CN 4(5H)-Thiazolone, 2-(cyclohexylamino)-5-[(2,3-dihydro-5-benzofuranyl)methylene]- (CA INDEX NAME)




RN 701293-27-8 CAPLUS

CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[(2-methylphenyl)amino]- (CA INDEX NAME)




RN 701293-28-9 CAPLUS

CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylene]-2-[(2-methylphenyl)amino]- (CA INDEX NAME)




RN 701293-29-0 CAPLUS

CN 2(3H)-Benzoxazolone, 5-[[2-[(2-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]- (CA INDEX NAME)




RN 701293-30-3 CAPLUS


CN 4(5H)-Thiazolone, 2-[(2-bromophenyl)amino]-5-[(2,3-dihydro-5-benzofuranyl)methylene]- (CA INDEX NAME)




RN 701293-31-4 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[[2-(trifluoromethyl)phenyl]amino]- (CA INDEX NAME)




RN 701293-32-5 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[(2,3-dihydro-5-benzofuranyl)methylene]- (CA INDEX NAME)




RN 701293-33-6 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[[2-(methylthio)phenyl]amino]- (CA INDEX NAME)




RN 701293-34-7 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[(2-fluorophenyl)amino]- (CA INDEX NAME)




RN 701293-35-8 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-(methylthio)phenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-36-9 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-bromophenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-37-0 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2,3-dimethylphenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-38-1 CAPLUS
CN 4(5H)-Thiazolone, 2-(1-naphthalenylamino)-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-39-2 CAPLUS
 CN 4(5H)-Thiazolone, 5-(6-quinolinylmethylene)-2-[[2-(trifluoromethyl)phenyl]amino]- (CA INDEX NAME)



RN 701293-40-5 CAPLUS
 CN 4(5H)-Thiazolone, 2-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-41-6 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-42-7 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-bromophenyl)amino]-5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylene]- (CA INDEX NAME)




RN 701293-43-8 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-(6-quinoxalinylmethylene)- (CA INDEX NAME)




RN 701293-44-9 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylene]- (CA INDEX NAME)




RN 701293-45-0 CAPLUS

CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylene]-2-[(2-nitrophenyl)amino]- (CA INDEX NAME)




RN 701293-46-1 CAPLUS


CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[(2-nitrophenyl)amino]- (CA INDEX NAME)




RN 701293-47-2 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-chloro-4-fluoro-5-methylphenyl)amino]-5-[(2,3-dihydro-5-benzofuranyl)methylene]- (CA INDEX NAME)




RN 701293-48-3 CAPLUS
CN Benzoic acid, 3-chloro-4-[[5-[(2,3-dihydro-5-benzofuranyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, methyl ester (CA INDEX NAME)




RN 701293-49-4 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylene]- (CA INDEX NAME)




RN 701293-50-7 CAPLUS
CN 4(5H)-Thiazolone, 2-[[2-chloro-4-(trifluoromethyl)phenyl]amino]-5-[(2,3-dihydro-5-benzofuranyl)methylene]- (CA INDEX NAME)




RN 701293-51-8 CAPLUS
CN 4(5H)-Thiazolone, 2-[(4-bromo-2-chlorophenyl)amino]-5-[(2,3-dihydro-5-benzofuranyl)methylene]- (CA INDEX NAME)




RN 701293-52-9 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[(2-(methylsulfinyl)phenyl)amino]- (CA INDEX NAME)




RN 701293-53-0 CAPLUS
CN Benzoic acid, 3-chloro-4-[[5-[(2,3-dihydro-5-benzofuranyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 701293-55-2 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-chloro-4-fluoro-5-methylphenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-56-3 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-chloro-5-fluorophenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-57-4 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-chloro-5-fluorophenyl)amino]-5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylene]- (CA INDEX NAME)




RN 701293-58-5 CAPLUS
CN 4(5H)-Thiazolone, 2-[[2-chloro-4-(trifluoromethyl)phenyl]amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-59-6 CAPLUS
CN 4(5H)-Thiazolone, 5-(6-benzothiazolylmethylene)-2-[(2-chlorophenyl)amino]- (CA INDEX NAME)




RN 701293-62-1 CAPLUS
CN 4(5H)-Thiazolone, 5-(6-benzothiazolylmethylene)-2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)




RN 701293-70-1 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-chlorophenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-71-2 CAPLUS
CN 4(5H)-Thiazolone, 5-(6-quinolinylmethylene)-2-[(2,4,6-trimethylphenyl)amino]- (CA INDEX NAME)




RN 701293-72-3 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-methylphenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-73-4 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-methoxyphenyl)amino]-5-(6-quinolinylmethylene)-
(CA INDEX NAME)




RN 701293-74-5 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[[2-(dimethylamino)ethyl]amino]- (CA INDEX NAME)




RN 701293-75-6 CAPLUS
CN Benzoic acid, 2-[4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]hydrazide (CA INDEX NAME)




RN 701293-76-7 CAPLUS
CN 4(5H)-Thiazolone, 2-[[2-(dimethylamino)ethyl]amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-77-8 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-(1-piperidinylamino)- (CA INDEX NAME)




RN 701293-78-9 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 701293-79-0 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[[4-(1,1-dimethylethyl)-2-thiazolyl]amino]- (CA INDEX NAME)




RN 701293-80-3 CAPLUS
CN Benzenesulfonamide, 4-[[[5-[(2,3-dihydro-5-benzofuranyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]methyl]- (CA INDEX NAME)




RN 701293-81-4 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[[3-(dimethylamino)propyl]amino]- (CA INDEX NAME)




RN 701293-82-5 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[[3-(1H-imidazol-1-yl)propyl]amino]- (CA INDEX NAME)




RN 701293-83-6 CAPLUS
CN Hydrazinecarboxamide, 2-[5-[(2,3-dihydro-5-benzofuranyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]-N-phenyl- (CA INDEX NAME)




RN 701293-84-7 CAPLUS
CN Benzoic acid, 2-[5-[(2,3-dihydro-5-benzofuranyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]hydrazide (CA INDEX NAME)




RN 701293-92-7 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-bromo-6-fluorophenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701293-93-8 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2-methoxy-6-methylphenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)



RN 701293-94-9 CAPLUS
CN 4(5H)-Thiazolone, 5-(6-quinolinylmethylene)-2-[(2,3,4-trifluorophenyl)amino]- (CA INDEX NAME)




RN 701293-95-0 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[(2-oxo-2H-1-benzopyran-6-yl)methylene]- (CA INDEX NAME)




RN 701293-99-4 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-bromophenyl)amino]-5-[(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)methylene]- (CA INDEX NAME)




RN 701294-03-3 CAPLUS

CN 4(5H)-Thiazolone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-[(2-methoxyphenyl)amino]- (CA INDEX NAME)




RN 701294-04-4 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-nitrophenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)



RN 701294-09-9 CAPLUS


CN Ethanimidamide, N-[4-chloro-3-[[4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 701294-10-2 CAPLUS

CN Benamide, 4-[[4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]- (CA INDEX NAME)




RN 701294-11-3 CAPLUS

CN Benzenesulfonamide, 3-[[4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]- (CA INDEX NAME)




RN 701294-12-4 CAPLUS


CN Benzenesulfonamide, 4-[[4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]-N-2-pyridinyl- (CA INDEX NAME)




RN 701294-13-5 CAPLUS
 CN 4(5H)-Thiazolone, 2-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701294-14-6 CAPLUS
 CN 4(5H)-Thiazolone, 2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701294-15-7 CAPLUS
 CN 4(5H)-Thiazolone, 2-[[3-[(methylsulfonyl)methyl]phenyl]amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701294-16-8 CAPLUS
 CN 4(5H)-Thiazolone, 2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701294-17-9 CAPLUS
 CN 4(5H)-Thiazolone, 2-[[2-(3-chlorophenyl)ethyl]amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701294-18-0 CAPLUS
 CN Benzenesulfonamide, 4-[2-[[4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]ethyl]- (CA INDEX NAME)



RN 701294-19-1 CAPLUS
 CN Benzamide, 3-[4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]- (CA INDEX NAME)




RN 701294-20-4 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(2,6-difluorophenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701294-21-5 CAPLUS

CN 4(5H)-Thiazolone, 2-[(4-chloro-2-methylphenyl)amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701294-22-6 CAPLUS

CN 4(5H)-Thiazolone, 5-(6-quinolinylmethylene)-2-[[2-(trifluoromethoxy)phenyl]amino]- (CA INDEX NAME)




RN 701294-23-7 CAPLUS

CN 4(5H)-Thiazolone, 2-[[2,4-dichloro-5-(2-methoxyethoxy)phenyl]amino]-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 701294-24-8 CAPLUS


CN Benzoic acid, 4-chloro-3-[[4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]- (CA INDEX NAME)



RN 701294-25-9 CAPLUS
 CN Acetic acid, 2-[2,4-dichloro-5-[[4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]phenoxy]- (CA INDEX NAME)




IT 701294-28-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thiazolone compds. as PI3 kinase inhibitors useful in combination therapy of diseases)
 RN 701294-28-2 CAPLUS
 CN 4-Thiazolidinone, 5-[(2,3-dihydro-5-benzofuranyl)methylene]-2-thioxo- (CA INDEX NAME)



L6 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:1022235 CAPLUS
 DOCUMENT NUMBER: 147:365482
 TITLE: Preparation of thiazolones for use as PI3 kinase inhibitors
 INVENTOR(S): Dhanak, Dashyant; Knight, Steven David
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007103758	A2	20070913	WO 2007-US63116	20070302
WO 2007103758	A3	20080306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1993538	A2	20081126	EP 2007-757759	20070302
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, JP 2009528386 T 20090806 JP 2008-557508 20070302				
PRIORITY APPLN. INFO.:			US 2006-778531P	P 20060302
			WO 2007-US63116	W 20070302
OTHER SOURCE(S): CASREACT 147:365482; MARPAT 147:365482				
GI				



AB The title compds. I [R = (un)substituted aryl; Q = quinolinyl, quinoxalyl; with the proviso], useful for inhibiting the activity/function of PI3 kinases were prepared and formulated. Thus, heating a mixture of 3-amino-2-chloropyridine, (5Z)-2-(methylthio)-5-(6-quinolinylmethylidene)-1,3-thiazol-4(5H)-one and dioxane in a pressure bottle at 160°C for 3 h afforded 19%

(5Z)-2-[(2-chloro-3-pyridinyl)amino]-5-(6-quinolinylmethylidene)-1,3-thiazol-4(5H)-one. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones I.

IT 916050-60-7P 916050-61-8P 916050-64-1P
 916050-66-3P 916050-68-5P 916050-69-6P
 916050-73-2P 916050-76-5P 916314-37-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of thiazolone compds. as PI3 kinase inhibitors useful in

combination therapy of diseases)

RN 916050-60-7 CAPLUS

CN 4(5H)-Thiazolone, 2-[(2-chloro-3-pyridinyl)amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 916050-61-8 CAPLUS

CN 4(5H)-Thiazolone, 2-[[2-chloro-5-(2-pyridinyl)phenyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 916050-64-1 CAPLUS

CN Cyclobutanecarboxamide, N-[4-chloro-3-[[4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 916050-66-3 CAPLUS

CN Propanamide, N-[4-chloro-3-[[4,5-dihydro-4-oxo-5-[(5Z)-6-quinoxalinylmethylene]-2-thiazolyl]amino]phenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 916050-68-5 CAPLUS

CN Methanesulfonamide, N-[4-chloro-3-[[[(5Z)-4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 916050-69-6 CAPLUS

CN Acetamide, N-[4-chloro-3-[[[(5Z)-4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]phenyl]methyl]-2-methoxy- (CA INDEX NAME)


Double bond geometry as shown.



RN 916050-73-2 CAPLUS

CN 4(5H)-Thiazolone, 2-[[[2-chloro-5-[[[(1-methylethyl)amino]methyl]phenyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 916050-76-5 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-cyclobutyl-3-[[[(5Z)-4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 916314-37-9 CAPLUS

CN 4(5H)-Thiazolone, 2-[(6-chloro-1H-benzimidazol-5-yl)amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



IT 916050-71-0P 916050-72-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thiazolone compds. as PI3 kinase inhibitors useful in combination therapy of diseases)

RN 916050-71-0 CAPLUS

CN Carbamic acid, N-[[4-chloro-3-[[5-(4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 916050-72-1 CAPLUS

CN 4(5H)-Thiazolone, 2-[[5-(aminomethyl)-2-chlorophenyl]amino]-5-(6-quinolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1022231 CAPLUS

DOCUMENT NUMBER: 147:365481

TITLE: Preparation of thiazolones for use as PI3 kinase inhibitors

INVENTOR(S): Dhanak, Dashyant; Knight, Steven David

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007103759	A2	20070913	WO 2007-US63117	20070302

WO 2007103759 A3 20080306

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW


RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1996191 A2 20081203 EP 2007-757760 20070302
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, HR
 JP 2009528387 T 20090806 JP 2008-557509 20070302
 US 20090082349 A1 20090326 US 2008-281187 20080829
 PRIORITY APPLN. INFO.: US 2006-778530P P 20060302
 WO 2007-US63117 W 20070302

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 147:365481; MARPAT 147:365481

GI




AB The title compds. I [R = (un)substituted aryl; Q = quinazoliny, cinnoliny, etc.], useful for inhibiting the activity/function of PI3 kinases, were prepared and formulated. E.g., a multi-step synthesis of (5Z)-2-[(2,6-dichlorophenyl)amino]-5-(6-quinazolinylmethylidene)-1,3-thiazol-4(5H)-one, starting from 5-chloro-2-nitrobenzaldehyde, was given. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones I.

IT 932368-32-6P 932368-33-7P 932368-34-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thiazolone compds. as PI3 kinase inhibitors useful in combination therapy of diseases)

RN 932368-32-6 CAPLUS


CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-(6-quinazolinylmethylene)-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 932368-33-7 CAPLUS
CN 4(5H)-Thiazolone, 2-[(2,6-dichlorophenyl)amino]-5-[[4-(4-morpholinyl)-6-quinazolinyl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 932368-34-8 CAPLUS
CN 4(5H)-Thiazolone, 5-(6-cinnolinylmethylene)-2-[(2,6-dichlorophenyl)amino]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:976821 CAPLUS

DOCUMENT NUMBER: 147:314505

TITLE: Phosphoinositide 3-kinase γ inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment

AUTHOR(S): Ferrandi, Chiara; Ardisson, Vittoria; Ferro, Pamela; Ruckle, Thomas; Zaratin, Paola; Ammannati, Elena;

CORPORATE SOURCE: Hauben, Ehud; Rommel, Christian; Cirillo, Rocco
Istituto di Ricerche Biomediche A. Marxer, Merck
Serono, Colleretto Giacosa, Italy

SOURCE: Journal of Pharmacology and Experimental Therapeutics
(2007), 322(3), 923-930
CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental
Therapeutics

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Leukocyte trafficking to inflammatory sites is a gradual process, which is dominated in its early phases by chemokine- and cytokine-mediated neutrophil recruitment. The chemokine regulated on activation normal T cell expressed and secreted (RANTES) has been shown to be highly expressed in the joints of patient with rheumatoid arthritis and to promote leukocyte trafficking into the synovial tissue. In this study, we investigated the effect of RANTES in a murine model of peritoneal chemotaxis, and we found that RANTES dose-dependently induces neutrophil recruitment. Then, through morphol. and histol. analyses, we observed that activated neutrophils represent the major infiltrating population in response to RANTES chemotactic stimulus. Furthermore, we demonstrated that oral administration of either nonisoform-specific phosphoinositide 3-kinase (PI3K) inhibitor LY294002 (morpholin-4-yl-8-phenyl-chromen-4-one) or selective PI3Ky inhibitor AS041164 (5-benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione) blocks RANTES-induced chemotaxis and reduces the level of AKT phosphorylation. Because the two compds. showed a similar pharmacokinetic profile in terms of bioavailability and half-life after oral route administration, the selective inhibition of the PI3Ky-isoform pathway through AS041164 was three times more potent in reducing neutrophil recruitment. Finally, to confirm the blockade of neutrophil infiltration that occurs in the early phase of the inflammatory response, AS041164 was also tested in a model of carrageenan-induced paw edema in rats. Therefore, the PI3Ky pathway plays an important role in controlling neutrophil chemotaxis during early steps of inflammation.

IT 6318-41-8, 5-Benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphoinositide 3-kinase γ inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment)

RN 6318-41-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-(1,3-benzodioxol-5-ylmethylene)- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)


REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:330181 CAPLUS
 DOCUMENT NUMBER: 146:358833
 TITLE: Preparation of thiazolinone and oxazolinone derivatives as PTP-1B inhibitors
 INVENTOR(S): Banerjee, Rakesh Kumar; Gupta, Ramesh Chandra; Tuli, Davinder; Rode, Milind; Shuthar, Bharat; Umrani, Dhananjay; Pathak, Padmaja; Choksi, Tejal; Chaudhary, Anita
 PATENT ASSIGNEE(S): Torrent Pharmaceuticals Ltd., India
 SOURCE: PCT Int. Appl., 110pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007032028	A1	20070322	WO 2006-IN368	20060915
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM IN 2005K000860 A 20090619 IN 2005-K0860 20050916 AU 2006290250 A1 20070322 AU 2006-290250 20060915 CA 2622518 A1 20070322 CA 2006-2622518 20060915 EP 1934192 A1 20080625 EP 2006-796203 20060915 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS JP 2009508848 T 20090305 JP 2008-530756 20060915 ZA 2008002078 A 20090826 ZA 2008-2078 20080305 CN 101268060 A 20080917 CN 2006-80034134 20080317 MX 2008003783 A 20080507 MX 2008-3783 20080318 KR 2008056730 A 20080623 KR 2008-709160 20080416 US 20090088432 A1 20090402 US 2008-992016 20080813 PRIORITY APPLN. INFO.: IN 2005-K0860 A 20050916 WO 2006-IN368 W 20060915				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 146:358833
 GI



AB The title thiazolinone and oxazolinone derivs. I [wherein ring A = naphthalene, biphenyl, etc.; ring B = (un)substituted (thiazolinone)methylene, (oxazolinone)methylene, etc.; ring C = benzene, naphthalene, etc.; L = NH, NHCH₂, etc.; Y = (un)substituted CH₂, CH₂CH₂, or CH₂CH₂CH₂; R₁ = H, -CH₂CO₂H, etc.; R₂ and R₃ = independently H, -CH₂CO₂H, etc.; R₅ = COCO₂H, (un)substituted CO₂H, etc.; R₈ and R₉ = independently H, halo, alkyl, etc.] or pharmaceutically acceptable salts or prodrugs thereof are prepared as protein tyrosine phosphatase (PTP) inhibitors for treating or preventing PTP-1B mediated diseases. For example, the compound II was prepared in a multi-step synthesis. Some of the compds. I showed good inhibitory activities against human PTP-1B.

IT	929701-19-9P	929701-21-3P	929701-24-6P
	929701-25-7P	929701-28-0P	929701-33-7P
	929701-35-9P	929701-40-6P	929701-41-7P
	929701-43-9P	929701-44-0P	929701-45-1P
	929701-51-9P	929701-52-0P	929701-60-0P
	929701-61-1P	929701-65-5P	929701-66-6P
	929701-67-7P	929701-68-8P	929701-71-3P
	929701-72-4P	929701-76-8P	929701-82-6P
	929701-88-2P	929701-89-3P	929701-92-8P
	929702-00-1P	929702-01-2P	929702-02-3P
	929702-03-4P	929702-05-6P	929702-06-7P
	929702-10-3P	929702-14-7P	929702-15-8P
	929702-17-0P	929702-18-1P	929702-23-8P
	929702-25-0P	929702-28-3P	929702-29-4P
	929702-30-7P	929702-31-8P	929702-32-9P
	929702-34-1P	929702-35-2P	929702-39-6P
	929702-41-0P	929702-43-2P	929702-45-4P
	929702-46-5P	929702-50-1P	929702-52-3P
	929702-53-4P	929702-55-6P	929702-56-7P
	929702-57-8P	929702-58-9P	929702-59-0P
	929702-60-3P	929702-61-4P	929702-63-6P
	929702-67-0P	929702-68-1P	929702-71-6P
	929702-72-7P	929702-73-8P	929702-77-2P
	929702-79-4P	929702-80-7P	929702-81-8P
	929702-82-9P	929702-83-0P	929702-84-1P
	929702-85-2P	929702-86-3P	929702-87-4P
	929702-88-5P	929702-94-3P	929702-96-5P
	929702-98-7P	929702-99-8P	929703-00-4P
	929703-01-5P	929703-02-6P	929703-03-7P
	929703-04-8P	929703-07-1P	929703-16-2P
	929703-22-0P	929703-24-2P	929703-33-3P
	929703-56-0P	929703-60-6P	929703-86-6P


929704-02-9P	929704-03-0P	929704-07-4P
929704-09-6P	929704-35-8P	929704-36-9P
929704-39-2P	929704-40-5P	929704-41-6P
929704-47-2P	929704-49-4P	929704-53-0P
929704-54-1P	929704-55-2P	929704-70-1P
929704-72-3P	929704-73-4P	929704-76-7P
929704-79-0P	929704-81-4P	929704-83-6P
929704-87-0P	929704-88-1P	929705-01-1P
929705-08-8P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of thiazolinone and oxazolinone derivs. as PTP-1B inhibitors)


RN 929701-19-9 CAPLUS

CN Benzeneacetic acid, 4-[[4,5-dihydro-5-(2-naphthalenylmethylene)-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929701-21-3 CAPLUS

CN Benzeneacetic acid, 4-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929701-24-6 CAPLUS


CN Benzeneacetic acid, 4-[[4,5-dihydro-5-[(4-methoxy-1-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929701-25-7 CAPLUS
 CN Benzenecetic acid, 4-[[4,5-dihydro-5-[(6-methoxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929701-28-0 CAPLUS
 CN Benzenecetic acid, 4-[[4,5-dihydro-5-[[3-(1-methylethoxy)-2-naphthalenyl]methylene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929701-33-7 CAPLUS
 CN Benzenecetic acid, 3-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929701-35-9 CAPLUS
CN Benzeneacetic acid, 3-[[4,5-dihydro-5-(2-naphthalenylmethylene)-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929701-40-6 CAPLUS
CN Benzeneacetic acid, 3-[[4,5-dihydro-5-[[3-(1-methylethoxy)-2-naphthalenyl]methylene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929701-41-7 CAPLUS
CN Benzeneacetic acid, 4-[[2-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]acetyl]amino]- (CA INDEX NAME)




RN 929701-43-9 CAPLUS
CN Phosphonic acid, P-[[4-[[4,5-dihydro-5-(2-naphthalenylmethylene)-4-oxo-2-thiazolyl]amino]phenyl]methyl]-, diethyl ester (CA INDEX NAME)




RN 929701-44-0 CAPLUS
 CN Benzeneacetamide, 4-[[4,5-dihydro-5-(2-naphthalenylmethylene)-4-oxo-2-thiazolyl]amino]-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



RN 929701-45-1 CAPLUS
 CN Benzeneacetamide, 4-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 929701-51-9 CAPLUS
 CN Benzeneacetic acid, 4-[[4,5-dihydro-5-[[3-(hydroxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 929701-52-0 CAPLUS
 CN 4(5H)-Thiazolone, 5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-[[4-

(2H-tetrazol-5-ylmethyl)phenyl]amino]- (CA INDEX NAME)




RN 929701-60-0 CAPLUS

CN 4(5H)-Thiazolone, 5-[(6-methoxy-2-naphthalenyl)methylene]-2-[[4-(2H-tetrazol-5-ylmethyl)phenyl]amino]- (CA INDEX NAME)




RN 929701-61-1 CAPLUS

CN Benzenepropanoic acid, 4-[[4,5-dihydro-5-[(2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929701-65-5 CAPLUS

CN Benzenepropanoic acid, 4-[[4,5-dihydro-5-[(6-methoxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929701-66-6 CAPLUS


CN 1H-Indole-1-acetic acid, 5-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929701-67-7 CAPLUS
 CN Benzenepropanoic acid, 4-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]-α-ethyl- (CA INDEX NAME)



RN 929701-68-8 CAPLUS
 CN Benzenepropanoic acid, 4-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929701-71-3 CAPLUS
 CN Benzenemethanesulfonamide, 4-[[4,5-dihydro-5-(2-naphthalenylmethylene)-4-oxo-2-thiazolyl]amino]-N-methyl- (CA INDEX NAME)




RN 929701-72-4 CAPLUS
 CN Benzenemethanesulfonamide, 4-[[4,5-dihydro-5-(2-naphthalenylmethylene)-4-oxo-2-

thiazolyl]amino]- α -methyl- (CA INDEX NAME)




RN 929701-76-8 CAPLUS

CN Benzeneacetic acid, 4-[[4,5-dihydro-5-[1-(6-methoxy-2-naphthalenyl)ethylidene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929701-82-6 CAPLUS

CN Benzenemethanesulfonamide, 4-[[4,5-dihydro-5-[(6-methoxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]-N-methyl- (CA INDEX NAME)



RN 929701-88-2 CAPLUS


CN Benzeneacetamide, 4-[[4,5-dihydro-5-[(6-methoxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]-N-[(4-methylphenyl)sulfonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 929701-89-3 CAPLUS

CN 4(5H)-Thiazolone, 5-(2-naphthalenylmethylene)-2-[[4-(2H-tetrazol-5-ylmethyl)phenyl]amino]- (CA INDEX NAME)




RN 929701-92-8 CAPLUS

CN Benzeneacetic acid, 4-[[4,5-dihydro-5-[[6-(1-methylethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]- (CA INDEX NAME)



RN 929702-00-1 CAPLUS


CN Benzeneacetic acid, 4-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 929702-01-2 CAPLUS


CN Benzeneacetic acid, 4-[[4,5-dihydro-5-(2-naphthalenylmethylene)-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 929702-02-3 CAPLUS


CN Benzeneacetic acid, 4-[[4,5-dihydro-5-[(6-methoxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 929702-03-4 CAPLUS


CN 1H-Indole-1-acetic acid, 5-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 929702-05-6 CAPLUS


CN Benzenecetic acid, 4-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]-α-ethyl-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 929702-06-7 CAPLUS

CN Benzenecetic acid, 4-[[5-[[3-[(4-fluorophenyl)methoxy]-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929702-10-3 CAPLUS

CN Benzenepropanoic acid, 4-[[4,5-dihydro-5-(2-naphthalenylmethylene)-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-14-7 CAPLUS
CN 4(5H)-Thiazolone, 5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-[[4-(5H-tetrazol-5-ylmethyl)phenyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-15-8 CAPLUS
CN Benzenepropanoic acid, 4-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-17-0 CAPLUS
CN 4(5H)-Thiazolone, 5-[[6-methoxy-2-naphthalenyl]methylene]-2-[[4-(5H-tetrazol-5-ylmethyl)phenyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-18-1 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[[4,5-dihydro-5-[(6-methoxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-23-8 CAPLUS
CN Benzeneacetamide, 4-[[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]-N-[(4-methylphenyl)sulfonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 929702-25-0 CAPLUS
CN Benzeneacetamide, N-[(4-chlorophenyl)sulfonyl]-4-[[[4,5-dihydro-5-[(6-methoxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 929702-28-3 CAPLUS


CN Benzenecetic acid, 4-[[5-[(6-bromo-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 929702-29-4 CAPLUS

CN Benzenecetic acid, 4-[[4,5-dihydro-5-(2-naphthalenylmethylene)-4-oxo-2-thiazolyl]amino]-α-oxo- (CA INDEX NAME)



RN 929702-30-7 CAPLUS


CN Benzeneacetamide, 4-[[[4,5-dihydro-5-(2-naphthalenylmethylene)-4-oxo-2-thiazolyl]amino]-N-[(4-methylphenyl)sulfonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 929702-31-8 CAPLUS


CN Benzenemethanesulfonamide, 4-[[5-[[3-[(4-fluorophenyl)methoxy]-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 929702-32-9 CAPLUS

CN Benzenemethanesulfonamide, 4-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]-N-methyl- (CA INDEX NAME)



RN 929702-34-1 CAPLUS


CN Benzenemethanesulfonamide, 4-[[4,5-dihydro-5-[[3-methoxy-2-naphthalenyl]methylene]-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 929702-35-2 CAPLUS


CN Benzenecetic acid, 4-[[5-[(3-ethoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 929702-39-6 CAPLUS

CN Benzenecetic acid, 4-[[5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929702-41-0 CAPLUS


CN Benzenecetic acid, 4-[[5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)



RN 929702-43-2 CAPLUS
 CN Benzeneacetamide, 4-[[5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 929702-45-4 CAPLUS
 CN 4-Thiazoleacetic acid, 2-[[4,5-dihydro-5-(2-naphthalenylmethylene)-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-46-5 CAPLUS
 CN Benzeneacetic acid, 4-[[4,5-dihydro-4-oxo-5-[[3-(2-phenylethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-50-1 CAPLUS
CN 4-Thiazoleacetic acid, 2-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929702-52-3 CAPLUS
CN Benzenecetic acid, 4-[[5-[[3-(cyclopentylmethoxy)-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-53-4 CAPLUS
CN Benzenepropanoic acid, α-[4-[[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]phenyl]-, sodium salt (1:1) (CA INDEX NAME)




RN 929702-58-9 CAPLUS

CN Benzenesacetic acid, 4-[[4,5-dihydro-4-oxo-5-[(1,2,3,4-tetrahydro-1-methyl-6-quinolinyl)methylene]-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929702-59-0 CAPLUS

CN Benzenesacetic acid, 4-[[4,5-dihydro-4-oxo-5-[[3-[(tetrahydro-2-furanyl)methoxy]-2-naphthalenyl]methylene]-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929702-60-3 CAPLUS

CN Benzenesacetic acid, 4-[[5-[(6-ethoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-61-4 CAPLUS
CN Benzenecetic acid, 4-[[5-[(3,5-diethoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-63-6 CAPLUS
CN Benzenecetic acid, 4-[[4,5-dihydro-5-[(1-methoxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929702-67-0 CAPLUS
CN Benzenecetic acid, 4-[[5-[(1-ethoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-68-1 CAPLUS
CN Benzenepropanoic acid, 4-[[4,5-dihydro-4-oxo-5-[[1-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-71-6 CAPLUS
CN Benzenepropanoic acid, 4-[[4,5-dihydro-5-[(1-hydroxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-72-7 CAPLUS
CN Benzenepropanoic acid, 4-[[4,5-dihydro-5-[(1-methoxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]-α-ethyl-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-73-8 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[[4,5-dihydro-5-[(1-methoxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-77-2 CAPLUS
CN Benzeneacetic acid, 4-[[5-[(2,3-dihydro-5-benzofuranyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-79-4 CAPLUS
CN Benzeneacetic acid, 4-[[5-[[3-[(4-nitrophenyl)methoxy]-2-naphthalenyl]methylene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929702-80-7 CAPLUS

CN Benzenecetic acid, 4-[[5-[[6-(carboxymethoxy)-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)



RN 929702-81-8 CAPLUS


CN Benzenecetic acid, 4-[[5-[[3,7-dimethoxy-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 929702-82-9 CAPLUS


CN Benzenecetic acid, 4-[[5-[[6-fluoro-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 929702-83-0 CAPLUS


CN Benzenecetic acid, 4-[[5-[(3,5-dimethoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 929702-84-1 CAPLUS

CN Benzenecetic acid, 4-[[4,5-dihydro-5-[[3-[(4-methylphenyl)methoxy]-2-naphthalenyl]methylene]-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-85-2 CAPLUS

CN Benzenacetamide, 4-[[4,5-dihydro-5-[[3-[(4-methylphenyl)methoxy]-2-naphthalenyl]methylene]-4-oxo-2-thiazolyl]amino]-N-[(4-methylphenyl)methyl]-, sodium salt (1:1) (CA INDEX NAME)


methylphenyl)sulfonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 929702-86-3 CAPLUS


CN Benzenecetic acid, 4-[[4,5-dihydro-4-oxo-5-[[3-(2-thienylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 929702-87-4 CAPLUS

CN Benzenecetic acid, 4-[[4,5-dihydro-5-(1H-indol-5-ylmethylene)-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929702-88-5 CAPLUS

CN Benzenecetic acid, 4-[[4,5-dihydro-5-(2-naphthalenylmethylene)-4-oxo-2-thiazolyl]amino]-, ethyl ester (CA INDEX NAME)




RN 929702-94-3 CAPLUS
 CN Benzenesacetamide, 4-[[4,5-dihydro-5-[(3-methoxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]-N-[(4-methylphenyl)sulfonyl]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-96-5 CAPLUS
 CN Benzenepropanoic acid, 4-[[4,5-dihydro-5-[(3-methoxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-98-7 CAPLUS
 CN Benzenesacetic acid, 4-[[5-[(3-(carboxymethoxy)-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929702-99-8 CAPLUS
 CN Benzenesulfonamide, 4-[[4,5-dihydro-5-[[3-[(2-methoxyphenyl)methoxy]-2-naphthalenyl]methylene]-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 929703-00-4 CAPLUS
 CN Benzenesulfonamide, 4-[[4,5-dihydro-5-[[3-[(3-methoxyphenyl)methoxy]-2-naphthalenyl]methylene]-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 929703-01-5 CAPLUS


CN Benzenecetic acid, 4-[[5-[[3-[(4-chlorophenyl)methoxy]-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 929703-02-6 CAPLUS


CN Benzenepropanoic acid, 4-[[4,5-dihydro-5-[[3-[(4-methylphenyl)methoxy]-2-naphthalenyl]methylene]-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 929703-03-7 CAPLUS

CN Benzenepropanoic acid, 4-[[5-[[3-[(4-chlorophenyl)methoxy]-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929703-04-8 CAPLUS
CN Benzenecetic acid, 4-[[4,5-dihydro-5-[(6-hydroxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929703-07-1 CAPLUS
CN Benzenecetic acid, 4-[[5-[(3,7-diethoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 929703-16-2 CAPLUS
CN Benzenecetic acid, 4-[[5-[[3-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 929703-22-0 CAPLUS

CN Benzenepropanoic acid, 4-[[5-[(3,8-dimethoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)



RN 929703-24-2 CAPLUS


CN Benzenepropanoic acid, 4-[[5-[(6-fluoro-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929703-33-3 CAPLUS

CN Acetic acid, 2-[[[3-[[2-[[4-[2-[[4-methylphenyl)sulfonyl]amino]-2-oxoethyl]phenyl]amino]-4-oxo-5(4H)-thiazolylidene]methyl]-2-naphthalenyl]oxy]- (CA INDEX NAME)




RN 929703-56-0 CAPLUS
 CN Benzenesacetic acid, 4-[[4,5-dihydro-5-[(6-methoxy-2-naphthalenyl)methylene]-4-oxo-2-thiazolyl]amino]-2-fluoro-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 929703-60-6 CAPLUS
 CN Benzenesacetic acid, 4-[[4,5-dihydro-4-oxo-5-[[6-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]-, sodium salt (1:1) (CA INDEX NAME)




● Na


RN 929703-86-6 CAPLUS
 CN Benzenepropanoic acid, 4-[[5-[[6-(2-ethoxy-2-oxoethoxy)-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929704-02-9 CAPLUS
 CN Benzeacetamide, 4-[[5-[(3-ethoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-N-(2-thienylsulfonyl)- (CA INDEX NAME)



RN 929704-03-0 CAPLUS
 CN Benzeacetic acid, α-bromo-4-[[5-[(3,5-dipropoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)




RN 929704-07-4 CAPLUS
 CN Benzeacetic acid, 4-[[4,5-dihydro-5-[[3-(1-methylethoxy)-2-naphthalenyl]methylene]-4-oxo-2-thiazolyl]amino]-α-(3-methylbutyl)- (CA INDEX NAME)




RN 929704-09-6 CAPLUS

CN Octanedioic acid, 2-[4-[[5-[[3-([1,1'-biphenyl]-4-ylmethoxy)-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]phenyl]- (CA INDEX NAME)




RN 929704-35-8 CAPLUS

CN Benzeneacetamide, 4-[5-[(3-ethoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-N-[(4-nitrophenyl)sulfonyl]- (CA INDEX NAME)




RN 929704-36-9 CAPLUS

CN Benzeneacetic acid, 4-[4,5-dihydro-4-oxo-5-[[3-(phenylmethoxy)-2-naphthalenyl]methylene]-2-thiazolyl]amino]-2-fluoro- (CA INDEX NAME)




RN 929704-39-2 CAPLUS

CN Benzeneacetic acid, 4-[5-[(3,5-dipropoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-2-(1-hydroxyethyl)- (CA INDEX NAME)




RN 929704-40-5 CAPLUS

CN Benzeneacetic acid, 4-[[5-[(1,4-diethoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-2-fluoro-α-propyl- (CA INDEX NAME)




RN 929704-41-6 CAPLUS

CN Benzeneacetamide, 4-[[5-[(1,4-diethoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-N-[(3-fluoro-4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 929704-47-2 CAPLUS


CN Benzeneacetic acid, 4-[[5-[[3-[(1,1'-biphenyl)-4-ylmethoxy]-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-α-bromo-2-fluoro- (CA INDEX NAME)




RN 929704-49-4 CAPLUS
 CN Benzenecetic acid, 4-[[5-[[3-[[4-(ethoxycarbonyl)phenyl]methoxy]-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-2-fluoro- α -propyl- (CA INDEX NAME)



RN 929704-53-0 CAPLUS
 CN Benzenecetic acid, 4-[[5-[[3-[[4-(ethoxycarbonyl)phenyl]methoxy]-2-naphthalenyl]methylene]-4,5-dihydro-5-[[3-(1-methylethoxy)-2-naphthalenyl]methylene]-4-oxo-2-thiazolyl]amino]- α -(ethylthio)- (CA INDEX NAME)




RN 929704-54-1 CAPLUS
 CN Benzenecetic acid, 4-[[5-[[3-[[4-(ethoxycarbonyl)phenyl]methoxy]-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-2-fluoro- α -methyl- (CA INDEX NAME)




RN 929704-55-2 CAPLUS

CN Benzeneacetic acid, 4-[5-[(3,5-dipropoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-α-ethyl-2-fluoro- (CA INDEX NAME)




RN 929704-70-1 CAPLUS

CN Octanedioic acid, 2-[4-[[5-[(3-ethoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]phenyl]- (CA INDEX NAME)




RN 929704-72-3 CAPLUS

CN Benzeneacetic acid, 4-[5-[[3-([1,1'-biphenyl]-4-ylmethoxy)-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-α-ethyl-2-fluoro- (CA INDEX NAME)




RN 929704-73-4 CAPLUS

CN Benzeneacetamide, 4-[[5-[[3-[(1,1'-biphenyl)-4-ylmethoxy]-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-N-[(4-methoxyphenyl)sulfonyl]- (CA INDEX NAME)




RN 929704-76-7 CAPLUS

CN Benzeneacetic acid, 4-[[5-[[3-[[4-(ethoxycarbonyl)phenyl]methoxy]-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-2-fluoro-α-hydroxy- (CA INDEX NAME)




RN 929704-79-0 CAPLUS

CN Benzoic acid, 4-[[[3-[[2-[[4-[2-[[4-(4-fluorophenyl)sulfonyl]amino]-2-oxoethyl]phenyl]amino]-4-oxo-5(4H)-thiazolylidene]methyl]-2-naphthalenyl]oxy]methyl]-, ethyl ester (CA INDEX NAME)




RN 929704-81-4 CAPLUS

CN Benzeneacetamide, N-[(3-fluoro-4-methylphenyl)sulfonyl]-4-[[5-[[3-[(4-fluorophenyl)methoxy]-2-naphthalenyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]- (CA INDEX NAME)



RN 929704-83-6 CAPLUS

CN Acetic acid, 2-[[[6-[[4-oxo-2-[[4-[2-oxo-2-[(2-thienylsulfonyl)amino]ethyl]phenyl]amino]-5(4H)-thiazolylidene]methyl]-2-naphthalenyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




PAGE 1-A




PAGE 1-B


RN 929704-87-0 CAPLUS

CN Benzeneacetic acid, α -bromo-4-[[5-[(3,5-dipropoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-2-fluoro-
(CA INDEX NAME)

RN 929704-88-1 CAPLUS


CN Benzeneacetic acid, 4-[[5-[[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]- α -ethyl-
2-fluoro- (CA INDEX NAME)

RN 929705-01-1 CAPLUS

CN Benzeneacetic acid, 4-[[5-[[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-2-fluoro-
(CA INDEX NAME)


RN 929705-08-8 CAPLUS

CN Benzeneacetic acid, 4-[[5-[(3,5-dipropoxy-2-naphthalenyl)methylene]-4,5-dihydro-4-oxo-2-oxazolyl]amino]-2-fluoro- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:81255 CAPLUS
 DOCUMENT NUMBER: 146:316860
 TITLE: Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinasey
 AUTHOR(S): Lanni, Thomas B.; Greene, Keri L.; Kolz, Christine N.; Para, Kimberly S.; Visnick, Melean; Mobley, James L.; Dudley, David T.; Baginski, Theodore J.; Llimatta, Marya B.
 CORPORATE SOURCE: Chemistry Department, Pfizer Global Research and Development, Ann Arbor, MI, 48105, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(3), 756-760
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 146:316860
 GI



I

AB The Type 1 PI3-Kinases comprise a family of enzymes, which primarily phosphorylate PIP2 to give the second messenger PIP3, a key player in many intracellular signaling processes. Of the four type 1 PI3Ks, the γ -isoform, which is expressed almost exclusively in leukocytosis of particular interest with respect to its role in inflammatory diseases such as rheumatoid arthritis (RA) and chronic obstructive pulmonary disease


(COPD). Investigation of a series of 4,6-disubstituted-4H-benzo[1,4]oxazin-3-ones, e.g., I, has led to the identification of single-digit nanomolar inhibitors of PI3Ky, several of which had good cell based activity and were shown to be active in vivo in an aspecific peritonitis model of inflammatory cell migration.

IT 711021-28-2P 711021-30-6P 711022-13-8P
 711022-24-1P 711023-25-5P 711023-29-9P
 711023-30-2P 711023-31-3P 711023-32-4P
 711023-33-5P 711023-67-5P 711023-69-7P
 711023-73-3P 711023-74-4P 711023-75-5P
 711023-76-6P 711023-77-7P 711023-78-8P
 711023-80-2P 711023-83-5P 711023-98-2P
 711024-17-8P 928776-17-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and PI3Ky-kinase inhibitors, and structure-activity
 relationship of benzoxazinones starting from hydroxy(nitro)benzaldehyde
 and benzyl bromides or phenylethyl iodides)


RN 711021-28-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 711021-30-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(2-phenylethyl)- (CA INDEX NAME)




RN 711022-13-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3,5-dimethylphenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-24-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-(1,1-dimethylethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-25-5 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,4-dimethylphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-29-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3-methylphenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-30-2 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(4-bromophenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-31-3 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3,4-dichlorophenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-32-4 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[2-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 711023-33-5 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(2,4-dichlorophenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-67-5 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3,5-dimethoxyphenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-69-7 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-[4-(1,1-dimethylethyl)phenyl]ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinydene)methyl]- (CA INDEX NAME)




RN 711023-73-3 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3,4-difluorophenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinydene)methyl]- (CA INDEX NAME)



RN 711023-74-4 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(4-chlorophenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-75-5 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3-chlorophenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-76-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(4-methoxyphenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-77-7 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3-methoxyphenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-78-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(4-methylphenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711023-80-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(4-methylphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711023-83-5 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3-methylphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-98-2 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 711024-17-8 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(4-chlorophenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 928776-17-4 CAPLUS
 CN Benzonitrile, 4-[[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
 (7 CITINGS)
 REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:1225881 CAPLUS
 DOCUMENT NUMBER: 146:7948
 TITLE: Preparation of 2,5-disubstituted thiazol-4-ones as
 vanilloid receptor VR1 ligands.
 INVENTOR(S): Frank, Robert; Kless, Achim; Jostock, Ruth
 PATENT ASSIGNEE(S): Gruenenthal G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 153pp.


DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: German

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006122777	A2	20061123	WO 2006-EP4666	20060517
WO 2006122777	A3	20070222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM DE 102005024012 A1 20061123 DE 2005-102005024012 20050520 CA 2609002 A1 20061123 CA 2006-2609002 20060517 EP 1890695 A2 20080227 EP 2006-753682 20060517 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR JP 2008540595 T 20081120 JP 2008-511622 20060517 US 20090215758 A1 20090827 US 2008-915156 20080610 PRIORITY APPLN. INFO.: DE 2005-102005024012A 20050520 WO 2006-EP4666 W 20060517				
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT OTHER SOURCE(S): CASREACT 146:7948; MARPAT 146:7948 GI				




AB Title compds. [I; R1 = (substituted) (unsatd.) (heteroatom-containing) (condensed) cycloaliphatic, aryl, amino, acylamino, ureido; R2 = (substituted) (unsatd.) (heteroatom-containing) (condensed) cycloaliphatic, CHUX, etc.; U = O, S, NH, NMe, NEt, NCHMe2; X = (substituted) (fused) aryl, heteroaryl], were prepared. Thus, 4-hydroxy-3-methoxybenzonitrile, thioglycolic acid, and Et3N were kept in EtOH to give 37% 2-(4-hydroxy-3-methoxyphenyl)thiazol-4-one. The latter was refluxed overnight with 4-methylbenzaldehyde and NaOAc in HOAc to give 74% 2-(4-hydroxy-3-methoxyphenyl)-5-(4-methylbenzylidene)thiazolin-4-one. Tested I showed EC50 values for affinity to human VR1 receptors of 1.02 to >25.


IT 915312-03-7 915312-05-9 915312-09-3
 915312-15-1 915312-20-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (preparation of thiazolones as vanilloid receptor VR1 ligands)
 RN 915312-03-7 CAPLUS
 CN 4(5H)-Thiazolone, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-5-(1-
 naphthalenylmethylene)- (CA INDEX NAME)




RN 915312-05-9 CAPLUS
 CN 4(5H)-Thiazolone, 2-[[4-methylphenyl)methyl]amino]-5-(1-
 naphthalenylmethylene)- (CA INDEX NAME)




RN 915312-09-3 CAPLUS
 CN 4(5H)-Thiazolone, 2-[[4-methylphenyl)methyl]amino]-5-(2-
 naphthalenylmethylene)- (CA INDEX NAME)



RN 915312-15-1 CAPLUS
 CN 4(5H)-Thiazolone, 5-(1-naphthalenylmethylene)-2-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)



RN 915312-20-8 CAPLUS
 CN 4(5H)-Thiazolone, 5-(2-naphthalenylmethylene)-2-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:722252 CAPLUS

DOCUMENT NUMBER: 146:197307
 TITLE: Phosphoinositide 3-kinase- γ as a target in rheumatoid arthritis and systemic lupus
 AUTHOR(S): Doggrell, Sheila A.
 CORPORATE SOURCE: Charles Darwin University, School of Science, Casuarina, 0811, Australia
 SOURCE: Expert Opinion on Therapeutic Targets (2006), 10(4), 627-630
 CODEN: EOTTAO; ISSN: 1472-8222
 PUBLISHER: Informa Healthcare
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review. Rheumatoid arthritis and systemic lupus erythematosus are autoimmune diseases, which may involve phosphoinositide 3-kinase gamma (PI3Ky). AS605240 is a new and selective PI3Ky inhibitor. The direct administration of collagen II-specific antibodies produced the features of rheumatoid arthritis in mice, and when AS605240 was administered orally after the collagen antibodies, it reduced the clin. and histol. signs of joint inflammation. Collagen can also be used to induce the clin. and histopathol. symptoms similar to rheumatoid arthritis in mice and this can be prevented or reduced by treatment with AS605240. MRL-lpr mice develop lupus-like disease and AS605240 prolonged the life of these mice. MRL-lpr mice also develop kidney disease and this can be reversed with AS605240 treatment. These results suggest that PI3Ky is a therapeutic target in chronic inflammation and that the PI3Ky inhibitor AS605240 may have potential in the treatment of chronic inflammatory conditions.

IT 648450-29-7, AS 605240
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phosphoinositide 3-kinase- γ as target in rheumatoid arthritis and systemic lupus)

RN 648450-29-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-(6-quinoxalinylmethylene)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:318485 CAPLUS
 DOCUMENT NUMBER: 144:370081
 TITLE: Carbostyryl compounds and their preparation, pharmaceutical compositions, and their transcription promoting activity of TFF2 for treatment and/or prevention of various diseases
 INVENTOR(S): Kuroda, Takeshi; Yamauchi, Takahito; Shinohara, Tomoichi; Oshima, Kunio; Kitajima, Chiharu; Nagao,

Hitoshi; Fukushima, Tae; Tomoyasu, Takahiro; Ishiyama,
Hironobu; Ohta, Kazuhide; Takano, Masaaki; Sumida,
Takumi



PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 468 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006035954	A1	20060406	WO 2005-JP18217	20050926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005288080	A1	20060406	AU 2005-288080	20050926
CA 2580811	A1	20060406	CA 2005-2580811	20050926
JP 3906471	B1	20070418	JP 2006-519041	20050926
JP 2007512220	T	20070517		
EP 1797082	A1	20070620	EP 2005-788152	20050926
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101068810	A	20071107	CN 2005-80037090	20050926
BR 2005016219	A	20080826	BR 2005-16219	20050926
US 20070179173	A1	20070802	US 2006-582014	20060607
IN 2007DN01824	A	20070817	IN 2007-DN1824	20070308
ZA 2007002228	A	20090624	ZA 2007-2228	20070316
MX 2007003735	A	20070423	MX 2007-3735	20070328
KR 2007061902	A	20070614	KR 2007-709483	20070426
KR 823414	B1	20080417		
KR 2007072632	A	20070704	KR 2007-714064	20070621
KR 840465	B1	20080620		
PRIORITY APPLN. INFO.:			JP 2004-282814	A 20040928
			WO 2005-JP18217	W 20050926
			KR 2007-709483	A3 20070426

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 144:370081; MARPAT 144:370081
GI



AB The invention provides carbostyryl compds. represented by formula I or salts thereof, and their pharmaceutical compns., prepn. and use for transcription promotion activity of TFF2. The carbostyryl compds. or salts thereof, of the invention, induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds. Compds. of formula I wherein A is a bond, a lower alkylene group, or a lower alkylidene group; X is O or S; the dotted line is a single or a double bond; R4 and R5 are independently H, with the provision that dotted line is a double bond; or R4-R5 may be linked together to form a CH=CH-CH=CH group; R1 is H, lower alkyl, (un)substituted Ph lower alkyl, cycloalkyl lower alkyl, phenoxy lower alkyl, naphthyl lower alkyl, lower alkoxy lower alkyl, carboxyl lower alkyl, lower alkoxy carbonyl lower alkyl, (un)substituted pyridyl lower alkyl, cyano lower alkyl, etc.; R2 is H, lower alkoxy, lower alkyl, carboxy lower alkyl, lower alkoxy carbonyl lower alkoxy, HO, (un)substituted Ph lower alkoxy, (un)substituted piperidinyl(oxy) lower alkyl, lower alkenyloxy, (un)substituted pyridyl lower alkoxy, lower alkenyloxy, Ph lower alkenyloxy, Ph lower alkynyl, (un)substituted furyl lower alkoxy, (un)substituted oxadiazolyl lower alkyl, or (un)substituted thiazolyl lower alkoxy, etc.; R3 is H, lower (HO-substituted) alkyl, cycloalkyl lower alkyl, carboxyl lower alkyl, lower alkoxy carbonyl lower alkyl, (un)substituted Ph lower alkyl, naphthyl lower alkyl, (un)substituted furyl lower alkyl, (un)substituted thiazolyl lower alkyl, (un)substituted tetrazolyl, or (un)substituted benzothienyl, etc.; and their pharmaceutically acceptable salts are claimed. Example compound II was prepared by heterocyclization of 2-chloro-3-(8-methoxy-1-methyl-2-oxo-1,2-dihydroquinolin-5-yl)propionic

acid with thiourea. All the invention compds. were evaluated for the transcription promoting activity of hTFF2. From the assay, it was determined that some invention compds., including compound III, showed TFF2 production activity of 1000% or higher at a test compound concentration of 10⁻⁶M concentration. Some invention compds. showed a TFF2 production promoting activity of 300% or higher at a test compound concentration is less than 10⁻⁵M and preferably more than


10⁻⁶M. Example compound III and a few other compds. showed >20% healing ratio of the ulcerated area, which indicated that these compds. may be effective in preventing and/or treating mucosal injury.

IT 882007-18-3P 882007-24-1P 882007-32-1P
882007-38-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of carbostyryl compds. and their transcription promoting activity of TFF2 for treatment and/or prevention of various diseases)


RN 882007-18-3 CAPLUS

CN Benzoic acid, 4-[[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3,4-dihydro-8-methoxy-2-oxo-1(2H)-quinolinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 882007-24-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-hydroxy-2-oxo-1-(phenylmethyl)-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-32-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[5,6-dihydro-6-oxo-5-(phenylmethyl)-2-phenanthridinyl]methylene]- (CA INDEX NAME)



RN 882007-38-7 CAPLUS

CN 2(1H)-Quinolinone, 1-([1,1'-biphenyl]-4-ylmethyl)-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




IT 882007-48-9P 882019-15-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of carbostyryl compds. and their transcription promoting activity of TFF2 for treatment and/or prevention of various diseases)


RN 882007-48-9 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-[(4-nitrophenyl)methyl]-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)



RN 882019-15-0 CAPLUS

CN 2(1H)-Quinolinone, 1-[(4-bromophenyl)methyl]-3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



IT	882007-03-6P	882007-05-8P	882007-06-9P
	882007-07-0P	882007-39-8P	882007-43-4P
	882007-44-5P	882007-45-6P	882007-46-7P
	882007-47-8P	882007-49-0P	882007-50-3P
	882007-51-4P	882007-52-5P	882007-53-6P
	882007-54-7P	882007-55-8P	882007-56-9P
	882007-57-0P	882007-58-1P	882007-59-2P
	882007-60-5P	882007-61-6P	882007-62-7P
	882007-63-8P	882007-64-9P	882007-65-0P
	882007-66-1P	882007-67-2P	882007-68-3P
	882007-69-4P	882007-70-7P	882007-71-8P
	882007-72-9P	882007-73-0P	882007-74-1P
	882007-75-2P	882007-76-3P	882007-77-4P
	882007-78-5P	882007-79-6P	882007-80-9P
	882007-81-0P	882007-82-1P	882007-83-2P
	882007-84-3P	882007-85-4P	882007-86-5P
	882007-87-6P	882007-88-7P	882007-89-8P
	882007-90-1P	882007-91-2P	882007-92-3P
	882007-93-4P	882007-94-5P	882007-95-6P
	882007-96-7P	882007-97-8P	882007-98-9P
	882007-99-0P	882008-00-6P	882008-01-7P
	882013-64-1P	882013-65-2P	882013-67-4P
	882013-69-6P	882018-67-9P	882018-70-4P
	882018-72-6P	882018-74-8P	882018-76-0P
	882018-78-2P	882018-80-6P	882018-82-8P
	882018-85-1P	882018-87-3P	882018-88-4P
	882018-90-8P	882018-92-0P	882018-94-2P
	882018-96-4P	882018-98-6P	882019-00-3P
	882019-01-4P	882019-03-6P	882019-05-8P
	882019-06-9P	882019-08-1P	882019-09-2P


882019-11-6P	882019-13-8P	882019-14-9P
882019-17-2P	882019-19-4P	882019-21-8P
882019-23-0P	882019-25-2P	882019-27-4P
882019-29-6P	882019-31-0P	882019-33-2P
882019-78-5P	882019-79-6P	882019-80-9P
882019-81-0P	882019-82-1P	882019-83-2P
882019-84-3P	882019-85-4P	882019-86-5P
882019-87-6P	882019-88-7P	882019-89-8P
882019-90-1P	882019-91-2P	882019-92-3P
882019-93-4P	882019-94-5P	882019-95-6P
882019-96-7P	882019-97-8P	882019-98-9P
882019-99-0P	882020-00-0P	882020-01-1P
882020-02-2P	882020-03-3P	882020-04-4P
882020-05-5P	882020-06-6P	882020-07-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of carbostyryl compds. and their transcription promoting activity of TFF2 for treatment and/or prevention of various diseases)


RN 882007-03-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(1,2-dihydro-8-methoxy-1-methyl-2-oxo-5-quinolinyl)methylene]- (CA INDEX NAME)




RN 882007-05-8 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1-[(4-bromophenyl)methyl]-1,2-dihydro-8-methoxy-2-oxo-5-quinolinyl)methylene]- (CA INDEX NAME)




RN 882007-06-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-2-oxo-7-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-07-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-2-oxo-8-quinolinyl]methylene]- (CA INDEX NAME)



RN 882007-39-8 CAPLUS
 CN 2(1H)-Quinolinone, 1-[(4-bromophenyl)methyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 882007-43-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(phenylmethyl)-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-44-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-yl)methyl]-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-45-6 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methyl]-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)



RN 882007-46-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-3-ylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-47-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-2-ylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-49-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-(4-methoxyphenyl)methyl]-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-50-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-(4-chlorophenyl)methyl]-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-51-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(4-bromophenyl)methyl]-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-52-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[(4-(phenylmethoxy)phenyl)methyl]-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-53-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(4-fluorophenyl)methyl]-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-54-7 CAPLUS


CN Benzonitrile, 4-[[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3,4-dihydro-8-methoxy-2-oxo-1(2H)-quinolinyl]methyl]- (CA INDEX NAME)




RN 882007-55-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-[(4-methylphenyl)methyl]-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-56-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[(4-phenoxyphenyl)methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-57-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(1,2,3,4-tetrahydro-8-methoxy-1-methyl-2-oxo-5-quinolinyl)methylene]- (CA INDEX NAME)




RN 882007-58-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl)methylene]- (CA INDEX NAME)



RN 882007-59-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(1-butyl-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl)methylene]- (CA INDEX NAME)




RN 882007-60-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(3-phenylpropyl)-5-quinolinyl)methylene]- (CA INDEX NAME)




RN 882007-61-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(2-phenylethyl)-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-62-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(1-ethyl-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl)methylene]- (CA INDEX NAME)




RN 882007-63-8 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1-(cyclopropylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)



RN 882007-64-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(2-phenoxylethyl)-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-65-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-(cyclohexylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-66-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-(2-methoxyethyl)-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-67-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-(diphenylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-68-3 CAPLUS

CN 1(2H)-Quinolinepropanenitrile, 5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3,4-dihydro-8-methoxy-2-oxo- (CA INDEX NAME)




RN 882007-69-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(4-phenylbutyl)-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-70-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(5-phenylpentyl)-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-71-8 CAPLUS


CN 1(2H)-Quinolinepropanoic acid, 5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3,4-dihydro-8-methoxy-2-oxo-, ethyl ester (CA INDEX NAME)



RN 882007-72-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-(1-naphthalenylmethyl)-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-73-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-(2-naphthalenylmethyl)-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-74-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-8-butoxy-1,2,3,4-tetrahydro-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-75-2 CAPLUS

CN Acetic acid, 2-[[1-([1,1'-biphenyl]-4-ylmethyl)-5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-1,2,3,4-tetrahydro-2-oxo-8-quinolinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882007-78-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[(6-(3-thienyl)-3-pyridinyl)methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-79-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[(6-phenyl-3-pyridinyl)methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)



RN 882007-80-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-[[6-(4-morpholinyl)-3-pyridinyl]methyl]-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 882007-81-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[[6-(4-phenyl-1-piperazinyl)-3-pyridinyl]methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 882007-82-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-1-[[6-(4-methyl-1-piperazinyl)-3-pyridinyl]methyl]-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 882007-83-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([2,2'-bipyridin]-5-ylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 882007-84-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-(2-quinolinylmethyl)-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-85-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-1-(2-naphthalenylmethyl)-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-86-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(1,2,3,4-tetrahydro-2-oxo-1-phenyl-5-quinolinyl)methylene]- (CA INDEX NAME)




RN 882007-87-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(6-chloro-3-pyridinyl)methyl]-1,2,3,4-tetrahydro-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-88-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(1,1'-biphenyl)-4-ylmethyl]-1,2,3,4-tetrahydro-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-89-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(4-bromophenyl)methyl]-1,2,3,4-tetrahydro-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-90-1 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydro-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)



RN 882007-91-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-1-[(4-methylphenyl)methyl]-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-92-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-2-oxo-5-phenyl-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882007-93-4 CAPLUS

CN Benzoic acid, 4-[[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3,4-dihydro-2-oxo-1(2H)-quinolinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 882007-94-5 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-1-[(4-nitrophenyl)methyl]-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-95-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-8-methyl-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-96-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-8-chloro-1,2,3,4-tetrahydro-2-oxo-5-quinolinyl]methylene]- (CA INDEX NAME)



RN 882007-97-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-2-oxo-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-98-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-[(4-bromophenyl)methyl]-1,2,3,4-tetrahydro-2-oxo-6-quinolinyl]methylene]- (CA INDEX NAME)




RN 882007-99-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-1-[(4-nitrophenyl)methyl]-2-oxo-6-quinoliny]methylene]- (CA INDEX NAME)




RN 882008-00-6 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-8-methoxy-2-oxo-6-quinoliny]methylene]- (CA INDEX NAME)



RN 882008-01-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-8-methyl-2-oxo-6-quinoliny]methylene]- (CA INDEX NAME)




RN 882013-64-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(5-ethyl-5,6-dihydro-6-oxo-2-phenanthridinyl)methylene]- (CA INDEX NAME)




RN 882013-65-2 CAPLUS

CN 6(5H)-Phenanthridinone, 2-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-5-(phenylmethyl)- (CA INDEX NAME)




RN 882013-67-4 CAPLUS

CN 6(5H)-Phenanthridinone, 5-ethyl-2-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882013-69-6 CAPLUS

CN 6(5H)-Phenanthridinone, 5-([1,1'-biphenyl]-4-ylmethyl)-2-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-67-9 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(phenylmethyl)- (CA INDEX NAME)




RN 882018-70-4 CAPLUS

CN 2(1H)-Quinolinone, 1-[[4-(1,1-dimethylethyl)phenyl]methyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-72-6 CAPLUS

CN 2(1H)-Quinolinone, 1-[[[1,1'-biphenyl]-3-ylmethyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-74-8 CAPLUS

CN 2(1H)-Quinolinone, 1-[(1,1'-biphenyl)-2-ylmethyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-76-0 CAPLUS


CN 2(1H)-Quinolinone, 1-[(4-chlorophenyl)methyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 882018-78-2 CAPLUS
 CN 2((1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[(4-phenoxyphenyl)methyl]- (CA INDEX NAME)




RN 882018-80-6 CAPLUS
 CN 2((1H)-Quinolinone, 3,4-dihydro-8-methoxy-1-methyl-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-82-8 CAPLUS

CN 2(1H)-Quinololinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-85-1 CAPLUS


CN 2(1H)-Quinololinone, 1-butyl-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-87-3 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(3-phenylpropyl)- (CA INDEX NAME)



RN 882018-88-4 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(2-phenylethyl)- (CA INDEX NAME)




RN 882018-90-8 CAPLUS
 CN 2(1H)-Quinolinone, 1-ethyl-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-92-0 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(2-phenoxyethyl)- (CA INDEX NAME)




RN 882018-94-2 CAPLUS

CN 2(1H)-Quinolinone, 1-(cyclohexylmethyl)-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-96-4 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-1-(2-methoxyethyl)-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882018-98-6 CAPLUS

CN 2(1H)-Quinolinone, 1-(diphenylmethyl)-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-00-3 CAPLUS

CN 2(1H)-Quinolinone, 1-(cyclopropylmethyl)-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-01-4 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-phenyl- (CA INDEX NAME)




RN 882019-03-6 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(4-phenylbutyl)- (CA INDEX NAME)




RN 882019-05-8 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(5-phenylpentyl)- (CA INDEX NAME)




RN 882019-06-9 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-1-(1-naphthalenylmethyl)-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-08-1 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-1-(2-naphthalenylmethyl)-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-09-2 CAPLUS

CN 2-(1H)-Quinolinone, 1-([1,1'-biphenyl]-4-ylmethyl)-8-methoxy-3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-11-6 CAPLUS

CN Acetic acid, 2-[[1-([1,1'-biphenyl]-4-ylmethyl)-1,2,3,4-tetrahydro-2-oxo-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-8-quinolinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 882019-13-8 CAPLUS

CN 2((1H)-Quinolinone, 1-([1,1'-biphenyl]-4-ylmethyl)-3,4-dihydro-8-hydroxy-5-[(4-oxo-2-thioxo-5-thiazolidinylydene)methyl]- (CA INDEX NAME)




RN 882019-14-9 CAPLUS


CN 2((1H)-Quinolinone, 1-([1,1'-biphenyl]-4-ylmethyl)-3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylydene)methyl]- (CA INDEX NAME)




RN 882019-17-2 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-1-[(1-naphthalenyl)methyl]-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-19-4 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[[6-(3-thienyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



RN 882019-25-2 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-1-(2-quinolinylmethyl)- (CA INDEX NAME)




RN 882019-27-4 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-1-[[6-(methylphenylamino)-3-pyridinyl]methyl]-5-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 882019-29-6 CAPLUS

CN 2(1H)-Quinolinone, 1-[(6-chloro-3-pyridinyl)methyl]-3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882019-31-0 CAPLUS

CN 2(1H)-Quinolinone, 8-methoxy-1-methyl-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 882019-33-2 CAPLUS


CN 2-(1H)-Quinolinone, 1-[(4-bromophenyl)methyl]-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 882019-78-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-2-oxo-1-[[4-(1-piperidinylmethyl)phenyl)methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 882019-79-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-2-oxo-1-[[3-(1-piperidinylmethyl)phenyl]methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)



RN 882019-80-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[[1,2,3,4-tetrahydro-2-oxo-1-[[6-(1-piperidinylmethyl)-2-pyridinyl]methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882019-81-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[[1,2,3,4-tetrahydro-2-oxo-1-[[6-[(phenylthio)methyl]-2-pyridinyl]methyl]-5-quinolinyl]methylene]- (CA INDEX NAME)




RN 882019-82-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-[(6-[1,1'-biphenyl]-4-yl-3-pyridinyl)methyl]-
 1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinolinyl]methylene]- (CA INDEX
 NAME)

PAGE 1-A






RN 882019-83-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[[6-(phenylamino)-3-pyridinyl)methyl]-5-quinolinyl)methylene]- (CA INDEX NAME)




RN 882019-84-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[[6-(trifluoromethyl)-3-pyridinyl)methyl]-5-quinolinyl)methylene]- (CA INDEX NAME)



RN 882019-85-4 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[[6-(2-pyridinylamino)-3-pyridinylmethyl]-5-quinolinyl]methylene]- (CA INDEX NAME)

PAGE 1-A






RN 882019-86-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-[(2-chloro-5-thiazolyl)methyl]-1,2,3,4-tetrahydro-8-methoxy-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882019-87-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[(2-phenyl-5-thiazolyl)methyl]-5-quinoliny]methylene]- (CA INDEX NAME)




RN 882019-88-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[(2-(3-phenylthienyl)-5-thiazolyl)methyl]-5-quinoliny)methylene]- (CA INDEX NAME)




RN 882019-89-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(1,2,3,4-tetrahydro-8-methoxy-2-oxo-1-[(2-(3-pyridinyl)-5-thiazolyl)methyl]-5-quinoliny)methylene]- (CA INDEX NAME)




RN 882019-90-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-1-[[4-[(methylphenylamino)methyl]phenyl]methyl]-2-oxo-5-quinoliny]methylene]-
 (CA INDEX NAME)




RN 882019-91-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1,2,3,4-tetrahydro-2-oxo-1-[[3-[(methylphenylamino)methyl]phenyl]methyl]-2-oxo-5-quinoliny]methylene]-

[(phenylthio)methyl]phenyl)methyl]-5-quinoliny]methylene)- (CA INDEX NAME)



RN 882019-92-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[1-[[4-[(2,3-dihydro-1H-indol-1-yl)methyl]phenyl)methyl]-1,2,3,4-tetrahydro-2-oxo-5-quinoliny]methylene]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 882019-93-4 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[(4-(1-piperidinylmethyl)phenyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 882019-94-5 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[[3-(1-piperidinylmethyl)phenyl]methyl]- (CA INDEX NAME)




RN 882019-95-6 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[[4-[(phenylthio)methyl]phenyl]methyl]- (CA INDEX NAME)



RN 882019-96-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[5-[[3,4-dihydro-8-methoxy-2-oxo-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1(2H)-quinolinyl]methyl]-2-pyridinyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 882019-97-8 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[[6-(trifluoromethyl)-3-pyridinyl)methyl]-
 (CA INDEX NAME)




RN 882019-98-9 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[6-(phenylamino)-3-pyridinyl]methyl- (CA INDEX NAME)



RN 882019-99-0 CAPLUS
 CN 2(1H)-Quinolinone, 1-[(6-[1,1'-biphenyl]-4-yl-3-pyridinyl)methyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 882020-00-0 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[[6-(1-piperidinylmethyl)-2-pyridinyl]methyl]-
 (CA INDEX NAME)




RN 882020-01-1 CAPLUS

CN 2(1H)-Quinolinone, 1-[(2-chloro-5-thiazolyl)methyl]-3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882020-02-2 CAPLUS


CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[(2-phenyl-5-thiazolyl)methyl]- (CA INDEX NAME)




RN 882020-03-3 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[[2-(3-thienyl)-5-thiazolyl]methyl]- (CA INDEX NAME)



RN 882020-04-4 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-8-methoxy-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-[[2-(3-pyridinyl)-5-thiazolyl]methyl]- (CA INDEX NAME)




RN 882020-05-5 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-1-[[4-
 [(methylphenylamino)methyl]phenyl]methyl]-5-[(4-oxo-2-thioxo-5-
 thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 882020-06-6 CAPLUS
 CN 2(1H)-Quinolinone, 3,4-dihydro-5-[(4-oxo-2-thioxo-5-

thiazolidinylidene)methyl]-1-[[3-[(phenylthio)methyl]phenyl]methyl]- (CA
INDEX NAME)




RN 882020-07-7 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-1-[(4-methoxy-3,5-dimethyl-2-
pyridinyl)methyl]-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA
INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:973681 CAPLUS
 DOCUMENT NUMBER: 143:318709
 TITLE: Blockade of PI3Ky suppresses joint
 inflammation and damage in mouse models of
 rheumatoid arthritis
 AUTHOR(S): Camps, Montserrat; Rueckle, Thomas; Ji, Hong;
 Ardisson, Vittoria; Rintelen, Felix; Shaw, Jeffrey;
 Ferrandi, Chiara; Chabert, Christian; Gillieron,
 Corine; Francon, Bernard; Martin, Thierry; Gretener,
 Denise; Perrin, Dominique; Leroy, Didier; Vitte,
 Pierre-Alain; Hirsch, Emilio; Wymann, Matthias P.;
 Cirillo, Rocco; Schwarz, Matthias K.; Rommel,
 Christian
 CORPORATE SOURCE: Serono Pharmaceutical Research Institute, Serono
 International S.A., Geneva, 1228, Switz.
 SOURCE: Nature Medicine (New York, NY, United States) (2005),
 11(9), 936-943
 CODEN: NAMEFI; ISSN: 1078-8956
 PUBLISHER: Nature Publishing Group
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Phosphoinositide 3-kinases (PI3K) have long been considered promising drug
 targets for the treatment of inflammatory and autoimmune disorders as well
 as cancer and cardiovascular diseases. But the lack of specificity,
 isoform selectivity and poor biopharmaceutical profile of PI3K inhibitors
 have so far hampered rigorous disease-relevant target validation. Here we
 describe the identification and development of specific, selective and
 orally active small-mol. inhibitors of PI3Ky (encoded by Pik3cg).
 We show that Pik3cg^{-/-} mice are largely protected in mouse models of
 rheumatoid arthritis; this protection correlates with defective neutrophil
 migration, further validating PI3Ky as a therapeutic target. We
 also describe that oral treatment with a PI3Ky inhibitor suppresses
 the progression of joint inflammation and damage in two distinct
 mouse models of rheumatoid arthritis, reproducing the protective effects
 shown by Pik3cg^{-/-} mice. Our results identify selective PI3Ky
 inhibitors as potential therapeutic mols. for the treatment of chronic
 inflammatory disorders such as rheumatoid arthritis.
 IT 648449-76-7P, AS 604850 648450-29-7P, AS 605240
 865188-81-4P, AS 605091
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP
 (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP
 (Preparation)
 (blockade of PI3Ky suppresses joint inflammation and
 damage in mouse models of rheumatoid arthritis)
 RN 648449-76-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-
 (CA INDEX NAME)



RN 648450-29-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-(6-(quinoxalinylmethylene)- (CA INDEX NAME)



RN 865188-81-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)methylene]- (CA INDEX NAME)





OS.CITING REF COUNT: 169 THERE ARE 169 CAPLUS RECORDS THAT CITE THIS RECORD (170 CITINGS)
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:120737 CAPLUS
DOCUMENT NUMBER: 142:219270
TITLE: Preparation of
2-imino-4-(thio)oxo-5-polycyclovinyldiazolines as PI3
kinase inhibitors
INVENTOR(S): Rueckle, Thomas; Shaw, Jeffrey; Church, Denis; Covini,
David
PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth.
SOURCE: PCT Int. Appl., '72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	-----	-----	-----
WO 2005011686	A1	20050210	WO 2004-EP51625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004260836	A1	20050210	AU 2004-260836
CA 2531140	A1	20050210	CA 2004-2531140
EP 1648452	A1	20060426	EP 2004-766335
EP 1648452	B1	20090722	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007500171	T	20070111	JP 2006-521581
US 20070021447	A1	20070125	US 2004-565976
ES 2328146	T3	20091110	ES 2004-766335
NO 2006000573	A	20060203	NO 2006-573
PRIORITY APPLN. INFO.:			EP 2003-102313 A
			WO 2004-EP51625 W
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT			
OTHER SOURCE(S):			
			CASREACT 142:219270; MARPAT 142:219270
GI			



AB The title compds. I [A = 5-8 membered heterocyclic or carbocyclic group which may be fused with an aryl, heteroaryl, cycloalkyl or heterocycloalkyl; X = S, O, NR₃, Y = S, O; R₁ = H, CN, CO₂H, acyl, etc.; R₂ = H, halo, acyl, NH₂, etc.; G = alkoxy, alkyl, CN, etc.; R₃ = H, alkyl; with provisos], useful in particular for the treatment and/or prophylaxis

of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries, were prepared and formulated. Thus, reacting 5-benzol[1,3]dioxol-5-ylmethylene-2-iminothiazolidin-4-one (preparation given) with 2-chlorobenzenesulfonyl chloride afforded 17% II. The tested compds.

IT	I showed IC50 of < 10 µM with regard to P13Ky.		
	1044645-30-8	1044645-32-0	1044645-33-1
	1044645-34-2	1044645-38-6	1044645-40-0
	1044645-41-1	1044645-42-2	1044645-45-5
	1044645-48-8	1044645-49-9	1044645-51-3
	1044645-55-7	1044645-56-8	1044645-57-9
	1044645-58-0	1044645-62-6	1044645-63-7
	1044645-65-9	1044645-66-0	1044645-70-6
	1044645-72-8	1044645-73-9	1044645-77-3
	1044645-78-4		


RL: PRPH (Prophetic)

(Preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as P13 kinase inhibitors)

RN 1044645-30-8 CAPLUS

CN Ethanesulfonamide, N-[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-2-thiazolidinylidene]-, [N(E)]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-32-0 CAPLUS

CN 1H-Pyrazole-4-sulfonamide, N-[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-2-thiazolidinylidene]-5-chloro-1,3-dimethyl-, [N(E)]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-33-1 CAPLUS

CN 4(5H)-Thiazolone, 5-[[4-(dimethylamino)-6-quinazoliny]methylene]-2-(methylamino)-, (5E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-34-2 CAPLUS

CN Methanesulfonamide, N-[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-2-thiazolidinylidene]-, [N(E)]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-38-6 CAPLUS

CN Benzenesulfonamide, N-[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-2-thiazolidinylidene]-2-chloro-, [N(E)]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-40-0 CAPLUS

CN 8-Quinolinesulfonamide, N-[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-2-thiazolidinylidene]-, [N(E)]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-41-1 CAPLUS

CN Benzenesulfonamide, N-[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-2-thiazolidinyldene]-, [N(E)]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-42-2 CAPLUS

CN Methanesulfonamide, N-[(5Z)-5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-4-oxo-2-thiazolidinyldene]-, [N(E)]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-45-5 CAPLUS


CN 3-Pyridinesulfonamide, N-[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-2-thiazolidinyldene]-, [N(E)]- (CA INDEX NAME)

Double bond geometry as shown.




RN 1044645-48-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RN 1044645-49-9 CAPLUS
CN 3-Pyridinesulfonamide, N-[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-2-thiazolidinylidene]-6-chloro-, [N(E)]- (CA INDEX NAME)

Double bond geometry as shown.



RN 1044645-51-3 CAPLUS
CN 4-Thiazolidinone, 5-[(1,3-benzodioxol-5-ylmethylene)-2-(propylimino)-, (2E,5Z)]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-55-7 CAPLUS

CN Benzenesulfonamide, N-[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-2-thiazolidinylidene]-, [N(E)]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-56-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[E)-[(5Z)-4-oxo-5-(6-quinolinylmethylene)-2-thiazolidinylidene]amino]sulfonyl]-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-57-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[E)-[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-2-thiazolidinylidene]amino]sulfonyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-58-0 CAPLUS

CN 4-Thiazolidinone, 5-(1,3-benzodioxol-5-ylmethylene)-2-[(phenylmethyl)imino]-, (2E,5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-62-6 CAPLUS

CN 4-Thiazolidinone, 2-(propylimino)-5-(6-quinolinylmethylene)-, (2E,5E)-
(CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-63-7 CAPLUS

CN Benzenesulfonamide, N-[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-2-thiazolidinylidene]-3-chloro-, [N(E)]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-65-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[E)-[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-2-thiazolidinylidene]amino]sulfonyl]-, methyl ester
(CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-66-0 CAPLUS

CN Benzenesulfonamide, N-[(5Z)-5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-4-oxo-2-thiazolidinylidene]-, [N(E)]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-70-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(1,3-benzodioxol-5-yl)methylene]-, 2-(O-methyloxime), (2E,5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-72-8 CAPLUS

CN Benzenesulfonamide, 2-chloro-N-[(5Z)-4-oxo-5-(6-quinolinylmethylene)-2-thiazolidinylidene]-, [N(E)]- (CA INDEX NAME)


Double bond geometry as shown.



RN 1044645-73-9 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RN 1044645-77-3 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-2-thiazolidinylidene]-, [N(E)]- (CA INDEX NAME)

Double bond geometry as shown.




RN 1044645-78-4 CAPLUS
CN Benzenesulfonamide, N-[(5Z)-5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-4-oxo-2-thiazolidinylidene]-4-methyl-, [N(E)]- (CA INDEX NAME)

Double bond geometry as shown.



IT 843641-13-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-imino-4-(thio)oxo-5-polycyclovinyldiazolines as PI3 kinase inhibitors)
RN 843641-13-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[5-(1,3-benzodioxol-5-ylmethylene)-4,5-dihydro-4-oxo-2-thiazolyl]amino]sulfonyl]-, methyl ester (CA INDEX NAME)




IT 176529-68-3P 326093-91-8P 419552-35-5P
 843641-09-8P 843641-10-1P 843641-11-2P
 843641-12-3P 843641-14-5P 843641-15-6P
 843641-16-7P 843641-17-8P 843641-18-9P
 843641-19-0P 843641-20-3P 843641-21-4P
 843641-22-5P 843641-23-6P 843641-24-7P
 843641-25-8P 843641-26-9P 843641-27-0P
 843641-28-1P 843641-29-2P 843641-30-5P
 888948-67-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazoles as PI3 kinase inhibitors)


RN 176529-68-3 CAPLUS

CN Cyanamide, [5-(1,3-benzodioxol-5-ylmethylene)-4,5-dihydro-4-oxo-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 326093-91-8 CAPLUS

CN Benzenesulfonamide, N-[5-(1,3-benzodioxol-5-ylmethylene)-4,5-dihydro-4-oxo-2-thiazolyl]- (CA INDEX NAME)




RN 419552-35-5 CAPLUS


CN Benzenesulfonamide, N-[5-(1,3-benzodioxol-5-ylmethylene)-4,5-dihydro-4-oxo-2-thiazolyl]-4-methyl- (CA INDEX NAME)




RN 843641-09-8 CAPLUS
 CN Benzenesulfonamide, N-[5-(1,3-benzodioxol-5-ylmethylene)-4,5-dihydro-4-oxo-2-thiazolyl]-2-chloro- (CA INDEX NAME)




RN 843641-10-1 CAPLUS
 CN Ethanesulfonamide, N-[5-(1,3-benzodioxol-5-ylmethylene)-4,5-dihydro-4-oxo-2-thiazolyl]- (CA INDEX NAME)



RN 843641-11-2 CAPLUS
 CN Benzenesulfonamide, N-[5-(1,3-benzodioxol-5-ylmethylene)-4,5-dihydro-4-oxo-2-thiazolyl]-3-chloro- (CA INDEX NAME)




RN 843641-12-3 CAPLUS
 CN 1H-Pyrazole-4-sulfonamide, N-[5-(1,3-benzodioxol-5-ylmethylene)-4,5-dihydro-4-oxo-2-thiazolyl]-5-chloro-1,3-dimethyl- (CA INDEX NAME)




RN 843641-14-5 CAPLUS

CN 3-Pyridinesulfonamide, N-[5-(1,3-benzodioxol-5-ylmethylene)-4,5-dihydro-4-oxo-2-thiazolyl]-6-chloro- (CA INDEX NAME)




RN 843641-15-6 CAPLUS

CN 8-Quinolinesulfonamide, N-[5-(1,3-benzodioxol-5-ylmethylene)-4,5-dihydro-4-oxo-2-thiazolyl]- (CA INDEX NAME)



RN 843641-16-7 CAPLUS


CN Methanesulfonamide, N-[5-(1,3-benzodioxol-5-ylmethylene)-4,5-dihydro-4-oxo-2-thiazolyl]- (CA INDEX NAME)



RN 843641-17-8 CAPLUS


CN Benzenesulfonamide, N-[5-(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-

4,5-dihydro-4-oxo-2-thiazolyl]- (CA INDEX NAME)




RN 843641-18-9 CAPLUS

CN Benzenesulfonamide, N-[5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]-4-methyl- (CA INDEX NAME)




RN 843641-19-0 CAPLUS

CN Methanesulfonamide, N-[5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]- (CA INDEX NAME)




RN 843641-20-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-[5-[(1,3-benzodioxol-5-yl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]- (CA INDEX NAME)




RN 843641-21-4 CAPLUS


CN 3-Pyridinesulfonamide, N-[5-[(1,3-benzodioxol-5-yl)methylene]-4,5-dihydro-4-oxo-2-thiazolyl]- (CA INDEX NAME)




RN 843641-22-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[[[4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]amino]sulfonyl]-, methyl ester (CA INDEX NAME)




RN 843641-23-6 CAPLUS
 CN Benzenesulfonamide, 2-chloro-N-[[4,5-dihydro-4-oxo-5-(6-quinolinylmethylene)-2-thiazolyl]- (CA INDEX NAME)




RN 843641-24-7 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[[[5-(1,3-benzodioxol-5-ylmethylene)-4,5-dihydro-4-oxo-2-thiazolyl]amino]sulfonyl]- (CA INDEX NAME)




RN 843641-25-8 CAPLUS
 CN 4(5H)-Thiazolone, 5-[(1,3-benzodioxol-5-ylmethylene)-2-(methoxyamino)- (CA INDEX NAME)




RN 843641-26-9 CAPLUS
CN Cyanamide, [4,5-dihydro-4-oxo-5-(6-quinoxalinylmethylene)-2-thiazolyl]-
(9CI) (CA INDEX NAME)




RN 843641-27-0 CAPLUS
CN 4(5H)-Thiazolone, 5-[(1,3-benzodioxol-5-ylmethylene)-2-
[(phenylmethyl)amino]- (CA INDEX NAME)




RN 843641-28-1 CAPLUS
CN 4(5H)-Thiazolone, 2-[(phenylmethyl)amino]-5-(6-quinolinylmethylene)- (CA
INDEX NAME)




RN 843641-29-2 CAPLUS
CN 4(5H)-Thiazolone, 2-(propylamino)-5-(6-quinolinylmethylene)- (CA INDEX
NAME)




RN 843641-30-5 CAPLUS
CN 4(5H)-Thiazolone, 5-[(1,3-benzodioxol-5-ylmethylene)-2-(propylamino)- (CA INDEX NAME)




RN 888948-67-2 CAPLUS
CN 4(5H)-Thiazolone, 5-[[4-(dimethylamino)-6-quinazolinyl]methylene]-2-(methylamino)- (CA INDEX NAME)



IT 28824-66-0P 300829-97-4P 304645-61-2P
648449-81-4P 648450-30-0P 843641-32-7P
843641-33-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)
RN 28824-66-0 CAPLUS
CN 4-Thiazolidinone, 5-(1,3-benzodioxol-5-ylmethylene)-2-thioxo- (CA INDEX NAME)




RN 300829-97-4 CAPLUS
CN 4(5H)-Thiazolone, 2-amino-5-(1,3-benzodioxol-5-ylmethylene)- (CA INDEX NAME)




RN 304645-61-2 CAPLUS

CN 4(5H)-Thiazolone, 2-amino-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 648449-81-4 CAPLUS

CN 4-Thiazolidinone, 5-(6-quinolinylmethylene)-2-thioxo- (CA INDEX NAME)




RN 648450-30-0 CAPLUS

CN 4-Thiazolidinone, 5-(6-quinoxalinylmethylene)-2-thioxo- (CA INDEX NAME)




RN 843641-32-7 CAPLUS

CN 4(5H)-Thiazolone, 2-amino-5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]- (CA INDEX NAME)



RN 843641-33-8 CAPLUS



CN 4-Thiazolidinone, 5-[[4-(dimethylamino)-6-quinazolinyl]methylene]-2-thioxo- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:546505 CAPLUS
DOCUMENT NUMBER: 141:106478
TITLE: Preparation of benzoxazines and related compounds as
inhibitors of PI3Ks
INVENTOR(S): Gogliotti, Rocco Dean; Muccioli, Keri Lynn; Para,
Kimberly Suzanne; Visnick, Melean
PATENT ASSIGNEE(S): Warner-Lambert Company Llc, USA
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056820	A1	20040708	WO 2003-IB5887	20031210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2510851	A1	20040708	CA 2003-2510851	20031210
AU 2003303231	A1	20040714	AU 2003-303231	20031210
EP 1581529	A1	20051005	EP 2003-813672	20031210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017572	A	20051122	BR 2003-17572	20031210
JP 2006512357	T	20060413	JP 2004-561828	20031210
US 20040138199	A1	20040715	US 2003-743852	20031222
MX 2005006742	A	20050908	MX 2005-6742	20050620
PRIORITY APPLN. INFO.:			US 2002-435227P	P 20021220
			WO 2003-IB5887	W 20031210
OTHER SOURCE(S):		MARPAT 141:106478		
GI				



AB Title compds. I [W = O, S, (un)substituted NH; Q = bond, CH₂, CHMe, CMe₂; D, E = CH₂, CHMe, CMe₂; A = bond, SO₂, CO, CO₂, CONH, CSNH; L = bond, alkylene, CH:CH, oxalkylene, thialakylene, oxoalkylene, oxoalkylenoxy, carbamoylalkylene, aminoalkylene; Y = CO, CS; K = NH, O, S, CH₂; R₁ = R₁ = H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, heteroaryl; R₂, R₄ = H, F, CF₃, Me; R₃ = H, CH₂CO₂H, Ph, alkyl, alkenyl; R₅ = H, alkoxy, alkyl, NO₂, (un)substituted NH₂, alkylthio, F, Cl] were prepared for use as inhibitors of PI3Ks in the treatment of inflammatory diseases, cardiovascular diseases, and cancers. Thus, 4,2-Br(O₂N)C₆H₃OH was reduced to the amine, N-protected, and cyclized with BrCH₂CH₂Br to 4-tert-butoxycarbonyl-6-bromo-2,3-dihydrobenz[1,4]oxazine which was converted to the 6-formyl derivative, deblocked, and treated with rhodanine to give the benzoxazine II. II had IC₅₀ for inhibition of PI3K of 0.056 μM.

IT	719309-03-2P	719309-04-3P	719309-05-4P
	719309-06-5P	719309-07-6P	719309-08-7P
	719309-09-8P	719309-10-1P	719309-11-2P
	719309-12-3P	719309-13-4P	719309-14-5P
	719309-15-6P	719309-16-7P	719309-17-8P
	719309-18-9P	719309-19-0P	719309-20-3P
	719309-21-4P	719309-22-5P	719309-23-6P
	719309-24-7P	719309-25-8P	719309-26-9P
	719309-27-0P	719309-28-1P	719309-29-2P
	719309-30-5P	719309-31-6P	719309-32-7P
	719309-33-8P	719309-34-9P	719309-35-0P
	719309-36-1P	719309-37-2P	719309-38-3P
	719309-39-4P	719309-40-7P	719309-41-8P
	719309-42-9P	719309-43-0P	719309-44-1P
	719309-45-2P	719309-46-3P	719309-47-4P
	719309-48-5P	719309-49-6P	719309-50-9P
	719309-51-0P	719309-52-1P	719309-53-2P
	719309-54-3P	719309-55-4P	719309-56-5P


719309-57-6P	719309-58-7P	719309-59-8P
719309-60-1P	719309-61-2P	719309-62-3P
719309-63-4P	719309-64-5P	719309-65-6P
719309-66-7P	719309-67-8P	719309-68-9P
719309-69-0P	719309-70-3P	719309-71-4P
719309-72-5P	719309-73-6P	719309-74-7P
719309-75-8P	719309-76-9P	719309-77-0P
719309-78-1P	719309-79-2P	719309-80-5P
719309-81-6P	719309-82-7P	719309-83-8P
719309-84-9P	719309-85-0P	719309-86-1P
719309-87-2P	719309-88-3P	719309-89-4P
719309-90-7P	719309-91-8P	719309-92-9P
719309-93-0P	719309-94-1P	719309-95-2P
719309-96-3P	719309-97-4P	719309-98-5P
719309-99-6P	719310-00-6P	719310-01-7P
719310-02-8P	719310-03-9P	719310-04-0P
719310-05-1P	719310-06-2P	719310-07-3P
719310-08-4P	719310-09-5P	719310-10-8P
719310-11-9P	719310-12-0P	719310-13-1P
719310-14-2P	719310-15-3P	719310-16-4P
719310-17-5P	719310-18-6P	719310-19-7P
719310-20-0P	719310-21-1P	719310-22-2P
719310-23-3P	719310-24-4P	719310-25-5P
719310-26-6P	719310-27-7P	719310-28-8P
719310-29-9P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazines and related compds. as inhibitors of PI3Ks)


RN 719309-03-2 CAPLUS

CN 4-Thiazolidinone, 5-[(4-benzoyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-04-3 CAPLUS

CN 4-Thiazolidinone, 5-[[4-(cyclohexylcarbonyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-05-4 CAPLUS

CN 4-Thiazolidinone, 5-[[[3,4-dihydro-4-(phenylsulfonyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-06-5 CAPLUS

CN 4-Thiazolidinone, 5-[[[4-[(3,5-dimethylphenyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-07-6 CAPLUS

CN 4-Thiazolidinone, 5-[[[4-[(3,5-bis(1,1-dimethylethyl)phenyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-08-7 CAPLUS

CN 4-Thiazolidinone, 5-[[5-[(3,5-dimethoxyphenyl)methyl]-2,3,4,5-tetrahydro-1,5-benzoxazin-7-yl)methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-09-8 CAPLUS

CN 4-Thiazolidinone, 5-[[5-[(3,5-dimethylphenyl)methyl]-2,3,4,5-tetrahydro-1,5-benzoxazin-7-yl)methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-10-1 CAPLUS


CN 4-Thiazolidinone, 5-[[4-benzoyl-3,4-dihydro-3-methyl-2H-1,4-benzoxazin-6-yl)methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-11-2 CAPLUS
 CN 4-Thiazolidinone, 5-[[4-[(3,5-dimethylphenyl)methyl]-3,4-dihydro-3-methyl-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 719309-12-3 CAPLUS
 CN 4-Thiazolidinone, 5-[[4-[(3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-13-4 CAPLUS
 CN 4-Thiazolidinone, 5-[[4-[(2-naphthalenyl)acetyl]-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-14-5 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(4-pyridinylcarbonyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-15-6 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(3-pyridinylcarbonyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-16-7 CAPLUS

CN 4-Thiazolidinone, 5-[[4-(3,5-dimethoxybenzoyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-17-8 CAPLUS

CN 4-Thiazolidinone, 5-[[4-[2-(3,4-dichlorophenyl)acetyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-18-9 CAPLUS

CN 4-Thiazolidinone, 5-[[2,3,4,5-tetrahydro-5-(2-phenylethyl)-1,5-benzoxazepin-7-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 719309-19-0 CAPLUS


CN 4H-1,4-Benzoxazine-4-carboxylic acid, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, phenyl ester (CA INDEX NAME)



RN 719309-20-3 CAPLUS


CN 4H-1,4-Benzoxazine-4-carboxylic acid,

2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-,
4-methylphenyl ester (CA INDEX NAME)




RN 719309-21-4 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(2-phenylacetyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-22-5 CAPLUS


CN 4-Thiazolidinone, 5-[[4-(2-(3,4-dimethoxyphenyl)acetyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 719309-23-6 CAPLUS
 CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(3-methoxybenzoyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-24-7 CAPLUS
 CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(3,4,5-trimethoxybenzoyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-25-8 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(3-methylbenzoyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-26-9 CAPLUS

CN 4-Thiazolidinone, 5-[[4-([1,1'-biphenyl]-4-ylcarbonyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-27-0 CAPLUS

CN 4-Thiazolidinone, 5-[[4-[4-(1,1-dimethylethyl)benzoyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-28-1 CAPLUS

CN 4-Thiazolidinone, 5-[[4-(4-ethylbenzoyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-29-2 CAPLUS


CN 4-Thiazolidinone, 5-[[4-(4-hexylbenzoyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-30-5 CAPLUS
 CN Benzonitrile, 4-[[2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]carbonyl]- (CA INDEX NAME)



RN 719309-31-6 CAPLUS
 CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(2-naphthalenylcarbonyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-32-7 CAPLUS
 CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(1-oxo-2-phenylbutyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-33-8 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(2-methyl-1-oxopropyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-34-9 CAPLUS

CN 4-Thiazolidinone, 5-[[4-(cyclopropylcarbonyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-35-0 CAPLUS

CN 4-Thiazolidinone, 5-[[4-(cyclopentylcarbonyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-36-1 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(1-oxocyclopentyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-37-2 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-[2-(2-thienyl)acetyl]-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-38-3 CAPLUS

CN 4-Thiazolidinone, 5-[[4-(3-cyclopentyl-1-oxopropyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-39-4 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(1-oxo-3-phenyl-2-propen-1-yl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-40-7 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(2-phenoxyacetyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-41-8 CAPLUS


CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-[2-(phenylmethoxy)acetyl]-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-42-9 CAPLUS
 CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-[2-(phenylthio)acetyl]-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 719309-43-0 CAPLUS
 CN 4-Thiazolidinone, 5-[[4-(2-furanylcarbonyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-44-1 CAPLUS
 CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(2-thienylcarbonyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-48-5 CAPLUS

CN 4-Thiazolidinone, 5-[[4-(3,5-difluorobenzoyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-49-6 CAPLUS

CN 4-Thiazolidinone, 5-[[4-[2-(4-chlorophenoxy)acetyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-50-9 CAPLUS

CN 4-Thiazolidinone, 5-[[4-[(2,2-difluoro-1,3-benzodioxol-5-yl)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-51-0 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(5-isoxazolylcarbonyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-52-1 CAPLUS


CN 4H-1,4-Benzoxazine-4-carboxylic acid, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-, 4-(methoxycarbonyl)phenyl ester (CA INDEX NAME)




RN 719309-53-2 CAPLUS
 CN 4-Thiazolidinone, 5-[[4-[(2,5-dichloro-3-thienyl)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-54-3 CAPLUS
 CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-[(5-methyl-3-isoxazolyl)carbonyl]-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-55-4 CAPLUS
 CN 4-Thiazolidinone, 5-[[4-[(3-chloro-2-thienyl)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 719309-56-5 CAPLUS
 CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(2-pyridinylcarbonyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-57-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 719309-58-7 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 719309-59-8 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-N-(4-methylphenyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719309-60-1 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-phenyl- (CA INDEX NAME)




RN 719309-61-2 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-N-(3-methoxyphenyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719309-62-3 CAPLUS

CN 4-Thiazolidinone, 5-[[4-[[[(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-63-4 CAPLUS

CN 4-Thiazolidinone, 5-[[4-(2,1,3-benzoxadiazol-5-ylcarbonyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-64-5 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-N-octyl-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719309-65-6 CAPLUS

CN 4-Thiazolidinone, 5-[[4-(3,5-dichlorobenzoyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-66-7 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-[2-(2-thienyl)ethyl]- (CA INDEX NAME)




RN 719309-67-8 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 719309-68-9 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 719309-69-0 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-(3,5-dimethoxyphenyl)-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719309-70-3 CAPLUS


CN 4H-1,4-Benzoxazine-4-carboxamide, N-cyclopentyl-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719309-71-4 CAPLUS
 CN 4H-1,4-Benzoxazine-4-carboxylic acid,
 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-,
 1-naphthalenyl ester (CA INDEX NAME)




RN 719309-72-5 CAPLUS
 CN 4-Thiazolidinone, 5-[[[3,4-dihydro-4-(1-oxo-3-phenylpropyl)-2H-1,4-
 benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-73-6 CAPLUS
 CN 4-Thiazolidinone, 5-[[4-(1,3-benzodioxol-5-ylcarbonyl)-3,4-dihydro-2H-1,4-
 benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 719309-74-7 CAPLUS
 CN 4-Thiazolidinone, 5-[[[3,4-dihydro-4-[4-(methylsulfonyl)benzoyl]-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-75-8 CAPLUS
 CN 4-Thiazolidinone, 5-[[[4-[2-(3,5-dimethoxyphenyl)acetyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-76-9 CAPLUS


CN 4-Thiazolidinone, 5-[[[3,4-dihydro-4-[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo-
(CA INDEX NAME)



RN 719309-77-0 CAPLUS
CN 4H-1,4-Benzoxazine-4-carboxamide, N-(3,4-dimethoxyphenyl)-2,3-dihydro-6-
[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719309-78-1 CAPLUS
CN 4H-1,4-Benzoxazine-4-carboxamide, N-(3,5-dichlorophenyl)-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719309-79-2 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-(4-chlorophenyl)-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719309-80-5 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-(3,4-dichlorophenyl)-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719309-81-6 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-(3,5-dimethylphenyl)-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719309-82-7 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-(3-chlorophenyl)-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719309-83-8 CAPLUS

CN 4-Thiazolidinone, 5-[[4-[3,5-bis(1,1-dimethylethyl)benzoyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-84-9 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(1-oxo-4-phenylbutyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-85-0 CAPLUS

CN 4-Thiazolidinone, 5-[[4-(cycloheptylcarbonyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-86-1 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(1-oxo-2-phenylpropyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-87-2 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-[(3-methylcyclohexyl)carbonyl]-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-88-3 CAPLUS


CN 4-Thiazolidinone, 5-[[4-(2,3-dimethyl-1-oxobutyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-89-4 CAPLUS
 CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-[[3-(2-methylcyclohexyl)-1-oxopropyl]-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 719309-90-7 CAPLUS
 CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(2-methoxy-5-methylbenzoyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-91-8 CAPLUS
 CN 4-Thiazolidinone, 5-[[4-(2-fluoro-5-methylbenzoyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-92-9 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(2,3,3-trimethyl-1-oxobutyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-93-0 CAPLUS

CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-[(2-methylcyclohexyl)carbonyl]-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-94-1 CAPLUS


CN 4-Thiazolidinone, 5-[[4-acetyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-95-2 CAPLUS
 CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(1-oxopropyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-96-3 CAPLUS
 CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(1-oxobutyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-97-4 CAPLUS
 CN 4-Thiazolidinone, 5-[[3,4-dihydro-4-(1-oxohexyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-98-5 CAPLUS
 CN 4-Thiazolidinone, 5-[[[3,4-dihydro-4-(1-oxopentyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719309-99-6 CAPLUS
 CN 4-Thiazolidinone, 5-[[[4-(2,2-dimethyl-1-oxopropyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-00-6 CAPLUS
 CN 4-Thiazolidinone, 5-[[[3,4-dihydro-4-(1-oxononyl)-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-01-7 CAPLUS
 CN 4-Thiazolidinone, 5-[[[4-(2-ethyl-1-oxohexyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-02-8 CAPLUS
CN 4-Thiazolidinone, 5-[[4-[2-(acetyloxy)-1-oxopropyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 719310-03-9 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2,3-dihydro-γ-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-,
methyl ester (CA INDEX NAME)




RN 719310-04-0 CAPLUS
CN 4-Thiazolidinone, 5-[[4-[(1-acetyl-4-piperidinyl)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-05-1 CAPLUS

CN 4-Thiazolidinone, 5-[(2,3,4,5-tetrahydro-1,5-benzoxazepin-8-yl)methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-06-2 CAPLUS

CN 4-Thiazolidinone, 5-[[5-(cyclopropylcarbonyl)-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-yl)methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-07-3 CAPLUS


CN 1,5-Benzoxazepine-5(2H)-carboxylic acid, 3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, phenyl ester (CA INDEX NAME)



RN 719310-08-4 CAPLUS
 CN 1,5-Benzoxazepine-5(2H)-carboxylic acid,
 3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-,
 1-naphthalenyl ester (CA INDEX NAME)




RN 719310-09-5 CAPLUS
 CN 1,5-Benzoxazepine-5(2H)-carboxylic acid,
 3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-,
 4-methylphenyl ester (CA INDEX NAME)




RN 719310-10-8 CAPLUS

CN 1,5-Benzoxazepine-5(2H)-carboxylic acid,
3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-,
4-(methoxycarbonyl)phenyl ester (CA INDEX NAME)




RN 719310-11-9 CAPLUS

CN 4-Thiazolidinone, 5-[[5-[2-(4-chlorophenoxy)acetyl]-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-12-0 CAPLUS


CN 1,5-Benzoxazepine-5(2H)-carboxamide,
3,4-dihydro-N-(4-methylphenyl)-7-[(4-oxo-2-thioxo-5-
thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 719310-13-1 CAPLUS
 CN 4-Thiazolidinone, 5-[[5-(cyclopentylcarbonyl)-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-14-2 CAPLUS
 CN 4-Thiazolidinone, 5-[[2,3,4,5-tetrahydro-5-[2-(2-thienyl)acetyl]-1,5-benzoxazepin-7-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-15-3 CAPLUS

CN 1,5-Benzoxazepine-5(2H)-carboxamide,
N-(3,5-dimethoxyphenyl)-3,4-dihydro-7-[(4-oxo-2-thioxo-5-
thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719310-16-4 CAPLUS

CN 4-Thiazolidinone, 5-[[5-(3,4-dichlorobenzoyl)-2,3,4,5-tetrahydro-1,5-
benzoxazepin-7-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-17-5 CAPLUS


CN 4-Thiazolidinone, 5-[[2,3,4,5-tetrahydro-5-(1-oxo-3-phenyl-2-propen-1-yl)-
1,5-benzoxazepin-7-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-18-6 CAPLUS
 CN 4-Thiazolidinone, 5-[[5-(2,1,3-benzoxadiazol-5-ylcarbonyl)-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-yl]methylene]-2-thioxo- (CA INDEX NAME)



RN 719310-19-7 CAPLUS
 CN 4-Thiazolidinone, 5-[[2,3,4,5-tetrahydro-5-(3-pyridinylcarbonyl)-1,5-benzoxazepin-7-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-20-0 CAPLUS
 CN 1,5-Benzoxazepine-5(2H)-carboxamide,
 3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 719310-21-1 CAPLUS

CN 4-Thiazolidinone, 5-[[2,3,4,5-tetrahydro-5-[2-(phenylmethoxy)acetyl]-1,5-benzoxazepin-7-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-22-2 CAPLUS

CN 1,5-Benzoxazepine-5(2H)-carboxamide,
N-[4-chloro-2-(trifluoromethyl)phenyl]-3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719310-23-3 CAPLUS

CN Benzonitrile, 4-[[3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1,5-benzoxazepin-5(2H)-yl]carbonyl]- (CA INDEX NAME)




RN 719310-24-4 CAPLUS

CN 1,5-Benzoxazepine-5(2H)-carboxamide, 3,4-dihydro-N-(3-methoxyphenyl)-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 719310-25-5 CAPLUS

CN 4-Thiazolidinone, 5-[[5-(2-furanylcarbonyl)-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-26-6 CAPLUS

CN 4-Thiazolidinone, 5-[[2,3,4,5-tetrahydro-5-[1-oxo-3-[(trifluoromethyl)phenyl]-2-propen-1-yl]-1,5-benzoxazepin-7-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-27-7 CAPLUS

CN 4-Thiazolidinone, 5-[[5-[[5-(1,1-dimethylethyl)-2-methyl-3-furanyl]carbonyl]-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-yl]methylene]-2-thioxo- (CA INDEX NAME)




RN 719310-28-8 CAPLUS

CN 4-Thiazolidinone, 5-[[5-(4-hexylbenzoyl)-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-yl]methylene]-2-thioxo- (CA INDEX NAME)





RN 719310-29-9 CAPLUS
 CN 9,10-Anthracenedione, 2-[[[3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1,5-benzoxazepin-5(2H)-yl]carbonyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2004:513546 CAPLUS
 DOCUMENT NUMBER: 141:71552
 TITLE: Preparation of benzoxazin-3-ones and derivatives as inhibitors of PI3K kinase for treating inflammations, cardiovascular diseases and cancers
 INVENTOR(S): Barvian, Nicole Chantel; Kolz, Christine Nylund; Para, Kimberly Suzanne; Patt, William Chester; Visnick, Melean
 PATENT ASSIGNEE(S): Warner-Lambert Company Llc, USA
 SOURCE: PCI Int. Appl., 146 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052373	A1	20040624	WO 2003-IB5451	20031125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508601	A1	20040624	CA 2003-2508601	20031125
AU 2003280188	A1	20040630	AU 2003-280188	20031125
EP 1569653	A1	20050907	EP 2003-772558	20031125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016386	A	20050927	BR 2003-16386	20031125
JP 2006510661	T	20060330	JP 2004-558912	20031125
US 20040121996	A1	20040624	US 2003-730680	20031208
US 7205295	B2	20070417		
MX 2005005585	A	20050727	MX 2005-5585	20050525
PRIORITY APPLN. INFO.:			US 2002-431528P	P 20021206
			WO 2003-IB5451	W 20031125
OTHER SOURCE(S):		MARPAT 141:71552		
GI				



AB Title compds. I [wherein W = O, S, NH and derivs.; Q, E = independently

(CH₂)_n; n = 0-1; R₁ = H, carbonyl/cyclo/alkylcyclo/alkyl, alkylenealkoxy, alkyleneheteroaryl, etc.; R₂ = H, CF₃, CH₃; R₃ = H, CH₂CO₂H, Ph, CH₃, alkyl, alkenyl; Y = C(=O), C(=S); K = NH, O, CH₂, S; G = N, C; R₄ = H, F, CF₃, CH₃; R₅ = H, alkoxy, alkyl, NO₂, NH₂ and derivs., etc.; and their pharmaceutically acceptable salts] were prepared as inhibitors of phosphatidylinositol-3 (PI3K) kinase for treating inflammations, cardiovascular diseases and cancers. For example, II was prepared from 4-hydroxy-3-nitrobenzaldehyde and Et bromoacetate via condensation of rhodamine with benzo[1,4]oxazine carboxaldehyde. In an in vitro assay, selected II inhibited PI3K with IC₅₀ values in the range of 0.002 to 0.29 μM. I are useful for treating rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, inflammations, and autoimmune diseases.

II 648915-87-1P, 5-[(4-Benzyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]thiazolidine-2,4-dione 711021-17-9P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one 711021-20-4P, 4-Methyl-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one 711021-26-0P, [3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]acetic acid 711021-28-2P, 4-Benzyl-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one 711021-30-6P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-phenethyl-4H-1,4-benzoxazin-3-one 711021-38-4P, [3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]acetic acid methyl ester 711021-40-8P, 3-[[3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzoic acid methyl ester 711021-42-0P, 4-[(Biphenyl-4-yl)methyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711021-47-5P, 4-[(Naphthalen-2-yl)methyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711021-49-7P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[(pyridin-3-yl)methyl]-4H-1,4-benzoxazin-3-one 711021-55-5P, 711021-57-7P, 4-(3,5-Dimethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711021-59-9P, 4-(3-Benzoyloxybenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711021-67-9P, 5,8-Dimethyl-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one 711021-73-7P, 3-[[3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzoic acid 711021-75-9P, (S)-4-Benzyl-2-methyl-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one 711021-81-7P, 4-[4-(Piperidin-1-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711021-83-9P, 4-[4-(Morpholin-4-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711021-85-1P, 4-[4-[(Diethylamino)methyl]benzyl]-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one 711021-87-3P, Acetic acid 2-[[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzyl ester 711021-89-5P, 4-(4-Benzoyloxybenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711021-95-3P, 4-(2-Hydroxymethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711021-99-7P, 4-[4-(Naphthalen-1-yloxy)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-01-4P, 4-(3,5-Dimethoxybenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-

1,4-benzoxazin-3-one 711022-02-5P,
 4-[4-[(2S,6R)-2,6-Dimethylpiperidin-1-yl)methyl]benzyl]-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one
 711022-09-2P, 4-(3,5-Dimethylbenzyl)-8-methyl-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711022-11-6P, 4-[3,5-Bis(trifluoromethyl)benzyl]-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one
 711022-13-8P, 4-[2-(3,5-Dimethylphenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711022-15-0P, 4-(2,6-Dimethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-17-2P,
 4-(3,5-Di-tert-butylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-19-4P,
 4-[4-(4-Methylpiperazin-1-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-20-7P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(3-phenylpropyl)-4H-1,4-benzoxazin-3-one 711022-22-9P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[4-[(4-phenylpiperazin-1-yl)methyl]benzyl]-4H-1,4-benzoxazin-3-one 711022-24-1P,
 4-(4-tert-Butylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-25-2P,
 (S)-4-(3,5-Di-tert-butylbenzyl)-2-methyl-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-29-6P,
 4-[(Biphenyl-3-yl)methyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-31-0P,
 4-[3,5-Dimethyl-4-(morpholin-4-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711022-33-2P, 4-(3-Iodobenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-35-4P,
 4-(3-Bromo-5-iodobenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-37-6P,
 4-[3-Methyl-5-(morpholin-4-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-39-8P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(1',1',3',1''-terphenyl)-5'-ylmethyl-4H-1,4-benzoxazin-3-one 711022-41-2P,
 Trifluoromethanesulfonic acid 3-[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-ylmethyl]-5-[(trifluoromethylsulfonyl)oxy]phenyl ester 711022-43-4P,
 4-[(2,6-Di-tert-butylpiperidin-4-yl)methyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-51-4P,
 4-Benzyl-8-fluoro-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one 711022-54-7P,
 8-Chloro-4-(3,5-di-tert-butylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-55-8P,
 4-[3-(4-Methylpiperazin-1-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-56-9P,
 8-Chloro-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one 711022-57-0P, 4-Benzyl-8-chloro-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one
 711022-58-1P, 4-(3,5-Di-tert-butylbenzyl)-8-methoxy-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711022-59-2P, 4-(3-tert-Butyl-5-iodobenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711022-60-5P, 8-Fluoro-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one 711022-61-6P,
 4-(3,5-Di-tert-butylbenzyl)-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-65-0P,

3-tert-Butyl-5-[[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzonitrile 711022-67-2P,
 4-(3-tert-Butyl-5-vinylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-68-3P,
 3-tert-Butyl-5-[[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzoic acid methyl ester 711022-71-8P,
 3-tert-Butyl-5-[[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzoic acid 711022-73-0P,
 [[3-tert-Butyl-5-[[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzoyl]amino]acetic acid tert-butyl ester 711022-74-1P,
 [[3-tert-Butyl-5-[[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzoyl]amino]acetic acid 711022-75-2P,
 4-(3,5-Di-tert-butylbenzyl)-8-methyl-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-76-3P,
 4-[1-(3,5-Di-tert-butylphenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-79-6P,
 4-(3-tert-Butyl-5-ethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-80-9P,
 4-(3-Acetyl-5-tert-butylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-81-0P,
 4-(5-tert-Butylbiphenyl-3-ylmethyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-82-1P,
 5-[4-(2,6-Di-tert-butylpyridin-4-yl)methyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]thiazolidine-2,4-dione 711022-83-2P,
 8-Chloro-4-(3,5-dimethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-84-3P,
 5-[[8-Chloro-4-(3,5-dimethylbenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]thiazolidine-2,4-dione 711022-85-4P,
 4-(3,5-Dimethylbenzyl)-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-89-8P, Acetic acid 3-tert-butyl-5-[[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzyl ester 711022-90-1P,
 2,8-Fluoro-4-[4-(morpholin-4-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-91-2P,
 4-[4-[(Diethylamino)methyl]benzyl]-8-fluoro-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one 711022-92-3P,
 8-Fluoro-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[4-[(piperidin-1-yl)methyl]benzyl]-4H-1,4-benzoxazin-3-one 711022-93-4P,
 4-[4-[[3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzyl]piperazine-1-carboxylic acid tert-butyl ester 711022-94-5P,
 4-[4-[[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)-3-oxo-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzyl]piperazine-1-carboxylic acid tert-butyl ester 711022-95-6P,
 5-[[8-Fluoro-3-oxo-4-[4-(piperidin-1-ylmethyl)benzyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]thiazolidine-2,4-dione 711022-96-7P,
 4-[4-(4-Butylpiperazin-1-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711022-99-0P,
 8-Chloro-4-[4-[(diethylamino)methyl]benzyl]-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one 711023-00-6P,
 8-Chloro-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[4-[(piperidin-1-yl)methyl]benzyl]-4H-1,4-benzoxazin-3-one 711023-01-7P,
 8-Chloro-4-[4-(morpholin-4-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711023-03-9P,
 4-Benzyl-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzothiazin-

3-one 711023-04-0P, 4-(3,5-Di-tert-butylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzothiazin-3-one 711023-05-1P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzothiazin-3-one 711023-06-2P, 6-(4-Oxo-2-thioxooxazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one 711023-07-3P, 5-[[4-(3,5-Di-tert-butylbenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]thiazolidine-2,4-dione 711023-09-5P, 5-[(3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)methylene]imidazolidine-2,4-dione 711023-13-1P, 4-(3,4-Dichlorobenzoyloxy)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-14-2P, 4-(3,5-Dimethylbenzyloxy)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-18-6P, 4-Benzoyloxy-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one 711023-19-7P, 8-Methyl-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[4-(piperidin-1-yl)methyl]benzyl]-4H-benzo[1,4]oxazin-3-one 711023-20-0P, 4-[4-[(Diethylamino)methyl]benzyl]-8-methyl-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one 711023-21-1P, 5-[[4-[4-[(Diethylamino)methyl]benzyl]-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methylene]thiazolidine-2,4-dione 711023-22-2P, 4-(3,5-Diisopropoxybenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-23-3P, 4-(5-tert-Butyl-2-methoxybenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711023-24-4P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(2,3,5,6-tetramethylbenzyl)-4H-1,4-benzoxazin-3-one 711023-25-5P, 4-(3,4-Dimethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711023-26-6P, 4-(2,3-Dimethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-27-7P, 4-(2,5-Dimethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711023-28-8P, 4-(2,4-Dimethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711023-29-9P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[2-(m-tolyl)ethyl]-4H-benzo[1,4]oxazin-3-one 711023-30-2P, 4-[2-(4-Bromophenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-31-3P, 4-[2-(3,4-Dichlorophenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-32-4P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[2-(4-trifluoromethylphenyl)ethyl]-4H-benzo[1,4]oxazin-3-one 711023-33-5P, 4-[2-(2,4-Dichlorophenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-34-6P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[2-(3-trifluoromethylphenyl)ethyl]-4H-benzo[1,4]oxazin-3-one 711023-35-7P, 8-Chloro-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[2-(4-trifluoromethylphenyl)ethyl]-4H-benzo[1,4]oxazin-3-one 711023-36-8P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[2-(2-trifluoromethylphenyl)ethyl]-4H-benzo[1,4]oxazin-3-one 711023-37-9P, (S)-4-[2-(3,4-Dichlorophenyl)ethyl]-2-methyl-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-38-0P, 8-Chloro-4-[2-(3,4-dichlorophenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-39-1P, 4-[2-(3,4-Dichlorophenyl)ethyl]-8-fluoro-6-[(4-oxo-2-

thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711023-40-4P, 4-[2-(3,4-Dichlorophenyl)ethyl]-8-methyl-6-[(4-oxo-2-
 thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711023-43-7P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[3-(
 pyridin-4-yl)benzyl]-4H-benzo[1,4]oxazin-3-one 711023-47-1P,
 4-[3-(Furan-3-yl)-5-methylbenzyl]-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-49-3P,
 4-[3-Methyl-5-(thiophen-3-yl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-51-7P,
 4-[3-(3,5-Dimethylisoxazol-4-yl)-5-methylbenzyl]-6-[(4-oxo-2-
 thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711023-52-8P, 3-Methyl-5-[[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]methyl]benzoic acid methyl
 ester 711023-54-0P, 4-[3-Methyl-5-(thiazol-2-yl)benzyl]-6-[(4-
 oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711023-56-2P, 3-Methyl-5-[[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]methyl]benzonitrile
 711023-58-4P, 4-[3-Methyl-5-(pyrazin-2-yl)benzyl]-6-[(4-oxo-2-
 thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711023-60-8P, 4-[3-(4-Methoxyphenyl)propyl]-6-[(4-oxo-2-
 thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711023-61-9P, 5-[[[3-(4-Methoxyphenyl)propyl]-3-oxo-3,4-dihydro-
 2H-benzo[1,4]oxazin-6-yl]methylene]thiazolidine-2,4-dione
 711023-62-0P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[3-(
 3,4,5-trimethoxyphenyl)propyl]-4H-benzo[1,4]oxazin-3-one
 711023-63-1P, Acetic acid 2,6-dimethyl-4-[3-[3-oxo-6-(4-oxo-2-
 thioxothiazolidin-5-ylidenemethyl)-2,3-dihydrobenzo[1,4]oxazin-4-
 yl]methyl]phenyl ester 711023-64-2P,
 4-[3-(2,3-Dichlorophenyl)propyl]-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-65-3P,
 4-[(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)methyl]-6-[(4-oxo-2-
 thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711023-66-4P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[2-(
 4-phenoxyphenyl)ethyl]-4H-1,4-benzoxazin-3-one 711023-67-5P,
 4-[2-(3,5-Dimethoxyphenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-69-7P,
 4-[2-(4-tert-Butylphenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-70-0P,
 4-[2-(4-Dimethylaminophenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-73-3P,
 4-[2-(3,4-Difluorophenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-74-4P,
 4-[2-(4-Chlorophenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-1,4-benzoxazin-3-one 711023-75-5P,
 4-[2-(3-Chlorophenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-1,4-benzoxazin-3-one 711023-76-6P,
 4-[2-(4-Methoxyphenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-1,4-benzoxazin-3-one 711023-77-7P,
 4-[2-(3-Methoxyphenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-1,4-benzoxazin-3-one 711023-78-8P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[2-(p-tolyl)ethyl]-4H-1,4-
 benzoxazin-3-one 711023-79-9P,
 4-Ethyl-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-
 3-one 711023-80-2P, 4-(4-Methylbenzyl)-6-[(4-oxo-2-
 thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711023-82-4P, 2-[3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]acetamide

711023-83-5P, 4-(3-Methylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-84-6P,
 4-Cyclohexylmethyl-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one 711023-85-7P,
 4-(3-Methylbutyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-86-8P,
 4-Cyclopropylmethyl-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one 711023-87-9P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[(thiophen-3-yl)methyl]-4H-benzo[1,4]oxazin-3-one 711023-89-1P
 , 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[(pyridin-2-yl)methyl]-4H-benzo[1,4]oxazin-3-one 711023-90-4P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[(pyridin-4-yl)methyl]-4H-benzo[1,4]oxazin-3-one 711023-91-5P,
 3-[[3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydrobenzo[1,4]oxazin-4-yl]methyl]benzonitrile 711023-92-6P,
 (S)-2-Methyl-4-[(naphthalen-2-yl)methyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711023-93-7P,
 4-Benzyl-8-methoxy-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one 711023-94-8P,
 8-Methyl-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one 711023-95-9P, 4-(3,3-Dimethylbutyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711023-96-0P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(3-trifluoromethoxybenzyl)-4H-1,4-benzoxazin-3-one 711023-97-1P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(3-trifluoromethylbenzyl)-4H-1,4-benzoxazin-3-one 711023-98-2P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(4-trifluoromethylbenzyl)-4H-1,4-benzoxazin-3-one 711023-99-3P,
 4-[(Biphenyl-2-yl)methyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-00-9P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(3-phenoxypropyl)-4H-1,4-benzoxazin-3-one 711024-01-0P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(4-styrylbenzyl)-4H-1,4-benzoxazin-3-one 711024-02-1P,
 4-(3-Difluoromethoxybenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-03-2P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[3-(trifluoromethylsulfanyl)benzyl]-4H-1,4-benzoxazin-3-one 711024-04-3P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(2-trifluoromethoxybenzyl)-4H-1,4-benzoxazin-3-one 711024-05-4P,
 4-(4-Methoxy-3-trifluoromethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-06-5P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[4-(trifluoromethylsulfanyl)benzyl]-4H-1,4-benzoxazin-3-one 711024-07-6P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[2-(trifluoromethylsulfanyl)benzyl]-4H-1,4-benzoxazin-3-one 711024-08-7P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(3-phenoxybenzyl)-4H-1,4-benzoxazin-3-one 711024-09-8P,
 4-Bicyclo[2.2.1]hept-5-en-2-ylmethyl-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one 711024-10-1P,
 3-[[3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzamide 711024-11-2P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(2-phenylpropyl)-4H-1,4-benzoxazin-3-one 711024-12-3P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(4-phenylbutyl)-4H-1,4-benzoxazin-3-one 711024-13-4P,


6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(5-phenylpentyl)-4H-1,4-benzoxazin-3-one 711024-14-5P,
 4-[[3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzamide 711024-15-6P,
 N-[4-[[3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]phenyl]acetamide 711024-16-7P,
 4-(3,4-Dichlorobenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-17-8P,
 4-(4-Chlorobenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-18-9P,
 4-(4-Methoxybenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-19-0P,
 4-(4-Nitrobenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-20-3P,
 4-[2-(Dibenzofuran-3-yl)-2-oxoethyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-21-4P,
 4-(3-Fluoro-5-trifluoromethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-27-0P,
 4-Methyl-7-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-3,4-dihydro-1H-quinoxalin-2-one 711024-28-1P,
 4-(3,4-Dichlorobenzyl)-6-[(4-oxo-2-thioxooxazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-29-2P,
 4-[4-(Methanesulfonyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-30-5P,
 4-[4-(Methanesulfonyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one potassium salt 711024-31-6P,
 4-(4-Chloro-3-trifluoromethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one potassium salt 711024-33-8P,
 4-(4-Chloro-3-trifluoromethylbenzyl)-6-[(4-oxo-2-thioxooxazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-34-9P,
 1-Benzyl-4-methyl-7-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-3,4-dihydro-1H-quinoxalin-2-one 711024-35-0P,
 4-(3,4-Dichlorobenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzothiazin-3-one 711024-36-1P,
 4-(3,4-Dichlorobenzyl)-6-[(4-oxo-2-thioxooxazolidin-5-ylidene)methyl]-4H-benzo[1,4]thiazin-3-one 711024-37-2P,
 6-(5-Oxo-2-thioxoimidazolidin-4-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one 711024-40-7P,
 4-(2,6-Di-tert-butylpyridin-4-ylmethyl)-6-[(4-oxo-2-thioxooxazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-41-8P,
 5-[(3-Oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]oxazolidine-2,4-dione 711024-44-1P,
 4-[(2-Chloro-6-methoxy-pyridin-4-yl)methyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711024-45-2P,
 4-[(2,6-Dimethoxy-pyridin-4-yl)methyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711024-46-3P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-(4-trifluoromethylbenzyloxy)-4H-benzo[1,4]oxazin-3-one 711024-47-4P,
 4-(Cyclohexylmethoxy)-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one 711024-48-5P,
 4-(2,6-Di-tert-butylpyridin-4-ylmethoxy)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711024-49-6P,
 4-(3,5-Diisopropylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711024-50-9P,
 4-(3-tert-Butyl-5-methylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-52-1P,
 4-(3-tert-Butyl-5-hydroxymethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-55-4P,

4-[2-(3,5-Dimethylpiperidin-1-yl)-2-oxoethyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-56-5P, 4-[2-[3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]acetyl]piperazine-1-carboxylic acid tert-butyl ester 711024-57-6P, 4-[2-Oxo-2-(piperazin-1-yl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-59-8P, 3-tert-Butyl-5-[[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzamide 711024-60-1P, 4-(3,5-Dibromobenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-61-2P, 4-[1-(3,5-Dimethylphenyl)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-62-3P, 5-[(4-(3,5-Di-tert-butyl-4-hydroxybenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]thiazolidine-2,4-dione 711024-63-4P, 4-(2,6-Di-tert-butylpyridin-4-ylmethyl)-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-64-5P, 4-(2,6-Di-tert-butylpyridin-4-ylmethyl)-8-methyl-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-65-6P, 4-[3-tert-Butyl-5-(4-methylpiperazin-1-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-68-9P, 2-Methyl-4-[4-(4-methylpiperazin-1-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-69-0P, 5-[4-(2,6-Di-tert-butylpyridin-4-yl)methyl]-[8-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]thiazolidine-2,4-dione 711024-70-3P, 4-(2,6-Dichloropyridin-4-ylmethyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711024-71-4P, 5-[4-(2,6-Dichloropyridin-4-yl)methyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-ylmethylene]thiazolidine-2,4-dione
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PI3K inhibitor; preparation of benzoxazinones as PI3K inhibitors for treating inflammations, cardiovascular diseases and cancers)


RN 648915-87-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[3,4-dihydro-3-oxo-4-(phenylmethyl)-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711021-17-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711021-20-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-methyl-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711021-26-0 CAPLUS

CN 4H-1,4-Benzoxazine-4-acetic acid, 2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711021-28-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 711021-30-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-4-(2-phenylethyl)- (CA INDEX NAME)




RN 711021-38-4 CAPLUS

CN 4H-1,4-Benzoxazine-4-acetic acid, 2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, methyl ester (CA INDEX NAME)




RN 711021-40-8 CAPLUS

CN Benzoic acid, 3-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 711021-42-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-([1,1'-biphenyl]-4-ylmethyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711021-47-5 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(2-naphthalenylmethyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711021-49-7 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 711021-55-5 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 2-methyl-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.




RN 711021-57-7 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,5-dimethylphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711021-59-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-4-[[3-(phenylmethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 711021-67-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 5,8-dimethyl-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711021-73-7 CAPLUS
 CN Benzoic acid, 3-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]- (CA INDEX NAME)




RN 711021-75-9 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 2-methyl-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(phenylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 711021-81-7 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[4-(1-piperidinylmethyl)phenyl]methyl]- (CA INDEX NAME)




RN 711021-83-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-(4-morpholinylmethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711021-85-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-[(diethylamino)methyl]phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711021-87-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[2-[(acetyloxy)methyl]phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711021-89-5 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 711021-95-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[2-(hydroxymethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711021-99-7 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-(1-naphthalenyloxy)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)



RN 711022-01-4 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,5-dimethoxyphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)



RN 711022-02-5 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-[(2S,6R)-2,6-dimethyl-1-piperidinyl]methyl]phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 711022-09-2 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,5-dimethylphenyl)methyl]-8-methyl-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-11-6 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-
 [(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711022-13-8 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3,5-dimethylphenyl)ethyl]-6-[(4-oxo-2-
 thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-15-0 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(2,6-dimethylphenyl)methyl]-6-[(4-oxo-2-
 thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-17-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3,5-bis(1,1-dimethylethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-19-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-20-7 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(3-phenylpropyl)- (CA INDEX NAME)




RN 711022-22-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[4-[(4-phenyl-1-piperazinyl)methyl]phenyl]methyl]- (CA INDEX NAME)



RN 711022-24-1 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-(1,1-dimethylethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinydene)methyl]- (CA INDEX NAME)



RN 711022-25-2 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3,5-bis(1,1-dimethylethyl)phenyl]methyl]-2-methyl-6-[(4-oxo-2-thioxo-5-thiazolidinydene)methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 711022-29-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-([1,1'-biphenyl]-3-ylmethyl)-6-[(4-oxo-2-thioxo-5-thiazolidinydene)methyl]- (CA INDEX NAME)




RN 711022-31-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3,5-dimethyl-4-(4-morpholinylmethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinydene)methyl]- (CA INDEX NAME)




RN 711022-33-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3-iodophenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-35-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3-bromo-5-iodophenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-37-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-methyl-5-(4-morpholinylmethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711022-39-8 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[1,1':3',1''-terphenyl]-5'-ylmethyl]- (9CI)
(CA INDEX NAME)



RN 711022-41-2 CAPLUS


CN Methanesulfonic acid, trifluoro-, 5-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-

5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl)methyl]-1,3-phenylene ester (9CI) (CA INDEX NAME)




RN 711022-43-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[2,6-bis(1,1-dimethylethyl)-4-pyridinyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711022-51-4 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(phenylmethyl)- (CA INDEX NAME)



RN 711022-54-7 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3,5-bis(1,1-dimethylethyl)phenyl]methyl]-

8-chloro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-55-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-56-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 8-chloro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-57-0 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 8-chloro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 711022-58-1 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[[3,5-bis(1,1-dimethylethyl)phenyl]methyl]-8-methoxy-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-59-2 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[[3-(1,1-dimethylethyl)-5-iodophenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-60-5 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-61-6 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3,5-bis(1,1-dimethylethyl)phenyl]methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711022-65-0 CAPLUS
 CN Benzonitrile, 3-[[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 711022-67-2 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-5-ethenylphenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-68-3 CAPLUS

CN Benzoic acid, 3-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]-5-(1,1-dimethylethyl)-, methyl ester (CA INDEX NAME)




RN 711022-71-8 CAPLUS

CN Benzoic acid, 3-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 711022-73-0 CAPLUS

CN Glycine, N-[3-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]-5-(1,1-dimethylethyl)benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 711022-74-1 CAPLUS

CN Glycine, N-[3-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]-5-(1,1-dimethylethyl)benzoyl]- (CA INDEX NAME)




RN 711022-75-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[[3,5-bis(1,1-dimethylethyl)phenyl]methyl]-8-methyl-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-76-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[1-[3,5-bis(1,1-dimethylethyl)phenyl]ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711022-79-6 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-5-ethylphenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711022-80-9 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-acetyl-5-(1,1-

dimethylethyl)phenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-81-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[5-(1,1-dimethylethyl)[1,1'-biphenyl]-3-yl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-82-1 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[[2,6-bis(1,1-dimethylethyl)-4-pyridinyl]methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711022-83-2 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 8-chloro-4-[(3,5-dimethylphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-84-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[8-chloro-4-[(3,5-dimethylphenyl)methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711022-85-4 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,5-dimethylphenyl)methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711022-89-8 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-[(acetyloxy)methyl]-5-(1,1-dimethylethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-90-1 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-4-[[4-(4-morpholinylmethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-91-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-[(diethylamino)methyl]phenyl]methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)



RN 711022-92-3 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-4-[[4-(1-piperidinylmethyl)phenyl]methyl]- (CA INDEX NAME)



RN 711022-93-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 711022-94-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 711022-95-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[8-fluoro-3,4-dihydro-3-oxo-4-[[4-(1-piperidinylmethyl)phenyl]methyl]-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711022-96-7 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-[(4-butyl-1-piperazinyl)methyl]phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711022-99-0 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 8-chloro-4-[[4-[(diethylamino)methyl]phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-00-6 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 8-chloro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[4-(1-piperidinylmethyl)phenyl]methyl]- (CA INDEX NAME)




RN 711023-01-7 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 8-chloro-4-[[4-(4-morpholinylmethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711023-03-9 CAPLUS
 CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 711023-04-0 CAPLUS
 CN 2H-1,4-Benzothiazin-3(4H)-one, 4-[[3,5-bis(1,1-dimethylethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711023-05-1 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-06-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-oxazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-07-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[[3,5-bis(1,1-dimethylethyl)phenyl]methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711023-09-5 CAPLUS

CN 2,4-Imidazolidinedione, 5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methylene]- (CA INDEX NAME)




RN 711023-13-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,4-dichlorophenyl)methoxy]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711023-14-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,5-dimethylphenyl)methoxy]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711023-18-6 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-4-(phenylmethoxy)- (CA INDEX NAME)




RN 711023-19-7 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 8-methyl-6-[[4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[4-(1-piperidinylmethyl)phenyl)methyl]- (CA INDEX NAME)



RN 711023-20-0 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-[(diethylamino)methyl]phenyl)methyl]-8-methyl-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-21-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[[4-[(diethylamino)methyl]phenyl)methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methylene]- (CA INDEX NAME)




RN 711023-22-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3,5-bis(1-methylethoxy)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-23-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-24-4 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[(2,3,5,6-tetramethylphenyl)methyl]- (CA INDEX NAME)



RN 711023-25-5 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,4-dimethylphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-26-6 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(2,3-dimethylphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-27-7 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(2,5-dimethylphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinydene)methyl]- (CA INDEX NAME)



RN 711023-28-8 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(2,4-dimethylphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinydene)methyl]- (CA INDEX NAME)



RN 711023-29-9 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3-methylphenyl)ethyl]-6-[(4-oxo-2-

thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-30-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(4-bromophenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-31-3 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3,4-dichlorophenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-32-4 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[2-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 711023-33-5 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(2,4-dichlorophenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-34-6 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[2-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 711023-35-7 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 8-chloro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[2-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 711023-36-8 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[2-[2-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 711023-37-9 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3,4-dichlorophenyl)ethyl]-2-methyl-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 711023-38-0 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 8-chloro-4-[2-(3,4-dichlorophenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-39-1 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3,4-dichlorophenyl)ethyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-40-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3,4-dichlorophenyl)ethyl]-8-methyl-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-43-7 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[3-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 711023-47-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(3-furanyl)-5-methylphenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-49-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-methyl-5-(3-thienyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-51-7 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(3,5-dimethyl-4-isoxazolyl)-5-methylphenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-52-8 CAPLUS

CN Benzoic acid, 3-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]-5-methyl-, methyl ester (CA INDEX NAME)




RN 711023-54-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-methyl-5-(2-thiazolyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-56-2 CAPLUS

CN Benzonitrile, 3-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]-5-methyl- (CA INDEX NAME)




RN 711023-58-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-methyl-5-(2-pyrazinyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-60-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[3-(4-methoxyphenyl)propyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-61-9 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[3,4-dihydro-4-[3-(4-methoxyphenyl)propyl]-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711023-62-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[3-(3,4,5-trimethoxyphenyl)propyl]- (CA INDEX NAME)




RN 711023-63-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-(acetyloxy)-3,5-dimethylphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-64-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[3-(2,3-dichlorophenyl)propyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-65-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711023-66-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-4-[2-(4-phenoxyphenyl)ethyl]- (CA INDEX NAME)




RN 711023-67-5 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3,5-dimethoxyphenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711023-69-7 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-[4-(1,1-dimethylethyl)phenyl]ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-70-0 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-[4-(dimethylamino)phenyl]ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711023-73-3 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3,4-difluorophenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-74-4 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(4-chlorophenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-75-5 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3-chlorophenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-76-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(4-methoxyphenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-77-7 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3-methoxyphenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-78-8 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(4-methylphenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-79-9 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-ethyl-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711023-80-2 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(4-methylphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-82-4 CAPLUS
 CN 4H-1,4-Benzoxazine-4-acetamide, 2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-83-5 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3-methylphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-84-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(cyclohexylmethyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-85-7 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(3-methylbutyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-86-8 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(cyclopropylmethyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711023-87-9 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(3-thienylmethyl)- (CA INDEX NAME)




RN 711023-89-1 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 711023-90-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 711023-91-5 CAPLUS


CN Benzonitrile, 3-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]- (CA INDEX NAME)




RN 711023-92-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 2-methyl-4-(2-naphthalenylmethyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.




RN 711023-93-7 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 8-methoxy-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 711023-94-8 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 8-methyl-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-95-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(3,3-dimethylbutyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711023-96-0 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 711023-97-1 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 711023-98-2 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 711023-99-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-([1,1'-biphenyl]-2-ylmethyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-00-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(3-phenoxypropyl)- (CA INDEX NAME)




RN 711024-01-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[4-(2-phenylethenyl)phenyl]methyl]- (CA INDEX NAME)




RN 711024-02-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(difluoromethoxy)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-03-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[3-[(trifluoromethyl)thio]phenyl]methyl]- (CA INDEX NAME)




RN 711024-04-3 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 711024-05-4 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-methoxy-3-(trifluoromethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-06-5 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[4-[(trifluoromethyl)thio]phenyl]methyl]- (CA INDEX NAME)



RN 711024-07-6 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[2-[(trifluoromethyl)thio]phenyl]methyl]- (CA INDEX NAME)




RN 711024-08-7 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[[3-phenoxyphenyl]methyl]- (CA INDEX NAME)




RN 711024-09-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(bicyclo[2.2.1]hept-2-en-1-ylmethyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-10-1 CAPLUS

CN Benzamide, 3-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]- (CA INDEX NAME)




RN 711024-11-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(2-phenylpropyl)- (CA INDEX NAME)




RN 711024-12-3 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(4-phenylbutyl)- (CA INDEX NAME)




RN 711024-13-4 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(5-phenylpentyl)- (CA INDEX NAME)



RN 711024-14-5 CAPLUS
CN Benzamide, 4-[[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]- (CA INDEX NAME)




RN 711024-15-6 CAPLUS
CN Acetamide, N-[4-[[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]phenyl]- (CA INDEX NAME)




RN 711024-16-7 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,4-dichlorophenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinydene)methyl]- (CA INDEX NAME)




RN 711024-17-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(4-chlorophenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinydene)methyl]- (CA INDEX NAME)




RN 711024-18-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(4-methoxyphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-19-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(4-nitrophenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-20-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3-dibenzofuranyl)-2-oxoethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-21-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-27-0 CAPLUS

CN 2(1H)-Quinoxalinone, 3,4-dihydro-4-methyl-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-28-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,4-dichlorophenyl)methyl]-6-[(4-oxo-2-thioxo-5-oxazolidinylidene)methyl]- (CA INDEX NAME)



RN 711024-29-2 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-(methylsulfonyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711024-30-5 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-(methylsulfonyl)phenyl]methyl]-6-[(4-


oxo-2-thioxo-5-thiazolidinyldene)methyl]-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 711024-31-6 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-, potassium salt (1:1) (CA INDEX NAME)



● K


RN 711024-33-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-oxazolidinyldene)methyl]- (CA INDEX NAME)




RN 711024-34-9 CAPLUS

CN 2-[(1H)-4-Quinoxalinone, 3,4-dihydro-4-methyl-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1-(phenylmethyl)- (CA INDEX NAME)




RN 711024-35-0 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 4-[(3,4-dichlorophenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-36-1 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 4-[(3,4-dichlorophenyl)methyl]-6-[(4-oxo-2-thioxo-5-oxazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-37-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(5-oxo-2-thioxo-4-imidazolidinylidene)methyl]- (2-chlorophenyl)methyl- (CA INDEX NAME)




RN 711024-40-7 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(2,6-bis(1,1-dimethylethyl)-4-pyridinyl)methyl]-6-[(4-oxo-2-thioxo-5-oxazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-41-8 CAPLUS


CN 2,4-Oxazolidinedione, 5-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methylene]- (2,6-di-tert-butylpyridin-4-yl)methyl- (CA INDEX NAME)




RN 711024-44-1 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(2-chloro-6-methoxy-4-pyridinyl)methyl]-6-
[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-45-2 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(2,6-dimethoxy-4-pyridinyl)methyl]-6-[(4-
oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-46-3 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-
thiazolidinylidene)methyl]-4-[[4-(trifluoromethyl)phenyl]methoxy]- (CA
INDEX NAME)



RN 711024-47-4 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(cyclohexylmethoxy)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-48-5 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[2,6-bis(1,1-dimethylethyl)-4-pyridinyl)methoxy]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-49-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3,5-bis(1-methylethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-50-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-5-methylphenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-52-1 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-5-(hydroxymethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711024-55-4 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-(3,5-dimethyl-1-piperidinyl)-2-oxoethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-56-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 711024-57-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[2-oxo-2-(1-piperazinyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-59-8 CAPLUS

CN Benzamide, 3-[[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 711024-60-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,5-dibromophenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711024-61-2 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[1-(3,5-dimethylphenyl)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-62-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[[3,5-bis(1,1-dimethylethyl)-4-


hydroxyphenyl)methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methylene]-
(CA INDEX NAME)



RN 711024-63-4 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[2,6-bis(1,1-dimethylethyl)-4-pyridinyl)methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-
(CA INDEX NAME)




RN 711024-64-5 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[2,6-bis(1,1-dimethylethyl)-4-pyridinyl)methyl]-8-methyl-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-
(CA INDEX NAME)




RN 711024-65-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-5-[(4-methyl-1-piperazinyl)methyl]phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-68-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 2-methyl-4-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-69-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[2-[2,6-bis(1,1-dimethylethyl)-4-pyridinyl]-1-(3,4-dihydro-8-methyl-3-oxo-2H-1,4-benzoxazin-6-yl)ethylidene]- (CA INDEX NAME)




RN 711024-70-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(2,6-dichloro-4-pyridinyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711024-71-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(2,6-dichloro-4-pyridinyl)methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




IT 711024-72-5P, 5-[[3-Oxo-4-[(pyridin-4-yl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]thiazolidine-2,4-dione
 711024-73-6P, 5-[[4-[(4-Methylpiperazin-1-ylmethyl)benzyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]thiazolidine-2,4-dione
 711024-75-8P, 4-(2,6-Dimethylpyridin-4-ylmethyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711024-76-9P, 5-[[4-(2,6-Dimethylpyridin-4-ylmethyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]thiazolidine-2,4-dione
 711024-77-0P, 5-Methoxy-2-[[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]pyrimidine-4-carboxylic acid methyl ester 711024-78-1P,
 4-(4,6-Dimethylpyrimidin-2-ylmethyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711024-79-2P,
 4-(4-Chloro-3-trifluoromethylbenzyl)-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711024-80-5P, 4-(4,6-Di-tert-butylpyrimidin-2-ylmethyl)-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one
 711024-81-6P, 4-(4,6-Di-tert-butylpyrimidin-2-ylmethyl)-8-fluoro-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one
 711024-82-7P, 4-[3-tert-Butyl-5-(1-hydroxy-1-methylethyl)benzyl]-8-fluoro-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one
 711024-83-8P, 4-[3-tert-Butyl-5-(1-hydroxy-1-methylethyl)benzyl]-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-

benzo[1,4]oxazin-3-one 711024-84-9P,
 4-[4-(3-Azaspiro[5.5]undec-3-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711024-85-0P, 5-[[4-(3-Azaspiro[5.5]undec-3-ylmethyl)benzyl]-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methylene]thiazolidine-2,4-dione
 711024-86-1P, 4-[4-[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)-3-oxo-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzyl]piperazine-1-carboxylic acid ethyl ester 711024-87-2P,
 4-[4-[3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydrobenzo[1,4]oxazin-4-yl]methyl]benzyl]piperazine-1-carboxylic acid ethyl ester 711024-90-7P,
 8-Fluoro-4-[3-(morpholin-4-yl)propyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711024-91-8P,
 8-Fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4-[3-(piperidin-1-yl)propyl]-4H-benzo[1,4]oxazin-3-one 711024-92-9P,
 4-[3-(3,5-Dimethylpiperidin-1-yl)propyl]-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711024-93-0P, 4-(3-Diisopropylaminopropyl)-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711024-94-1P, 5-[[4-(3,4-Dichlorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methylene]thiazolidine-2,4-dione
 711024-95-2P, 4-(3,5-Di-tert-butylbenzyl)-6-[(4-oxo-2-thioxooxazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711024-96-3P, Acetic acid 4-[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]phenyl ester
 711024-97-4P, 5-[[4-(4-Benzyloxybenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]thiazolidine-2,4-dione 711024-98-5P,
 4-(3,5-Di-tert-butylcyclohexylmethyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711025-00-2P,
 5-[[4-[3-Methyl-5-(4-methylpiperazin-1-ylmethyl)benzyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]thiazolidine-2,4-dione
 711025-01-3P, 5-[[3-Oxo-4-[3-(propan-2-ylsulfonyl)benzyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]thiazolidine-2,4-dione
 711025-02-4P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[3-(propan-2-ylsulfonyl)benzyl]-4H-1,4-benzoxazin-3-one
 711025-03-5P, 4-(3-Isopropylsulfonylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711025-04-6P, 4-[3-Methyl-5-(4-methylpiperazin-1-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711025-05-7P, 3-[[6-(2,4-Dioxothiazolidin-5-ylidenemethyl)-3-oxo-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]-N,N-dimethylbenzenesulfonamide
 711025-06-8P, 4-[3-[3-(Morpholin-4-yl)sulfonyl]benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711025-07-9P, 5-[[4-(Cyclohexylmethyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]thiazolidine-2,4-dione 711025-08-0P,
 4-[4-[3-(Morpholin-4-yl)sulfonyl]benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711025-09-1P,
 4-(3-Isopropyl-2-methoxybenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711025-10-4P,
 4-Cyclohexylmethyl-6-(4-oxo-2-thioxooxazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one 711025-11-5P,
 N,N-Dimethyl-3-[[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydro-1,4-benzoxazin-4-yl]methyl]benzenesulfonamide
 711025-12-6P, 4-(3-tert-Butylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711025-13-7P,
 (Z)-N,N-Dimethyl-4-[3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydrobenzo[1,4]oxazin-4-yl]methyl]benzenesulfonamide

711025-14-8P, (Z)-5-[1-[4-(3-Methylsulfonylbenzyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methylidene]thiazolidine-2,4-dione
 711025-15-9P, (Z)-4-Benzyl-6-[1-(4-oxo-2-thioxothiazolidin-5-ylidene)ethyl]-4H-benzo[1,4]oxazin-3-one 711025-17-1P,
 (Z)-6-[1-(4-Oxo-2-thioxothiazolidin-5-ylidene)ethyl]-4H-benzo[1,4]oxazin-3-one 711025-18-2P, 8-Fluoro-4-[3-(methanesulfonylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711025-19-3P, (Z)-4-[3-(Methanesulfonylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711025-20-6P, (Z)-4-[3,5-Bis(trifluoromethyl)benzyl]-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one
 711025-21-7P, (Z)-5-[1-[4-[3,5-Bis(trifluoromethyl)benzyl]-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methylidene]thiazolidine-2,4-dione
 711025-22-8P, (Z)-4-[3,5-Bis(trifluoromethyl)benzyl]-8-fluoro-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one
 711025-23-9P, (Z)-4-[3-tert-Butyl-5-(2-methoxyethoxymethoxymethyl)benzyl]-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-benzo[1,4]oxazin-3-one 711025-24-0P,
 4-[3-tert-Butyl-5-[(morpholin-4-yl)carbonyl]benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711025-25-1P, (Z)-5-[1-[4-[3-tert-Butyl-5-(1-hydroxy-1-methylethyl)benzyl]-8-fluoro-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methylidene]thiazolidine-2,4-dione 711025-26-2P,
 (Z)-5-[1-[4-[3-tert-Butyl-5-(morpholin-4-ylmethyl)benzyl]-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methylidene]thiazolidine-2,4-dione
 711025-27-3P, (Z)-4-[3-tert-Butyl-5-(morpholin-4-ylmethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711025-28-4P, (Z)-4-[3-tert-Butyl-5-[(4-methylpiperazin-1-yl)carbonyl]benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-32-0P,
 (Z)-4-[4-[(4-Methylpiperazin-1-yl)carbonyl]benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711025-33-1P, (Z)-4-[4-[(Morpholin-4-yl)carbonyl]benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711025-34-2P, (Z)-4-[3-(1-Hydroxy-1-methylethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711025-35-3P, (Z)-4-[3-tert-Butyl-5-(1-methoxy-1-methylethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-40-0P,
 (Z)-4-(3-tert-Butyl-5-hydroxymethylbenzyl)-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711025-41-1P, (Z)-Acetic acid
 3-tert-butyl-5-[(8-fluoro-3-oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydrobenzo[1,4]oxazin-4-yl)methyl]benzyl ester
 711025-43-3P, (Z)-3-(3,4-Dichlorobenzyl)-5-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-3H-benzoxazol-2-one
 711025-44-4P, (Z)-4-(4-Iodobenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-45-5P,
 (Z)-4-[(3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydrobenzo[1,4]oxazin-4-yl)methyl]benzoic acid 711025-46-6P,
 (Z)-8-Fluoro-4-[4-(methanesulfonylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-47-7P,
 (Z)-3-Benzyl-5-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-3H-benzoxazol-2-one 711025-48-8P, 3-[4-(Methanesulfonylbenzyl)-5-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-3H-benzoxazol-2-one
 711025-49-9P, 8-Fluoro-4-(4-fluoro-3-trifluoromethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one


711025-50-2P, 4-[3-Chloro-5-(1-hydroxy-1-methylethyl)benzyl]-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-51-3P, 8-Fluoro-4-[4-(1-hydroxy-1-methylethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-52-4P, 4-(3,5-Difluoro-4-hydroxybenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-54-6P, 4-(3,5-Dibromobenzyl)-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-55-7P, 5-[(8-Fluoro-4-(4-fluorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)methylene]thiazolidine-2,4-dione 711025-56-8P, 8-Fluoro-4-(4-methoxy-3-trifluoromethylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-57-9P, 4-(3-Chloro-4-fluorobenzyl)-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-58-0P, 8-Fluoro-4-(4-fluorobenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-59-1P, 8-Fluoro-4-[4-fluoro-3-(1-hydroxy-1-methylethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-60-4P, 4-(4-Fluorobenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-61-5P, 4-[4-Fluoro-3-(1-hydroxy-1-methylethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-62-6P, 5-[[4-[4-Fluoro-3-(1-hydroxy-1-methylethyl)benzyl]-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methylene]thiazolidine-2,4-dione 711025-63-7P, 4-(4-Fluoro-3-methylbenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-64-8P, [[4-[3-(2-Fluorophenoxy)benzyl]-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methylene]thiazolidine-2,4-dione 711025-65-9P, 5-[[4-(3-Chloro-4-fluorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methylene]thiazolidine-2,4-dione 711025-66-0P, 4-(3-Chloro-4-fluorobenzyl)-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-67-1P, 8-Fluoro-4-[2-(4-fluorophenoxy)ethyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-68-2P, 4-(3-Chloro-4-fluorobenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-69-3P, 4-(3,4-Difluorobenzyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711025-70-6P, 4-[3-[Bis(2-methoxyethyl)amino]propyl]-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-71-7P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[(quinoxalin-6-yl)methyl]-4H-benzo[1,4]oxazin-3-one 711025-72-8P, 8-Fluoro-6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[(quinoxalin-6-yl)methyl]-4H-benzo[1,4]oxazin-3-one 711025-76-2P, 4-(2,5-Dimethylfuran-3-ylmethyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-77-3P, 4-(2,5-Dimethylfuran-3-ylmethyl)-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-78-4P, 4-(5-Chlorothiophen-2-ylmethyl)-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-83-1P, 4-(5-Chlorothiophen-2-ylmethyl)-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711025-84-2P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[(quinolin-3-yl)methyl]-4H-benzo[1,4]oxazin-3-one 711025-85-3P, 4-(5-Methyl-2-trifluoromethylfuran-3-ylmethyl)-6-[(4-oxo-2-

thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711025-87-5P, 4-[(1-tert-Butyl-5-methyl-1H-pyrazol-3-yl)methyl]-8-
 fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-
 3-one 711025-88-6P, 4-[(1-tert-Butyl-5-methyl-1H-pyrazol-3-
 yl)methyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-
 benzo[1,4]oxazin-3-one 711025-89-7P,
 4-[(2-Benzyl-5-tert-butyl-2H-pyrazol-3-yl)methyl]-6-[(4-oxo-2-
 thioxothiazolidin-5-ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 711025-90-0P, 8-Fluoro-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4-[(quinolin-6-yl)methyl]-4H-1,4-benzoxazin-3-one
 711025-91-1P, 4-[(1,5-Dimethyl-1H-pyrazol-3-yl)methyl]-6-[(4-oxo-2-
 thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711025-92-2P, 4-(5-Chloropyridin-3-ylmethyl)-8-fluoro-6-[(4-oxo-2-
 thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-one
 711025-93-3P, 4-[4-Chloro-3-(1-hydroxy-1-methylethyl)benzyl]-8-
 fluoro-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-benzoxazin-3-
 one 711025-94-4P, 4-[4-Chloro-3-(1-hydroxy-1-
 methylethyl)benzyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-1,4-
 benzoxazin-3-one 711025-95-5P,
 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-[(thiophen-2-yl)methyl]-4H-
 1,4-benzoxazin-3-one 711025-96-6P,
 4-(5-Methylpyridin-3-ylmethyl)-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-1,4-benzoxazin-3-one 711025-97-7P,
 4-[(1-Isopropyl-1H-benzimidazol-5-yl)methyl]-6-[(4-oxo-2-thioxothiazolidin-
 5-ylidene)methyl]-4H-1,4-benzoxazin-3-one 711025-98-8P
 711025-99-9P, 6-(4-Oxo-2-thioxothiazolidin-5-ylidenemethyl)-4-
 [(quinolin-6-yl)methyl]-4H-1,4-benzoxazin-3-one 711026-00-5P,
 5-[[4-[(Furan-3-yl)methyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-
 yl)methylene]thiazolidine-2,4-dione 711026-01-6P,
 4-[(2,5-Dimethyl-2H-pyrazol-3-yl)methyl]-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-1,4-benzoxazin-3-one 711026-02-7P,
 4-[(Furan-3-yl)methyl]-6-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]-4H-
 1,4-benzoxazin-3-one 711026-03-8P,
 (Z)-4-(3,4-Dichlorobenzyl)-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-benzo[1,4]oxazin-3-one 711026-04-9P,
 4-(3,4-Dichlorobenzyl)-8-fluoro-6-[(4-oxo-2-thioxothiazolidin-5-
 ylidene)methyl]-4H-benzo[1,4]oxazin-3-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (PI3K inhibitor; preparation of benzoxazinones as PI3K inhibitors for
 treating inflammations, cardiovascular diseases and cancers)
 711024-72-5 CAPLUS
 2,4-Thiazolidinedione, 5-[[3,4-dihydro-3-oxo-4-(4-pyridinylmethyl)-2H-1,4-
 benzoxazin-6-yl)methylene]- (CA INDEX NAME)




RN 711024-73-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 5-[[3,4-dihydro-4-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl)methyl]-3-oxo-2H-1,4-benzoxazin-6-yl)methylene]- (CA INDEX NAME)




RN 711024-75-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(2,6-dimethyl-4-pyridinyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-76-9 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(2,6-dimethyl-4-pyridinyl)methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711024-77-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]-5-methoxy-, methyl ester (CA INDEX NAME)




RN 711024-78-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(4,6-dimethyl-2-pyrimidinyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-79-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-80-5 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4,6-bis(1,1-dimethylethyl)-2-pyrimidinyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-81-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4,6-bis(1,1-dimethylethyl)-2-pyrimidinyl]methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-82-7 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-5-(1-hydroxy-1-methylethyl)phenyl]methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-83-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-5-(1-hydroxy-1-methylethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-
(CA INDEX NAME)




RN 711024-84-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-(3-azaspiro[5.5]undec-3-ylmethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-
(CA INDEX NAME)



RN 711024-85-0 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[[4-(3-azaspiro[5.5]undec-3-ylmethyl)phenyl]methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)



RN 711024-86-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl]methyl]phenyl]methyl]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 711024-87-2 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[4-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl)methyl]phenyl]methyl]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 711024-90-7 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-4-[3-(4-morpholinyl)propyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711024-91-8 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-6-[(4-oxo-2-thioxo-5-

thiazolidinyldene)methyl]-4-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 711024-92-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[3-(3,5-dimethyl-1-piperidinyl)propyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711024-93-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[3-[bis(1-methylethyl)amino]propyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711024-94-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711024-95-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3,5-bis(1,1-dimethylethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-oxazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-96-3 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-(acetyloxy)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711024-97-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[3,4-dihydro-3-oxo-4-[[4-(phenylmethoxy)phenyl]methyl]-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)



RN 711024-98-5 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3,5-bis(1,1-dimethylethyl)cyclohexyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-00-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[3,4-dihydro-4-[[3-methyl-5-[(4-methyl-1-piperazinyl)methyl]phenyl]methyl]-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711025-01-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[3,4-dihydro-4-[[3-[(1-methylethyl)sulfonyl]phenyl]methyl]-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711025-02-4 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-[(1-methylethyl)sulfonyl]phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-03-5 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-[(1-methylethyl)thio]phenyl]methyl]-6-
 [(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711025-04-6 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-methyl-5-[(4-methyl-1-piperazinyl)methyl]phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-05-7 CAPLUS
 CN Benzenesulfonamide, 3-[16-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl]methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 711025-06-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(4-morpholinylsulfonyl)phenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-07-9 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(cyclohexylmethyl)-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methylene]- (CA INDEX NAME)




RN 711025-08-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[[4-(4-morpholinylsulfonyl)phenyl]methyl]-6-
[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-09-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[[2-methoxy-3-(1-methylethyl)phenyl]methyl]-
6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-10-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(cyclohexylmethyl)-6-[(4-oxo-2-thioxo-5-
oxazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-11-5 CAPLUS

CN Benzenesulfonamide, 3-[[2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]-N,N-dimethyl- (CA INDEX NAME)



RN 711025-12-6 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711025-13-7 CAPLUS

CN Benzenesulfonamide, 4-[[2,3-dihydro-3-oxo-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]-N,N-dimethyl-
(CA INDEX NAME)


Double bond geometry as shown.



RN 711025-14-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[3,4-dihydro-4-[[3-(methylsulfonyl)phenyl]methyl]-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]-,
(5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 711025-15-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(6Z)-1-(4-oxo-2-thioxo-5-thiazolidinylidene)ethyl]-4-(phenylmethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 711025-17-1 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(6Z)-1-(4-oxo-2-thioxo-5-thiazolidinylidene)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 711025-18-2 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-4-[[3-(methylsulfonyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711025-19-3 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(methylsulfonyl)phenyl]methyl]-6-[(Z)- (4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 711025-20-6 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-
 [(Z)-(4-oxo-2-thioxo-5-oxazolidinylidene)methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 711025-21-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3,4-
 dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 711025-22-8 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-8-
 fluoro-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX
 NAME)


Double bond geometry as shown.



RN 711025-23-9 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-5-[methoxy(2-methoxyethoxy)methyl]phenyl]methyl]-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 711025-24-0 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-5-(4-morpholinylcarbonyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711025-25-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[[3-(1,1-dimethylethyl)-5-(1-hydroxy-1-methylethyl)phenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 711025-26-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[[3-(1,1-dimethylethyl)-5-(4-morpholinylmethyl)phenyl]methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]-, (5Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 711025-27-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-5-(4-morpholinylmethyl)phenyl]methyl]-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 711025-28-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]methyl]-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 711025-32-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]methyl]-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 711025-33-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-(4-morpholinylcarbonyl)phenyl]methyl]-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 711025-34-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1-hydroxy-1-methylethyl)phenyl]methyl]-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylydene)methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 711025-35-3 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-5-(1-methoxy-1-methylethyl)phenyl]methyl]-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylydene)methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 711025-40-0 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-5-(hydroxymethyl)phenyl]methyl]-8-fluoro-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 711025-41-1 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-[(acetyloxy)methyl]-5-(1,1-dimethylethyl)phenyl]methyl]-8-fluoro-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 711025-43-3 CAPLUS
 CN 2((3H)-Benzoxazolone, 3-[(3,4-dichlorophenyl)methyl]-5-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 711025-44-4 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(4-iodophenyl)methyl]-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 711025-45-5 CAPLUS


CN Benzoic acid, 4-[[2,3-dihydro-3-oxo-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-4H-1,4-benzoxazin-4-yl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 711025-46-6 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-4-[[4-(methylsulfonyl)phenyl]methyl]-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 711025-47-7 CAPLUS
CN 2(3H)-Benzoxazolone, 5-[(Z)-(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-3-(phenylmethyl)- (CA INDEX NAME)


Double bond geometry as shown.




RN 711025-48-8 CAPLUS
 CN 2(3H)-Benzoxazolone, 3-[[4-(methylsulfonyl)phenyl]methyl]-5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711025-49-9 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-4-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-50-2 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[[3-chloro-5-(1-hydroxy-1-methylethyl)phenyl]methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-51-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-4-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-52-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,5-difluoro-4-hydroxyphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-54-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,5-dibromophenyl)methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-55-7 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[8-fluoro-4-[(4-fluorophenyl)methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methylene]- (CA INDEX NAME)



RN 711025-56-8 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-4-[[4-methoxy-3-(trifluoromethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)




RN 711025-57-9 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3-chloro-4-fluorophenyl)methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-oxazolidinyldene)methyl]- (CA INDEX NAME)




RN 711025-58-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-4-[(4-fluorophenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-59-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-4-[[4-fluoro-3-(1-hydroxy-1-methylethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-60-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(4-fluorophenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-61-5 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-fluoro-3-(1-hydroxy-1-methylethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-62-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[[4-fluoro-3-(1-hydroxy-1-methylethyl)phenyl]methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711025-63-7 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(4-fluoro-3-methylphenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-64-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[[3-(2-fluorophenoxy)phenyl]methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711025-65-9 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[[3-chloro-4-fluorophenyl]methyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711025-66-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3-chloro-4-fluorophenyl)methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-67-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-4-[2-(4-fluorophenoxy)ethyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-68-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3-chloro-4-fluorophenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-69-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,4-difluorophenyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711025-70-6 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[3-bis(2-methoxyethyl)amino]propyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711025-71-7 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-

thiazolidinylidene)methyl]-4-(6-quinoxalinylmethyl)- (CA INDEX NAME)




RN 711025-72-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(6-quinoxalinylmethyl)- (CA INDEX NAME)



RN 711025-76-2 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(2,5-dimethyl-3-furanyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711025-77-3 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(2,5-dimethyl-3-furanyl)methyl]-8-fluoro-6-

[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-78-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(5-chloro-2-thienyl)methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-83-1 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(5-chloro-2-thienyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-84-2 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(3-quinolinylmethyl)- (CA INDEX NAME)




RN 711025-85-3 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[5-methyl-2-(trifluoromethyl)-3-furanyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-87-5 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[1-(1,1-dimethylethyl)-5-methyl-1H-pyrazol-3-yl]methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-88-6 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[1-(1,1-dimethylethyl)-5-methyl-1H-pyrazol-3-yl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-89-7 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[3-(1,1-dimethylethyl)-1-(phenylmethyl)-1H-pyrazol-5-yl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711025-90-0 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(6-quinolinylmethyl)- (CA INDEX NAME)




RN 711025-91-1 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-92-2 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(5-chloro-3-pyridinyl)methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-93-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-chloro-3-(1-hydroxy-1-methylethyl)phenyl]methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-94-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[4-chloro-3-(1-hydroxy-1-methylethyl)phenyl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-95-5 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]-4-(2-thienylmethyl)- (CA INDEX NAME)



RN 711025-96-6 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(5-methyl-3-pyridinyl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)



RN 711025-97-7 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[1-(1-methylethyl)-1H-benzimidazol-5-yl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinyldene)methyl]- (CA INDEX NAME)

NAME)




RN 711025-98-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[[1-(1-methylethyl)-1H-benzimidazol-6-yl]methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 711025-99-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(6-quinolinylmethyl)- (CA INDEX NAME)




RN 711026-00-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(3-furanylmethyl)-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 711026-01-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711026-02-7 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(3-furanylmethyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



RN 711026-03-8 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,4-dichlorophenyl)methyl]-8-fluoro-6-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 711026-04-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[(3,4-dichlorophenyl)methyl]-8-fluoro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




IT 711021-24-8P, [3-Oxo-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-2,3-dihydrobenzo[1,4]oxazin-4-yl]acetic acid tert-butyl ester 711021-36-2P, 8-Methoxy-6-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of benzoxazinones as PI3K inhibitors for treating inflammations, cardiovascular diseases and cancers)

RN 711021-24-8 CAPLUS

CN 4H-1,4-Benzoxazine-4-acetic acid, 2,3-dihydro-3-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 711021-36-2 CAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 8-methoxy-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
 (12 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2004:60505 CAPLUS
 DOCUMENT NUMBER: 140:128412
 TITLE: Preparation of azolidinone-vinyl fused-benzene
 derivatives for therapeutic uses as PI3 kinase
 inhibitors
 INVENTOR(S): Rueckle, Thomas; Jiang, Xuliang; Gaillard, Pascale;
 Church, Dennis; Vallotton, Tania
 PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth.
 Antilles
 SOURCE: PCT Int. Appl., 142 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007491	A1	20040122	WO 2003-EP50302	20030710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				


RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20040092561	A1	20040513	US 2002-289998	20021107
CA 2493843	A1	20040122	CA 2003-2493843	20030710
AU 2003255528	A1	20040202	AU 2003-255528	20030710
AU 2003255528	B2	20090716		
BR 2003012752	A	20050426	BR 2003-12752	20030710
BR 2003012650	A	20050503	BR 2003-12650	20030710
EP 1549644	A1	20050706	EP 2003-763907	20030710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1681811	A	20051012	CN 2003-821416	20030710
JP 2005538188	T	20051215	JP 2005-505076	20030710
IN 2004DN04114	A	20091127	IN 2004-DN4114	20041223
ZA 2005000162	A	20060726	ZA 2005-162	20050107
MX 2005000453	A	20050323	MX 2005-453	20050110
NO 2005000654	A	20050315	NO 2005-654	20050208
US 20060122176	A1	20060608	US 2005-520621	20050824
US 20090306069	A1	20091210	US 2009-469092	20090520
PRIORITY APPLN. INFO.:			EP 2002-100798	A 20020710
			US 2002-289998	A 20021107
			WO 2003-EP50302	W 20030710
			US 2005-520621	A1 20050824

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 140:128412
GI



I



II

AB The present invention is related to the preparation of azolidinedione-vinyl fused-benzene derivs., such as I [R1 = H, CN, carboxy, acyl, alkoxy, halogen, acyloxy, etc.; A = fused heterocyclic or carbocyclic ring; Y1, Y2 = S, O, NH], and their use in pharmaceutical compns. as PI3 kinase (PI3K) inhibitors. These azolidinones are claimed for use in the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, cancer, graft rejection, lung injuries, chronic obstructive pulmonary disease, anaphylactic shock, fibrosis, psoriasis, allergic diseases, asthma, stroke or ischemic conditions, ischemia-reperfusion, platelet aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastasis in melanoma and Kaposi's sarcoma, sepsis, transplantation, pancreatitis, multi-organ failure, glomerulosclerosis, glomerulonephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung or in general lung airways inflammation. Further, these azolidinones are claimed for use in the treatment of


atherosclerosis, hypertrophy, cardiac myocyte dysfunction, elevated blood pressure, vasoconstriction, Alzheimer's disease, Huntington's disease, CNS trauma, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, thrombosis, and brain infection/inflammation such as meningitis or encephalitis. Thus, azolidinone II was prepared via a condensation reaction of piperonal with 2,4-thiazolidinedione using β -alanine in acetic acid and stirring at 100° for 3 h. Some of the prepared azolidinones were assayed for PI3Ky inhibition using a high throughput PI3K lipid kinase binding assay. Tablet, capsule, liquid and injectable pharmaceutical compns. were presented.

IT 648449-93-8P 648449-94-9P 648450-32-2P
648450-35-5P 648450-36-6P 648450-56-0P
648450-61-7P 648915-83-7P 648915-96-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of azolidinone-vinyl fused-benzene derivs. for use in pharmaceutical compns. as PI3 kinase inhibitors)

RN 648449-93-8 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]-, ethyl ester (CA INDEX NAME)




RN 648449-94-9 CAPLUS

CN L-Proline, 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.




RN 648450-32-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(3-methyl-5-benzofuranyl)methylene]- (CA INDEX NAME)




RN 648450-35-5 CAPLUS
 CN 2-Propenoic acid, 3-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3-benzofuranyl]-, ethyl ester (CA INDEX NAME)




RN 648450-36-6 CAPLUS
 CN 2-Propenoic acid, 3-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3-benzofuranyl]- (CA INDEX NAME)




RN 648450-56-0 CAPLUS
 CN 3-Benzofuranpropanoic acid, 5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-, ethyl ester (CA INDEX NAME)




RN 648450-61-7 CAPLUS
 CN 4H-1,4-Benzoxazine-4-acetic acid, 6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2,3-dihydro-3-oxo-, methyl ester (CA INDEX NAME)



RN 648915-83-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]-(CA INDEX NAME)



RN 648915-96-2 CAPLUS
 CN 4H-1,4-Benzoxazine-4-acetic acid, 6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2,3-dihydro-3-oxo- (CA INDEX NAME)



IT	6318-41-8P	28824-66-0P	109208-80-2P
	128061-50-7P	184840-73-1P	300829-97-4P
	304645-61-2P	648449-74-5P	648449-75-6P


648449-76-7P	648449-78-9P	648449-79-0P
648449-80-3P	648449-81-4P	648449-82-5P
648449-83-6P	648449-84-7P	648449-85-8P
648449-86-9P	648449-87-0P	648449-88-1P
648449-89-2P	648449-90-5P	648449-91-6P
648449-92-7P	648449-95-0P	648449-96-1P
648449-97-2P	648449-98-3P	648449-99-4P
648450-00-4P	648450-01-5P	648450-02-6P
648450-03-7P	648450-05-9P	648450-06-0P
648450-07-1P	648450-08-2P	648450-09-3P
648450-11-7P	648450-12-8P	648450-13-9P
648450-14-0P	648450-15-1P	648450-16-2P
648450-17-3P	648450-18-4P	648450-19-5P
648450-20-8P	648450-21-9P	648450-22-0P
648450-23-1P	648450-24-2P	648450-25-3P
648450-26-4P	648450-27-5P	648450-28-6P
648450-29-7P	648450-30-0P	648450-31-1P
648450-33-3P	648450-34-4P	648450-37-7P
648450-39-9P	648450-40-2P	648450-41-3P
648450-42-4P	648450-43-5P	648450-44-6P
648450-45-7P	648450-46-8P	648450-47-9P
648450-48-0P	648450-49-1P	648450-50-4P
648450-51-5P	648450-52-6P	648450-53-7P
648450-54-8P	648450-55-9P	648450-57-1P
648450-58-2P	648450-59-3P	648450-60-6P
648450-62-8P	648450-65-1P	648450-66-2P
648450-67-3P	648450-70-8P	648450-72-0P
648450-73-1P	648450-74-2P	648450-75-3P
648450-76-4P	648915-80-4P	648915-82-6P
648915-84-8P	648915-85-9P	648915-86-0P
648915-87-1P	648915-89-3P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azolidinone-vinyl fused-benzene derivs. for use in pharmaceutical compns. as PI3 kinase inhibitors)


RN 6318-41-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-(1,3-benzodioxol-5-ylmethylene)- (CA INDEX NAME)




RN 28824-66-0 CAPLUS


CN 4-Thiazolidinone, 5-(1,3-benzodioxol-5-ylmethylene)-2-thio- (CA INDEX NAME)



RN 109208-80-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(2,3-dihydro-5-benzofuranyl)methylene]- (CA INDEX NAME)




RN 128061-50-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-(1,3-benzodioxol-5-ylmethylene)-, potassium salt (1:1) (CA INDEX NAME)




● K


RN 184840-73-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylene]- (CA INDEX NAME)




RN 300829-97-4 CAPLUS
CN 4(5H)-Thiazolone, 2-amino-5-(1,3-benzodioxol-5-ylmethylene)- (CA INDEX NAME)




RN 304645-61-2 CAPLUS
CN 4(5H)-Thiazolone, 2-amino-5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 648449-74-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(7-methoxy-1,3-benzodioxol-5-yl)methylene]- (CA INDEX NAME)




RN 648449-75-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(9,10-dihydro-9,10-dioxo-2-anthracenyl)methylene]- (CA INDEX NAME)




RN 648449-76-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]- (CA INDEX NAME)




RN 648449-78-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-(5-benzofuranylmethylene)- (CA INDEX NAME)




RN 648449-79-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzoxazin-6-yl)methylene]- (CA INDEX NAME)




RN 648449-80-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-(6-quinolinylmethylene)- (CA INDEX NAME)




RN 648449-81-4 CAPLUS
CN 4-Thiazolidinone, 5-(6-quinolinylmethylene)-2-thio- (CA INDEX NAME)




RN 648449-82-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(3-methyl-1,2-benzisoxazol-5-yl)methylene]- (CA INDEX NAME)




RN 648449-83-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-phenyl-6-quinazolinyl)methylene]- (CA INDEX NAME)




RN 648449-84-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(dimethylamino)-6-quinazolinyl)methylene]- (CA INDEX NAME)




RN 648449-85-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-amino-6-quinazolinyl)methylene]- (CA INDEX NAME)




RN 648449-86-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(1-piperidiny1)-6-quinazolinyl)methylene]- (CA INDEX NAME)




RN 648449-87-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-morpholinyl)-6-quinazolinyl]methylene]-
 (CA INDEX NAME)



RN 648449-88-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(phenylmethyl)amino]-6-quinazolinyl]methylene]- (CA INDEX NAME)




RN 648449-89-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(diethylamino)-6-quinazolinyl]methylene]-
 (CA INDEX NAME)




RN 648449-90-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(2-pyridinylmethyl)amino]-6-quinazolinyl]methylene]-

quinazolinyl)methylene]- (CA INDEX NAME)




RN 648449-91-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3-pyridinylmethyl)amino]-6-quinazolinyl)methylene]- (CA INDEX NAME)




RN 648449-92-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]-, ethyl ester (CA INDEX NAME)




RN 648449-95-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(4-methyl-1-piperazinyl)-6-quinazolinyl)methylene]- (CA INDEX NAME)




RN 648449-96-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(2-pyrimidinyl)-1-piperazinyl]-6-quinazolinyl]methylene]- (CA INDEX NAME)




RN 648449-97-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(4-(4-fluorophenyl)-1-piperidinyl)-6-quinazolinyl]methylene]- (CA INDEX NAME)




RN 648449-98-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[4-[4-(phenylmethyl)-1-piperidiny]-6-quinazoliny]methylene]- (CA INDEX NAME)




RN 648449-99-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[4-[4-(2-phenylethyl)-1-piperidiny]-6-quinazoliny]methylene]- (CA INDEX NAME)




RN 648450-00-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[4-[4-(4-methyl-1-piperidiny)-6-quinazoliny]methylene]- (CA INDEX NAME)




RN 648450-01-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[4-[4-(4-hydroxy-1-piperidiny)-6-quinazoliny]methylene]- (CA INDEX NAME)




RN 648450-02-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]- (CA INDEX NAME)




RN 648450-03-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]- (CA INDEX NAME)




RN 648450-05-9 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-(methylamino)-6-quinazolinyl]methylene]- (CA INDEX NAME)




RN 648450-06-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-methoxy-6-quinazoliny)methylene]- (CA INDEX NAME)




RN 648450-07-1 CAPLUS
CN 4(5H)-Thiazolone, 2-amino-5-[[4-(methylamino)-6-quinazoliny)methylene]- (CA INDEX NAME)




RN 648450-08-2 CAPLUS
CN 4(5H)-Thiazolone, 2-amino-5-[[4-(1-piperidiny)-6-quinazoliny)methylene]- (CA INDEX NAME)




RN 648450-09-3 CAPLUS
CN 4(5H)-Thiazolone, 2-amino-5-[[4-(dimethylamino)-6-quinazoliny)methylene]- (CA INDEX NAME)




RN 648450-11-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(1-methyl-1H-benzotriazol-6-yl)methylene]- (CA INDEX NAME)




RN 648450-12-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(1-ethyl-1H-benzimidazol-6-yl)methylene]- (CA INDEX NAME)



RN 648450-13-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[1-(4-phenylbutyl)-1H-benzimidazol-6-yl)methylene]- (CA INDEX NAME)




RN 648450-14-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[1-(2-propyn-1-yl)-1H-benzimidazol-6-yl)methylene]- (CA INDEX NAME)




RN 648450-15-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[2-[4-(trifluoromethyl)phenyl]ethyl]-1H-benzimidazol-6-yl]methylene]- (CA INDEX NAME)




RN 648450-16-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[2-(4-hydroxyphenyl)ethyl]-1H-benzimidazol-6-yl]methylene]- (CA INDEX NAME)




RN 648450-17-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[2-(5-methoxy-1H-indol-3-yl)ethyl]-1H-benzimidazol-6-yl]methylene]- (CA INDEX NAME)




RN 648450-18-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[(1-methyl-1H-pyrazol-4-yl)methyl]-1H-benzimidazol-6-yl]methylene]- (CA INDEX NAME)




RN 648450-19-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-1H-benzimidazol-6-yl]methylene]- (CA INDEX NAME)




RN 648450-20-8 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[1-[2-(4-phenoxyphenyl)ethyl]-1H-benzimidazol-6-yl]methylene]- (CA INDEX NAME)




RN 648450-21-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[1-[[4-(trifluoromethyl)phenyl]methyl]-1H-benzimidazol-6-yl]methylene]- (CA INDEX NAME)




RN 648450-22-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[1-(2-methylpropyl)-1H-benzimidazol-6-yl]methylene]- (CA INDEX NAME)




RN 648450-23-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[1-[[2-(1,3-benzodioxol-4-yl)ethyl]-1H-benzimidazol-6-yl]methylene]-1H-benzimidazol-6-yl]methylene]- (CA INDEX NAME)




RN 648450-24-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-[2-(2-phenoxyphenyl)ethyl]-1H-benzimidazol-6-yl]methylene]- (CA INDEX NAME)



RN 648450-25-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-(3,3-diphenylpropyl)-1H-benzimidazol-6-yl]methylene]- (CA INDEX NAME)




RN 648450-26-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[1-[(2-methoxyphenyl)methyl]-1H-benzimidazol-6-yl]methylene]- (CA INDEX NAME)




RN 648450-27-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[1-(3-furanylmethyl)-1H-benzimidazol-6-yl]methylene]- (CA INDEX NAME)




RN 648450-28-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(1-propyl-1H-benzimidazol-6-yl)methylene]- (CA INDEX NAME)




RN 648450-29-7 CAPLUS


CN 2,4-Thiazolidinedione, 5-(6-quinoxalinylmethylene)- (CA INDEX NAME)




RN 648450-30-0 CAPLUS
CN 4-Thiazolidinone, 5-(6-quinoxalinylmethylene)-2-thioxo- (CA INDEX NAME)




RN 648450-31-1 CAPLUS
CN 4(5H)-Thiazolone, 2-amino-5-(6-quinoxalinylmethylene)- (CA INDEX NAME)




RN 648450-33-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(2-bromo-3-methyl-5-benzofuranyl)methylene]- (CA INDEX NAME)



RN 648450-34-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(3-bromo-5-benzofuranyl)methylene]- (CA INDEX NAME)




RN 648450-37-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[3-[3-oxo-3-(1-piperidinyl)-1-propen-1-yl]-5-benzofuranyl]methylene]- (CA INDEX NAME)




RN 648450-39-9 CAPLUS
 CN D-Proline, 1-[3-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3-benzofuranyl]-1-oxo-2-propen-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 648450-40-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[3-[3-oxo-3-(1-pyrrolidinyl)-1-propen-1-yl]-5-benzofuranyl]methylene]- (CA INDEX NAME)




RN 648450-41-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[3-[3-(4-morpholinyl)-3-oxo-1-propen-1-yl]-5-benzofuranyl]methylene]- (CA INDEX NAME)



RN 648450-42-4 CAPLUS


CN L-Proline, 1-[3-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3-benzofuranyl]-1-oxo-2-propen-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 648450-43-5 CAPLUS

CN 2-Propenamide, N-cyclohexyl-3-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3-benzofuranyl]-N-methyl- (CA INDEX NAME)




RN 648450-44-6 CAPLUS

CN 2-Propenamide, 3-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3-benzofuranyl]-N-ethyl-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 648450-45-7 CAPLUS

CN 2-Propenamide, N-cyclobutyl-3-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3-benzofuranyl]- (CA INDEX NAME)




RN 648450-46-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[3-[3-(1-azetidiny)-3-oxo-1-propen-1-yl]-5-benzofuranyl]methylene]- (CA INDEX NAME)




RN 648450-47-9 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[3-[3-(1,3-dihydro-2H-indol-2-yl)-3-oxo-1-propen-1-yl]-5-benzofuranyl]methylene]- (CA INDEX NAME)




RN 648450-48-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[3-[3-(hexahydro-1H-azepin-1-yl)-3-oxo-1-propen-1-yl]-5-benzofuranyl]methylene]- (CA INDEX NAME)




RN 648450-49-1 CAPLUS


CN 2-Propenamide, 3-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3-benzofuranyl]-N-1-piperidinyl- (CA INDEX NAME)




RN 648450-50-4 CAPLUS
 CN 2-Propenamide, 3-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3-benzofuranyl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 648450-51-5 CAPLUS
 CN 2-Propenamide, N-cyclohexyl-3-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3-benzofuranyl]- (CA INDEX NAME)




RN 648450-52-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[3-[(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]-5-benzofuranyl]methylene]- (CA INDEX NAME)




RN 648450-53-7 CAPLUS
 CN 2-Propenamide, N-cycloheptyl-3-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3-benzofuranyl]- (CA INDEX NAME)




RN 648450-54-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[3-[(2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-1-propen-1-yl]-5-benzofuranyl]methylene]- (CA INDEX NAME)




RN 648450-55-9 CAPLUS
 CN 2-Propenamide, N-cyclopentyl-3-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3-benzofuranyl]- (CA INDEX NAME)




RN 648450-57-1 CAPLUS
 CN 3-Benzofuranpropanoic acid, 5-[(2,4-dioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




RN 648450-58-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[3-[3-oxo-3-(1-piperidinyl)propyl]-5-benzofuranyl]methylene]- (CA INDEX NAME)



RN 648450-59-3 CAPLUS
 CN 4H-1,4-Benzoxazine-4-carboxylic acid,
 6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2,3-dihydro-, 1,1-dimethylethyl
 ester (CA INDEX NAME)




RN 648450-60-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-carboxylic acid,
 6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-, 1,1-dimethylethyl ester (CA
 INDEX NAME)




RN 648450-62-8 CAPLUS

CN 4H-1,4-Benzoxazine-4-acetamide, 6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-
2,3-dihydro-3-oxo-N-(phenylmethyl)- (CA INDEX NAME)




RN 648450-65-1 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(2-chloro-5-benzofuranyl)methylene]- (CA INDEX NAME)




RN 648450-66-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(3-amino-1,2-benzisoxazol-5-yl)methylene]- (CA INDEX NAME)




RN 648450-67-3 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[3-(2-phenylethynyl)-5-benzofuranyl]methylene]- (CA INDEX NAME)




RN 648450-70-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(2-methyl-6-benzofuranyl)methylene]- (CA INDEX NAME)



RN 648450-72-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(3-bromo-2-fluoro-2,3-dihydro-6-benzofuranyl)methylene]- (CA INDEX NAME)




RN 648450-73-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(2-fluoro-6-benzofuranyl)methylene]- (CA INDEX NAME)




RN 648450-74-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(1,3-dihydro-5-isobenzofuranyl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 648450-75-3 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)



RN 648450-76-4 CAPLUS


CN Cyclohexanecarboxylic acid, 4-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 648915-80-4 CAPLUS

CN L-Proline, 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.




RN 648915-82-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-(6-benzothiazolylmethylene)- (CA INDEX NAME)




RN 648915-84-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-benzoyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]- (CA INDEX NAME)




RN 648915-85-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-acetyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]- (CA INDEX NAME)




RN 648915-86-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-butyl-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)methylene]- (CA INDEX NAME)



RN 648915-87-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[3,4-dihydro-3-oxo-4-(phenylmethyl)-2H-1,4-benzoxazin-6-yl]methylene]- (CA INDEX NAME)




RN 648915-89-3 CAPLUS
CN 2-Benzofurancarboxylic acid, 6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:170522 CAPLUS
DOCUMENT NUMBER: 139:316581
TITLE: Study of trends in interaction between structure and biological activity among thiazolidine derivatives
AUTHOR(S): Zimenkovsky, B. S.; Lesyk, R. B.; Lukyanchuk, V. D.; Shtoyko, N. Ye.; Nektegayev, I. O.; Roman, A. M.; Kazmirschuk, G. V.; Nekhlepochin, O. S.
CORPORATE SOURCE: L'viv. Derzhavnii Med. Univ. im. D. Galits'kogo, Lvov, Ukraine
SOURCE: Fiziologichno Aktivni Rechovini (2002), (2), 58-64
CODEN: FARICW
PUBLISHER: Natsional'na Farmatsevtichna Akademiya Ukraini

DOCUMENT TYPE: Journal
 LANGUAGE: Ukrainian
 AB We have systematized results of pharmacol. screening for new thiazolidine derivs. as anti-inflammatory, choleric, antioxidant and tuberculostatic activities. We have discussed probable pharmacophores with the aim for optimization of structure for biol. active substances as potential drugs.
 IT 613222-94-9
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mol. structure-biol. activity relations among thiazolidine derivs.)
 RN 613222-94-9 CAPLUS
 CN 4-Pyridinecarboxylic acid, 2-[5-(9-anthracenylmethylene)-2,5-dihydro-2-oxo-4-thiazolyl]hydrazide (CA INDEX NAME)




L6 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1998:710007 CAPLUS
 DOCUMENT NUMBER: 130:75735
 TITLE: Synthesis and biological activity of novel thiazolidinediones
 AUTHOR(S): Prabhakar, C.; Madhusudhan, G.; Sahadev, K.; Reddy, Ch. Maheedhara; Sarma, M. R.; Reddy, G. Om; Chakrabarti, R.; Rao, C. Seshagiri; Kumar, T. Dileep; Rajagopalan, R.
 CORPORATE SOURCE: Department of Process Research and Development, Department of Pharmacology, Dr. Reddy's Research Foundation, Hyderabad, 500 050, India
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1998), 8(19), 2725-2730
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Novel compds. having a dual pharmacophore were synthesized and evaluated for their insulin sensitizer and anti-inflammatory properties in different animal models.
 IT 218768-18-4P 218768-21-9P 218768-38-8P
 218768-46-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and structure activity of thiazolidinediones as antidiabetic and anti-inflammatory agents)

RN 218768-18-4 CAPLUS

CN 2-Naphthalenepropanal, β -(2,4-dioxo-5-thiazolidinylidene)-6-methoxy-, (BZ)- (CA INDEX NAME)


Double bond geometry as shown.



RN 218768-21-9 CAPLUS

CN 2-Naphthalenepropanal, β -(2,4-dioxo-5-thiazolidinylidene)-6-methoxy-, (BE)- (CA INDEX NAME)


Double bond geometry as shown.



RN 218768-38-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[1-(6-methoxy-2-naphthalenyl)ethylidene]-, (5E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 218768-46-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[1-(6-methoxy-2-naphthalenyl)ethylidene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
 REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1998:499452 CAPLUS

DOCUMENT NUMBER: 129:230592

ORIGINAL REFERENCE NO.: 129:46923a, 46926a

TITLE: New Cyclooxygenase-2/5-Lipoxygenase Inhibitors. 3. 7-tert-Butyl-2,3-dihydro-3,3-dimethylbenzofuran Derivatives as Gastrointestinal Safe Antiinflammatory and Analgesic Agents: Variations at the 5 Position
 AUTHOR(S): Janusz, John M.; Young, Patricia A.; Ridgeway, James M.; Scherz, Michael W.; Enzweiler, Kevin; Wu, Laurence I.; Gan, Lixian; Chen, Julian; Kellstein, David E.; Green, Shelley A.; Tulich, Jennifer L.; Rosario-Jansen, Theresa; Magrisso, I. Jack; Wehmeyer, Kenneth R.; Kuhlbeck, Deborah L.; Eichhold, Thomas H.; Dobson, Roy L. M.

CORPORATE SOURCE: Health Care Research Center, Procter Gamble Pharmaceuticals, Mason, OH, 45040, USA

SOURCE: Journal of Medicinal Chemistry (1998), 41(18), 3515-3529

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB An expansion of the scope of the initial discovery that 5-keto-substituted 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofurans (DHDMBFs) which antiinflammatory and analgesic agents was reported. Several other functional groups were introduced at the 5 position: amides, amidines, ureas, guanidines, amines, heterocycles, hetero aroms., and heteroaryl ethenyl substituents in the 5 position all provide active compds. These compds. are dual cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) inhibitors. They inhibit both COX-1 and COX-2 with up to 33-fold selectivity for COX-2.


IT 212849-16-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of (dimethylethyl)benzofuran derivs. as antiinflammatory and analgesic agents)

RN 212849-16-6 CAPLUS

CN 4(5H)-Thiazolone, 2-amino-5-[[7-(1,1-dimethylethyl)-2,3-dihydro-3,3-dimethyl-5-benzofuranyl]methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




OS.CITING REF COUNT: 34 THERE ARE 34 CAPLUS RECORDS THAT CITE THIS
RECORD (34 CITINGS)
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1996:580598 CAPLUS
DOCUMENT NUMBER: 125:247804
ORIGINAL REFERENCE NO.: 125:46321a,46324a
TITLE: Alpha-mercaptoacrylic acid derivatives having calpain
inhibitory activity
INVENTOR(S): Wang, Kevin K.; Yuen, Po-wai
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: U.S., 18 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5554767	A	19960910	US 1993-132624	19930521
US 5760048	A	19980602	US 1996-635081	19960419
PRIORITY APPLN. INFO.:			US 1993-132624	A3 19930521

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 125:247804
GI



II




III

AB The invention covers a novel series of α -mercaptoacrylic acid
derivs. R1R2C:C(SR3)CO2R [I; R = H, alk(en/yn)yl, cycloalk(en)yl,

aminoalkyl, aryl; R1, R2 = H, alk(en/yn)yl, cycloalk(en)yl, aryl, aralk(en/yn)yl, heterocyclyl, heterocyclylalk(en/yn)yl; R3 = as given for R, or COR4; R4 = alk(en/yn)yl, alkoxy, amino, aryl; or RR3 forms ring; or R1R2 forms ring. I inhibit both calpain I and calpain II with high affinity and selectivity. The compds. are useful for treatment of neurodegenerative disorders including cerebrovascular disorders, brain injury, spinal cord and peripheral nerve injury, cardiac infarction, cataracts, inflammation, restenosis, muscular dystrophy, and platelet aggregation. Pharmaceutical compns., methods of use, processes for preparation, and novel intermediates are also disclosed. For instance, condensation of rhodanine with 2-naphthaldehyde in refluxing glacial AcOH in the presence of NaOAc gave 87% intermediate II, which was hydrolyzed in aqueous NaOH at 85° to give title compound (Z)-III. The latter inhibited calpain I with IC50 of 2.4 μ M, but had IC50 >200 μ M against papain, trypsin, and thermolysin.


IT 181765-50-4P 181765-54-8P 181765-58-2P
 181765-61-7P 181765-63-9P 181765-64-0P
 181765-68-4P 181765-71-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of α -mercaptoacrylic acid derivs. as calpain inhibitors)
 RN 181765-50-4 CAPLUS
 CN 4-Thiazolidinone, 5-[(2-naphthalenylmethylene)-2-thio-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 181765-54-8 CAPLUS
 CN 4-Thiazolidinone, 5-[(9-ethyl-9H-carbazol-3-yl)methylene]-2-thio-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 181765-58-2 CAPLUS

CN 4-Thiazolidinone, 5-(1-naphthalenylmethylene)-2-thioxo-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 181765-61-7 CAPLUS

CN 4-Thiazolidinone, 5-(9-phenanthrenylmethylene)-2-thioxo-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 181765-63-9 CAPLUS

CN 4-Thiazolidinone, 5-[(6-methoxy-2-naphthalenyl)methylene]-2-thioxo-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 181765-64-0 CAPLUS


CN 4-Thiazolidinone, 5-(1,3-benzodioxol-5-ylmethylene)-2-thioxo-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 181765-68-4 CAPLUS
 CN 4-Thiazolidinone, 5-[(5,6,7,8-tetrahydro-2-naphthalenyl)methylene]-2-thioxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 181765-71-9 CAPLUS
 CN 4-Thiazolidinone, 5-(9H-fluoren-2-ylmethylene)-2-thioxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1980:586196 CAPLUS
 DOCUMENT NUMBER: 93:186196
 ORIGINAL REFERENCE NO.: 93:29675a,29678a
 TITLE: 2-Formyldibenzazepine derivatives
 INVENTOR(S): Suzuki, Yasushi; Tsukamoto, Kunio; Minami, Nobuyoshi; Hasegawa, Yukio; Watanabe, Tadaharu; Miyasaka, Katsuhiko; Mikami, Takashi; Funakoshi, Satoshi

PATENT ASSIGNEE(S): Teikoku Hormone Mfg. Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 55045648	A	19800331	JP 1978-119141	19780929
PRIORITY APPLN. INFO.: GI			JP 1978-119141	A 19780929




AB Title derivs. I [R, R1 = Me, CHO; PhCH2, CHO; H, CH2CO2H (II); Me, CH2CO2H (III), PhCH2, CH2CO2H] were prepared Analgesic and antiinflammatory data of II and III were given in mice and rats, resp. Thus, heating 33 g 2-HO2CC6H4CH2NMeC6H4CHO-4 with 660 g polyphosphoric acid 2 h at 90% gave 27.5 g I (R = Me, R1 = CHO) (IV). Heating a mixture of IV 30, 2-thioxo-4-thiazolidinone 20, and AcONa 40 g in AcOH 4 h, heating the resulting precipitate with 25 g NaOH in H2O 1 h, filtering, heating the filtrate with 30 g HONH2.HCl in H2O 1 h, filtering, acidifying the filtrate, refluxing the isolated precipitate with 150 mL Ac2O 3 h, concentrating, dissolving the residue in CHCl3, washing with aqueous NaHCO3, concentrating, and refluxing the residue with 10 g NaOH in aqueous MeOH 6 h gave 12 g III.

IT 75274-32-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and alkaline hydrolysis of)

RN 75274-32-7 CAPLUS

CN 11H-Dibenz[b,e]azepin-11-one, 5,6-dihydro-5-methyl-2-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)


L6 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1980:550045 CAPLUS
DOCUMENT NUMBER: 93:150045
ORIGINAL REFERENCE NO.: 93:23907a,23910a
TITLE: (+)-2-(6-Methoxy-2-naphthyl)propionic acids and their intermediates
INVENTOR(S): Kita, Chitsukazu; Yamada, Haruo
PATENT ASSIGNEE(S): Hamari Yakuhin Kogyo K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 55036429	A	19800314	JP 1978-109967	19780906
JP 61016264	B	19860428		
PRIORITY APPLN. INFO.:			JP 1978-109967	A 19780906

GI



I




II

AB Condensation (refluxing 8 h in PhMe-AcOH) of 2-thioxo-4-oxothiazolidine (9.3 g) with 2-acetyl-6-methoxynaphthalene (14.0 g) and ACONH4 gave I (16.8 g), which (5 g) was hydrolyzed (dilute NaOH, reflux, 1 h) to give II [R = C(S)CO2H] (3.4 g). This (30 g) was desulfurized (0.5 N aqueous NaOH, 75°, 45 min) to give II [R = C(O)CO2H] (25 g), which (25 g) was oxidized-decarboxylated (30% H2O2, dilute NaOH) to give II (R = CO2H) (III) (20 g). Optical resolution of III (1.15 g) by treating with L-tyrosine hydrazide (IV) (or L-PhCHMeNH2) gave (+)-III IV salt (0.6 g), which was acidified (HCl, AcOEt) to give (+)-III (0.3 g). (+)-III is an analgesic, antipyretic and antiinflammatory agent (no data).

IT 74888-49-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolytic ring cleavage of)

RN 74888-49-6 CAPLUS

CN 4-Thiazolidinone, 5-[1-(6-methoxy-2-naphthalenyl)ethylidene]-2-thioxo- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L6 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1977:50481 CAPLUS

DOCUMENT NUMBER: 86:50481

ORIGINAL REFERENCE NO.: 86:7981a,7984a

TITLE: Synthesis and antiinflammatory activity of some
2-substituted 4- and 7-benzoxazoleacetic and
 α -methylacetic acids

AUTHOR(S): Evans, Delme; Smith, Christine E.; Williamson, W. R.
Nigel

CORPORATE SOURCE: Org. Chem. Dep., Lilly Res. Cent. Ltd.,
Windlesham/Surrey, UK


SOURCE: Journal of Medicinal Chemistry (1977), 20(1), 169-71
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 86:50481

GI



HO₂CCHMe

I

AB Of six title compds. prepared and tested in the carrageenan-induced rat paw
assay only 2-phenyl- α -methyl-7-benzoxazoleacetic acid (I)

[60723-71-9] had activity which was significant, although of low order.


Structure-activity relations are discussed.

IT 60723-70-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiinflammatory activity of)

RN 60723-70-8 CAPLUS

CN 4-Thiazolidinone, 5-[1-(2-phenyl-4-benzoxazolyl)ethylidene]-2-thioxo- (CA
INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)

=> log h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

244.52	436.77
--------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-34.85	-34.85
--------	--------

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:45:19 ON 24 JAN 2010